Antitumor antagonists composed of mutant TGFβ1-RII extracellular domain and immunoglobulin scaffold

By developing TGFβ1RII ECD variants and binding to PD-1/PD-L1 or VEGF pathway antagonists, the problem of degradation or truncation of existing antagonists during storage is solved, improving the stability and treatment of bispecific antagonists Effect.

CN114340735BActive Publication Date: 2024-11-12SUZHOU ZELGEN BIOPHARML
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980098017.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-07-01
Filing Date
2019-12-06
Publication Date
2024-11-12
Estimated Expiration
2039-12-06

AI Technical Summary

Technical Problem

Existing antagonists with TGFβ1RII ECD regions are prone to protein degradation or truncation during storage, affecting their stability and effectiveness.

Method used

The variant of TGFβ1RII ECD was developed, which reduces protein degradation or truncation through specific amino acid mutations or deletion, and binds it to antagonists of the PD-1/PD-L1 or VEGF pathway to form a bispecific antagonist. To improve stability and functional durability.

Benefits of technology

It significantly reduces the degree of protein degradation or truncation of bispecific antagonists during storage, improves their biological activity and therapeutic effects, and enhances the ability to inhibit tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114340735B_ABST
    Figure CN114340735B_ABST
Patent Text Reader

Abstract

The present invention relates to an anti-tumor antagonist comprising a first targeting domain containing a mutated TGF-β1-R11 extracellular domain (mutated ECD); and an immunoglobulin scaffold having an amino terminus and a carboxyl terminus, wherein one or more mutations reduce proteolytic cleavage of the anti-tumor antagonist. Also disclosed herein are methods of using the anti-tumor antagonist as described herein to treat proliferative disorders, infections, and immune disorders.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to U.S. Provisional Application No. 62 / 869,111, filed July 1, 2019, and PCT Application No. PCT / US19 / 39979, filed June 28, 2019, the contents of which are expressly incorporated herein by reference for all purposes.

[0002] field

[0003] The present invention generally relates to cancer treatment, and more particularly to bispecific inhibitors capable of modulating pathways related to tumor neogenesis, tumor immunity, and angiogenesis.

[0004] background

[0005] The inability of the host to eliminate cancer cells remains a major problem. Although a growing number of therapeutic monoclonal antibodies have been approved for the treatment of various cancers, resistance to these antibodies is frequently observed due to the many different molecular pathways involved in cancer growth and metastasis. Although the immune system is a major mechanism for cancer prevention, cancer cells resist immunosurveillance. Natural control mechanisms have been identified that limit T cell activation to avoid collateral damage caused by excessive T cell activity. Tumor cells exploit this process to evade the immune response. Restoring the ability of immune effector cells, particularly T cells, to recognize and eliminate cancer is a major goal of immunotherapy.

[0006] There is a need for binding antagonists or antibodies with improved efficacy, and methods of using such agents to treat cancer and chronic viral infections.

[0007] Overview

[0008] The inventors of the present application have discovered that antagonists containing the TGFβ1RII ECD region exhibit unacceptable levels of protein degradation or clipping over time. One aspect of the present invention relates to anti-tumor antagonists comprising a first targeting domain that specifically binds to TGFβ1 and a second targeting domain that specifically binds to PD-1 or PD-L1, wherein the first targeting domain comprises a mutant TGF-β1RII extracellular domain (mutated ECD) that significantly reduces protein cleavage of the anti-tumor antagonist.

[0009] Another aspect of the present invention relates to an anti-tumor antagonist comprising a first targeting domain comprising a TGFβ pathway inhibitor and a second targeting domain that specifically binds to VEGF.

[0010] Another aspect of the present invention relates to a method for treating a proliferative disorder in an individual, comprising administering to the individual in need of such treatment an effective amount of an anti-tumor antagonist of the present invention.

[0011] BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 The complementary determining region (CDR) sequences of some anti-PD-1 monoclonal antibodies (anti-PD-1 mabs) are shown. The corresponding framework region (FR) sequence series are listed in Figure 53 SEQ ID NOs: 176-205.

[0013] Figures 2A-2B Several embodiments of anti-PD-1 antibody variable region sequences are shown.

[0014] Figure 3 The CDR sequences of some anti-PD-L1 monoclonal antibodies are shown. The corresponding FR sequences are listed in Figure 53 SEQ ID NOs: 206-228.

[0015] Figures 4A-4C Several embodiments of anti-PD-L1 antibody variable region sequences are shown.

[0016] Figures 5A-5B The structures of four different bispecific anti-tumor antagonists are shown: Bi-PB-1, Bi-PLB-1, Bi-PB-2, and Bi-PLB-2, each of which contains (1) an anti-PD-1 or anti-PD-L1 variable region and (2) a TGF-βRII ECD region.

[0017] Figure 6 Exemplary functional region sequences corresponding to the bispecific antibodies of Figure 5 are shown.

[0018] Figure 7 Exemplary heavy chain (HC) and light chain (LC) sequences corresponding to selected bispecific antibodies of FIG5 are shown.

[0019] Figures 8A-8CThree different bispecific antagonists are described: Bi-AB-1, Bi-A1B-1, and Bi-ZB-1, each containing a carboxy-terminal TGF-β1 RII extracellular domain (ECD) within a mutant IgG1 (K447A) scaffold. Both Bi-AB-1 and Bi-A1B-1 contain the amino-terminal anti-VEGF variable regions (VH1, VL1) from Avastin (bevacizumab); Bi-A1B-1 includes two amino acid substitutions (E6Q, L11V) in the VH region. Bi-ZB-1 contains the amino-terminal aflibercept region upstream of the IgG1 Fc (K447A) region.

[0020] Figure 9A and 9B The sequences of various functional regions in the bispecific antagonists depicted in FIG8 are shown.

[0021] Figure 10 The heavy chain (HC) and light chain (LC) amino acid sequences corresponding to the bispecific antagonists depicted in Figure 8 are shown.

[0022] Figure 11 The arrangement of functional domains in the bispecific antagonists depicted in FIG8 is summarized.

[0023] Figure 12 Figure 2 is a Coomassie Brilliant Blue-stained polyacrylamide gel showing increased expression levels of bispecific antibody antagonists Bi-AB-1 and Bi-A1B-1 containing E6Q and L11V mutations when transiently transfected into HEK293 cells, as determined by non-reducing polyacrylamide gel electrophoresis (PAGE).

[0024] Figure 13A Size exclusion chromatography (SEC) profiles of Bi-AB-1 and Bi-A1B-1 are shown. Figure 13B Protein A purified Bi-AB-1 and Bi-A1B-1 were shown to have low levels of high molecular weight (1%, 1%, respectively) and low molecular weight (0.4%, 0.4%, respectively) species compared to the dimer (98.6%, 98.7%, respectively).

[0025] Figure 14A and 14B Shows that in non-reduction ( Figure 14A ) and restore ( Figure 14B ) conditions.

[0026] Figure 15Shown is a size exclusion chromatography (SEC) profile showing that Protein A purified Bi-ZB-1 has lower levels of high molecular weight (HMW, 3.4%) and low molecular weight (LMW, 0.5%) species compared to the dimer (96.1%).

[0027] Figure 16 Shown are the results of a cell-based assay in which recombinant HEK-293 cells expressing huVEGFR2 and firefly luciferase under the control of an NFAT response element were stimulated with huVEGF165 in the presence of serially diluted two anti-VEGF antagonists (Bi-A1B-1 and Antibody A). Biological activity was determined by measuring the decrease in luciferase-mediated fluorescence.

[0028] Figure 17 ELISA analysis of Bi-A1B-1 binding to TGF-β1 and VEGF165 is shown, in which a 96-well plate coated with huTGF-β1 was incubated with serially diluted samples of Bi-A1B-1, followed by biotinylated huVEGF165, and the bound molecules were detected by Streptavidin-HRP using TMB substrate.

[0029] Figure 18 Shown are the results of a cellular assay in which recombinant HEK-293 cells expressing the human TGF-β1RII receptor and firefly luciferase under the control of a SMAD response element were stimulated with huTGF-β1 in the presence of serial dilutions of Bi-A1B-1, Bi-ZB-1, and a control group, each containing a fusion of the TGF-β1RII extracellular domain (ECD). Biological activity was determined by a luciferase-mediated decrease in fluorescence.

[0030] Figure 19 Pharmacokinetic diagram showing the in vivo half-life (T) of the bispecific antagonist Bi-A1B-1 after tail vein injection into 6-10 week old female CD1 mice. 1 / 2 Serum was collected at several time points after injection for Bi-A1B-1 antagonist analysis by ELISA.

[0031] Figures 20A-20B Describes two bispecific anti-tumor antagonists Bi-PB-1.2 ( Figure 20A ) and Bi-PLB-1.2( Figure 20B), each comprising an antibody backbone (IgG4 K447A or IgG1 K447A) derived from the variable region of PD-1 and PD-L1, respectively, and additionally including the TGF-β-RII ECD fused to the carboxyl terminus of each heavy chain CH3 region.

[0032] Figure 21 Shows the existence of Figure 20A and 20B The functional region sequence of the bispecific antibody.

[0033] Figure 22 Shows the corresponding Figure 20A and 20B Heavy chain (HC) and light chain (LC) amino acid sequences of the bispecific antagonists depicted.

[0034] Figure 23 Summarized in Figure 20A and 20B Arrangement of functional regions in the depicted bispecific antagonists.

[0035] Figure 24A Shown are native polyacrylamide gel (PAGE) analyses showing the expression of Bi-PB-1.2 and Bi-PLB-1.2 in a transient expression system compared to 1 μg of the parental control antibody (2P17). Figure 24B Depicted are size exclusion chromatography (SEC) profiles showing Protein A purified Bi-PB-1.2, Bi-PLB-1.2, and anti-PDL1-TGF-β1RII ECD benchmark molecules. Figure 24C Bi-PB-1.2, Bi-PLB-1.2, and anti-PDL1-TGF-β1RII ECD benchmark molecules were shown to have low levels of high molecular weight (HMW) and low molecular weight (LMW) species compared to the dimer.

[0036] Figures 25A-25B shows Bi-PB-1.2( Figure 25A ) and Bi-PLB-1.2( Figure 25B ) showed good stability at 4°C for at least 4 weeks in the dimer, HMW and LMW forms.

[0037] Figures 26A-26E Shown are the results of PD-1 and TGF-β1 binding to Bi-PB-1.2 (26A and 26B, respectively), and to their corresponding anti-PD-1 and anti-PDL1-TGF-β1RII ECD benchmark molecules (26C and 26D, respectively), and their resulting binding affinity constants (26E).

[0038] Figures 27A-27E Shown are the results of PD-L1 and TGF-β1 binding to Bi-PLB-1.2 (27A, 27B, respectively), and to their corresponding anti-PDL1 and anti-TGF-β1RII ECD benchmark molecules (27C, 27D), and their resulting binding affinity constants (27E).

[0039] Figure 28A ELISA analysis of Bi-PB-1.2 binding to TGF-β1 and PD-1 is shown, in which a 96-well plate coated with TGF-β1 was incubated with serially diluted samples of Bi-PB-1.2 followed by biotinylated huPD-1, and the bound molecules were detected by streptavidin-HRP using TMB substrate. Figure 28B ELISA analysis of Bi-PB-1.2 binding to TGF-β1 and PD-L1 is shown, in which a 96-well plate coated with TGF-β1 was incubated with serially diluted samples of Bi-PB-1.2 followed by biotinylated huPD-1, and the bound molecules were detected by streptavidin-HRP using TMB substrate.

[0040] Figure 29A The ability of Bi-PB-1.2 and an anti-PD-1 benchmark antibody to block PD-1 binding to PD-L1 is shown. Figure 29B Results from a cell-based assay are shown, demonstrating the ability of serially diluted Bi-PB-1.2 and anti-PDL1-TGF-β1RII ECD benchmark molecules to block TGF-β1-activated luciferase expression under the control of a SMAD response element. Biological activity was determined by a luciferase-mediated decrease in fluorescence.

[0041] Figures 30A-30B Bi-PB-1.2 and both anti-human PD-1 and anti-cynomolgus monkey PD-1 benchmark antibodies were shown to bind to human PD-1 ( Figure 30A ) and cynomolgus monkey PD-1 ( Figure 30B ), and its corresponding EC 50 Value, the EC 50 The values ​​reflect the half-maximal effective concentration (EC) that produces a response halfway between baseline and maximal response for binding to human PD-1 and cynomolgus monkey PD-1, respectively. 50 ).

[0042] Figure 31A The ability of Bi-PLB-1.2 and an anti-PD-L1 benchmark antibody to block the binding of PD-L1 to PD-1 is shown. Figure 31BResults from a cell-based assay are shown, demonstrating the ability of serial dilutions of Bi-PLB-1.2 and an anti-PDL1-TGF-β1RII ECD reference molecule to block TGF-β1-activated luciferase expression under the control of a SMAD response element. Biological activity was determined by a luciferase-mediated decrease in fluorescence.

[0043] Figures 32A-32B Bi-PLB-1.2 and both anti-human PD-L1 and anti-cynomolgus monkey PD-L1 benchmark antibodies were shown to bind to human PD-L1 ( Figure 32A ) and cynomolgus monkey PD-L1( Figure 32B ), and its corresponding EC 50 Value, the EC 50 The values ​​reflect the half-maximal effective concentration (EC) that produces a response halfway between baseline and maximal response for binding to human PD-L1 and cynomolgus monkey PD-L1, respectively. 50 ).

[0044] Figures 33A-33B Compared with the negative control group, Bi-PB-1.2 treatment increased the expression of human PBMCs (donor 1, Figure 33A ; Donor 2, Figure 33B ) of IFN-γ secretion. Figures 33C-33D Compared with the negative control group, Bi-PB-1.2 treatment increased the expression of human PBMCs (donor 1, Figure 33C ; Donor 2, Figure 33D ) of IL-2 secretion.

[0045] Figures 34A-34B The results showed that Bi-PLB-1.2 enhanced the expression of human PBMCs (donor 8, Figure 34A ; Donor 9, Figure 34B ) of IFN-γ secretion. Figures 34C-34D The results showed that Bi-PLB-1.2 enhanced the expression of human PBMCs (donor 8, Figure 34C ; Donor 9, Figure 34D ) of IL-2 secretion.

[0046] Figures 35A-35F Figure 2 shows improved pharmacokinetic profiles of Bi-PB-1.2 and Bi-PLB-1.2 compared to a baseline antibody following tail vein injection into 6-10 week old female CD1 mice. Serum samples of Bi-PB-1.2, Bi-PLB-1.2, and a baseline antibody antagonist were collected at several time points after injection and analyzed by ELISA (respectively Figure 35A 、 35C, 35E) and Western blotting (respectively Figure 35B 、 35D , 35F) for analysis.

[0047] Figure 36 The results show that the percentage of low molecular weight (LMW) species of Bi-PB-1.2 produced by stably transfected CHO cells and stored at 4°C increased over time, while the percentage of dimer species decreased over time, which was consistent with the increase in clipping measured by size exclusion ultra-high performance liquid chromatography (SE-UHPLC).

[0048] Figure 37 Shown are size exclusion chromatography (SEC) profiles of a bispecific antagonist (Bi-PB-1.2 (PD1-TGF-β1RII ECD) and a PLB-1 benchmark (BM) antibody expressed in stably transfected CHO cells, depicting a shoulder in the main peak consistent with an increase in truncation compared to Bi-PB-1.2 produced by transiently transfected HEK293 cells.

[0049] Figure 38 Shown is the SEC profile of the Bi-PB-1.2 fraction obtained by cation exchange chromatography (CEX).

[0050] Figure 39 The fragments and truncated fragments identified by mass spectrometry were confirmed, showing that Bi-A1B-1 and Bi-PB-1.2 had similar truncation sites.

[0051] Figure 40A and 40B The truncation sites of the heavy chain amino acid sequences of Bi-A1B-1 and Bi-PB-1.2 were revealed based on mass spectrometry.

[0052] Figures 41A-41C Different mutant TGF-β1RII ECD sequences used to study truncation of the wild-type TGF-β1RII ECD are shown.

[0053] Figures 42A-42H Shows the content Figures 41A-41C The Bi-PB-1.2 heavy chain sequence was modified with a TGF-β1RII ECD sequence. Analysis of these mutations is shown in Figures 46-52 below.

[0054] Figure 43 Shows the content Figure 41A and 41C The Bi-PLB-1.2 heavy chain sequence of the selected mutant TGF-β1RII ECD sequence. Analysis of these mutations is shown in Figure 52 below.

[0055] Figures 44A-44D Shows the following Figure 49 、 50 and Bi-A1B-1 heavy chain sequences of 52 selected mutant TGF-β1RII ECD sequences.

[0056] Figure 45 Shown in Figures 41A-41C The amino acids targeted by the mutated TGF-β1RII ECD sequence are shown.

[0057] Figures 46A-46C Reducing polyacrylamide gel (PAGE) analysis is described showing that the Bi-PB-1.2 TGFβ1 ECD mutant has similar expression levels and yields to the parental wild-type Bi-PB-1.2 following protein A-affinity purification of the molecule from stable Chinese hamster ovary cell (CHO) transformants.

[0058] Figure 47A Shown are SEC profiles corresponding to Bi-PB-1.2 and mutations (Bi-PB-1.2-Δ7, Bi-PB-1.2B to Bi-PB-1.2H), which demonstrate reduced truncation (no shoulder) for these mutations compared to Bi-PB-1.2. Figure 47B Shown are SEC profiles corresponding to Bi-PB-1.2 and mutations (Bi-PB-1.2-Δ15, and Bi-PB-1.2-Δ20), which demonstrate reduced truncation (no shoulder) for these mutations compared to Bi-PB-1.2.

[0059] Figure 48 Shows Figures 47A-47B The percentages of high molecular weight (HMW), dimer, and low molecular weight (LMW) species reflected in the SEC profile.

[0060] Figure 49 Results from a cell-based assay are shown, demonstrating the ability of serially diluted Bi-PB-1.2 and Bi-A1B-1 variants produced by transient transfection of HEK293 cells, and controls (i.e., parental Bi-PB-1.2, Bi-A1B-1, and PLB-BM (benchmark) and negative control antibodies) to block TGF-β1-activated luciferase expression under the control of a SMAD response element. Biological activity was determined by a luciferase-mediated decrease in fluorescence.

[0061] Figure 50 The IC values ​​of Bi-PB-1.2 and Bi-A1B-1 variants compared to the parental control group are shown. 50 , reflecting their ability to block TGF-β1-activated luciferase expression under the control of SMAD response elements. Biological activity was determined by a luciferase-mediated decrease in fluorescence.

[0062] Figures 51A-51C shows Bi-PB-1.2( Figure 51A )、Bi-PB-1.2C( Figure 51B ) and Bi-PB-1.2D( Figure 51C ) had similar pharmacokinetic profiles in paired mice, characterized by a T of approximately 5-8 days. 1 / 2 .

[0063] Figures 52A-52B Shown is a reducing polyacrylamide gel (PAGE) analysis showing reduced levels of truncated fragments from the C variant compared to the parental wild-type Bi-PB-1.2, Bi-PLB-1.2, and Bi-A1B-1.

[0064] Figure 53 Shows the corresponding Figure 1 and 3 The framework regions (FRs) of the anti-PD-1 CDRs (SEQ ID NOs: 176-205) and anti-PD-L1 CDRs (SEQ ID NOs: 206-228) are shown.

[0065] Details

[0066] definition

[0067] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the disclosed methods and compositions belong. It should be noted that, unless the context clearly indicates otherwise, the singular forms "a," "an," and "the" used herein and in the appended claims include the plural forms. Thus, for example, "a peptide" includes "one or more" peptides or "plural" peptides. With respect to the teachings herein, any issued patent or patent application publication described herein is expressly incorporated herein by reference.

[0068] As used herein, the term "PD-1" refers to any form of PD-1 and its variants, wherein the variants retain at least some of the PD-1 activity. Unless otherwise specified (e.g., referring specifically to human PD-1), PD-1 includes all mammalian (e.g., human, dog, cat, horse, and cow) native sequence PD-1.

[0069] As used herein, the term "PD-L1" refers to any form of PD-L1 and its variants, wherein the variants retain at least some of the PD-L1 activity. Unless otherwise specified (e.g., specifically referring to human PD-L1), PD-L1 includes all mammalian (e.g., human, dog, cat, horse, and cow) native sequence PD-L1.

[0070] The term "agonist" refers to a substance that promotes (i.e., induces, causes, enhances, or increases) the biological activity or effect of another molecule. The term agonist encompasses substances that bind to a receptor (e.g., antibodies), as well as substances that promote receptor function (e.g., by activating related proteins) when not bound to the receptor.

[0071] The term "antagonist" or "inhibitor" refers to a substance that prevents, blocks, inhibits, neutralizes, or reduces the biological activity or effect of another molecule, such as a receptor or ligand.

[0072] As used herein, the term "antibody" refers to a polypeptide or polypeptide complex that specifically recognizes and binds to an antigen through one or more immunoglobulin variable regions. An antibody can be a complete antibody, an antigen-binding fragment, or a single chain thereof. The term "antibody" encompasses a wide variety of biochemically distinguishable polypeptide species. Those skilled in the art understand that heavy chains are classified as α (alpha), δ (delta), ε (epsilon), γ (gamma), and μ (mu), as well as some subclasses thereof (e.g., γ1-γ4). The properties of this chain determine the antibody "class" as IgG, IgM, IgA, IgD, or IgE, respectively. The immunoglobulin subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, etc., are well characterized and known to have specialized functions. In view of the present specification, modified forms of each of these classes and isotypes are readily distinguishable to those skilled in the art and are within the scope of this specification. All immunoglobulin classes are within the scope of this specification, and the following discussion is generally directed to the IgG class of immunoglobulin molecules.

[0073] The antibodies or antibody antagonists of the present invention may include, but are not limited to, polyclonal, monoclonal, multispecific, bispecific, trispecific, human, humanized, primatized, chimeric, and single-chain antibodies. The antibodies disclosed herein may be from any animal source, including birds and mammals. Preferably, the antibodies are human, mouse, rat, donkey, rabbit, goat, guinea pig, camel, llama, horse, or chicken antibodies. In some embodiments, the variable region may be of condricthoid origin (e.g., from shark).

[0074] The term "antibody fragment" or "antigen-binding fragment" is used to refer to a portion of an antibody, such as F(ab')2, F(ab)2, Fab', Fab, Fv, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv), fragments comprising a VL or VH region, fragments produced by a Fab expression library, and anti-id antibodies. Regardless of the structure, the antibody fragment binds to the same antigen recognized by the intact antibody. The term "antibody fragment" includes DARTs and diabodies. The term "antibody fragment" also includes any synthetic or genetically engineered protein that contains an immunoglobulin variable region that acts like an antibody by binding to a specific antigen to form a complex. "Single-chain fragment variable or scFv" refers to a fusion protein of the heavy chain variable region (VH) or light chain variable region (VL) of an immunoglobulin. In certain aspects, the variable region is linked to a short connecting peptide of 10 to about 25 amino acids. The connecting peptide can be rich in glycine to improve flexibility, rich in serine or threonine to improve solubility, and can connect the N-terminus of VH to the C-terminus of VL, or vice versa. Despite the removal of the constant region and the introduction of the connecting peptide, this protein still retains the specificity of the original immunoglobulin. Regarding IgG, a standard immunoglobulin molecule contains two identical light chain polypeptides with a molecular weight of approximately 23,000 Daltons, and two identical heavy chain polypeptides with a molecular weight of 53,000-70,000. The four polypeptide chains are usually bound in a "Y" shape by disulfide bonds, where the light chain brackets the heavy chain, and the heavy chain starts at the opening of the "Y" and continues to extend to the variable region.

[0075] Both light and heavy chains are divided into structurally and functionally homologous regions. The terms "constant" and "variable" are used functionally. Here, it can be understood that the light chain variable region (VL) and the heavy chain variable region (VH) determine antigen recognition and specificity. Conversely, the light chain constant region (CL) and the heavy chain constant region (CH1, CH2, or CH3) confer important biological properties, such as secretion, transplacental mobility, Fc receptor binding, and complement fixation. By convention, in common antibodies, the numbering of the constant region increases as the region becomes more distal to the antigen-binding site or the amino-terminus of the antibody. In common antibodies, the N-terminus is divided into the variable region, while the C-terminus is divided into the constant region; the CH3 and CL domains actually comprise the carboxyl termini of the heavy and light chains, respectively.

[0076] As described above, the variable region enables the antibody to selectively recognize and specifically bind to the antigenic epitope. That is, the VL region and the VH region of the antibody, or a subset of the complementary determining regions (CDRs), combine to form a variable region that defines a three-dimensional antigen binding site. This four-level antibody structure forms an antigen binding site present at the end of each arm of the Y. More specifically, the antigen binding site is defined by three CDRs (i.e., HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3) on each of the VH and VL. In some examples, for example, certain immunoglobulins are derived from camelid species or are designed based on camelid immunoglobulins. Alternatively, the immunoglobulin molecule may consist only of heavy chains without light chains, or may consist only of light chains without heavy chains.

[0077] In naturally occurring antibodies, the six CDRs present in each antigen-binding region are short, non-contiguous amino acids, and when the antibody presents its three-dimensional structure in an aqueous environment, the CDRs form an antigen-binding region in a specific position. The remaining amino acids in the antigen-binding region, called the "framework" region, show less intermolecular variability. Most of the framework region adopts a β-sheet structure, and the CDRs form loops that link the β-sheet structure, and the loops form part of the β-sheet structure in some cases. Therefore, the framework region acts as a scaffold, positioning the CDRs in the correct direction through non-covalent interactions between the chains. The antigen-binding region formed by the CDR positioning defines a surface that is complementary to the immunoreactive antigen epitope. This complementary surface promotes non-covalent binding of the antibody to its cognate epitope. For any given heavy or light chain variable region, because it has been precisely defined, a person of ordinary skill in the art can easily identify the amino acids comprising the CDRs and framework region, respectively.

[0078] As used herein, the terms "VH1" and "VH2" refer to immunoglobulin heavy chain variable regions that correspond to two different binding specificities. Similarly, "VL1" and "VL2" refer to immunoglobulin light chain variable regions that correspond to two different binding specificities. It should be understood that when used together, the VH1 and VL1 regions define a common binding specificity, and the VH2 and VL2 define a second binding specificity.

[0079] As used herein, the term "framework region (FR)" refers to variable region residues other than the CDR residues. Each variable region typically has four FRs flanking the corresponding CDRs. For example, the VH region typically has four HFRs flanking the three HCDRs: HFR1, HFR2, HFR3, and HFR4, with a configuration of HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4. Similarly, the LH region typically has four LFRs flanking the three LCDRs, with a configuration of LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4. Exemplary FRs that can be used for the antagonists described herein are summarized in Figure 53 .

[0080] Light chains are classified as either kappa (κ) or lambda (λ). Each heavy chain can bind to a kappa or lambda light chain. Generally, when immunoglobulins are produced by fused tumor cells, B cells, or genetically engineered host cells, the light and heavy chains are covalently bound to each other, and the "Fc" portions of the two heavy chains are linked to each other by covalent disulfide bonds or non-covalent bonds. Within the heavy chain, the amino acid sequence extends from the N-terminus at the end of the Y-shaped bifurcation to the C-terminus at the base of each chain.

[0081] As used herein, the terms "light chain constant region" or "CL" are used interchangeably herein and are amino acid sequences derived from an antibody light chain. Preferably, the light chain constant region comprises at least a constant kappa region or a constant lambda region.

[0082] As used herein, the term "heavy chain constant region" includes an amino acid sequence derived from an immunoglobulin heavy chain. A polypeptide comprising a heavy chain constant region comprises at least a CH1 region, a hinge (e.g., upper, middle, and / or lower hinge region) region, a CH2 region, a CH3 region, or a variant or fragment thereof. For example, the antigen-binding polypeptides used in the present specification may include the following: a polypeptide chain comprising the CH1 region; a polypeptide chain comprising the CH1 region, at least a portion of the hinge region, and the CH2 region; a polypeptide chain comprising the CH1 region and the CH3 region; a polypeptide chain comprising the CH1 region, at least a portion of the hinge region, and the CH3 region; or a polypeptide chain comprising the CH1 region, at least a portion of the hinge region, the CH2 region, and the CH3 region. In some embodiments, the polypeptide of the present specification comprises a polypeptide chain containing the CH3 region. Further, the antibodies used in the present invention may lack at least a portion of the CH2 region (e.g., all or part of the CH2 region). It should be understood that the heavy chain constant region may be modified so that its amino acid sequence is different from that of a naturally occurring immunoglobulin molecule.

[0083] For example, as reflected in the disclosure herein below, Applicants have discovered that the CH3 region can tolerate or accommodate large insertions (e.g., greater than 100 amino acids) in the Fc loop of the CH3 region (see, e.g., Figure 5B Thus, in the present invention, any disclosed inhibitor region can be inserted into the Fc loop in a manner similar to the insertion of the TGFβ1RII ECD region into the Fc loop of the heavy chain sequences set forth in SEQ ID NOs: 151-154.

[0084] The heavy chain constant regions of the antibodies disclosed herein can be derived from different immunoglobulin molecules. For example, the heavy chain constant region of a polypeptide can comprise a CH1 region derived from an IgG1 molecule and a hinge region derived from an IgG3 molecule. In another example, the heavy chain constant region can comprise a hinge region that is partially derived from an IgG1 molecule and partially derived from an IgG3 molecule. In another example, the heavy chain constant region can comprise a chimeric hinge region that is partially derived from an IgG1 molecule and partially derived from an IgG4 molecule.

[0085] A "light chain-heavy chain pair" refers to a collection of light and heavy chains that can form dimers via a disulfide bond between the light chain CL region and the heavy chain CH1 region.

[0086] The subunit structures and three-dimensional configurations of the constant regions of various immunoglobulin types are known. As used herein, the term "VH region" includes the amino-terminal variable region of an immunoglobulin heavy chain, and the term "CH1 region" includes the first (most amino-terminal) constant region region of an immunoglobulin heavy chain. The CH1 region is adjacent to the VH region and is amino-terminal to the hinge region of the immunoglobulin heavy chain molecule.

[0087] As used herein, the term "CH2 region" includes the portion of the heavy chain molecule that, for example, extends from about residue 244 to residue 360 ​​of an antibody using the conventional numbering scheme (residues 244 to 360, Kabat numbering system; residues 231-340, EU numbering system). The CH2 region is characterized in that it is not tightly paired with other regions. Instead, two N-linked branched sugar chains are inserted between the two CH2 regions of the intact native IgG molecule. The CH3 region extends from the CH2 region to the C-terminus of the IgG molecule and comprises approximately 108 residues.

[0088] As used herein, the term "hinge region" includes the portion of the heavy chain molecule that connects the CH1 and CH2 regions. This hinge region comprises approximately 25 residues and is flexible, thus allowing the two N-terminal antigen-binding regions to move independently. The hinge region can be subdivided into three distinct regions: the upper hinge region, the middle hinge region, and the lower hinge region.

[0089] As used herein, the term "disulfide bond" includes a covalent bond formed between two sulfur atoms. The amino acid cysteine ​​contains a thiol group that can form a disulfide bond or bridge with a second thiol group. In most naturally occurring IgG molecules, the CH1 and CL regions are linked by a disulfide bond, with the two heavy chains linked by two disulfide bonds at positions corresponding to 239 and 242 in the Kabat numbering system (226 and 229 in the EU numbering system).

[0090] As used herein, a "variant" of an antibody, antibody fragment, or antibody region refers to an antibody, antibody fragment, or antibody region that: (1) has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the original antibody, antibody fragment, or antibody region; and, (2) specifically binds to the same target as the original antibody, antibody fragment, or antibody region. It should be understood that when a sequence identity value is expressed as "at least x% identical" or "at least x% identical," the embodiment includes any and all integer percentages equal to or greater than the lower limit. Further, it should be understood that an amino acid sequence appearing herein should be interpreted as additionally disclosing or encompassing an amino acid sequence that has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence.

[0091] It should be understood that when a range of sequence homology appears herein (e.g., the phrase "about 80% to about 100%"), this embodiment includes any and all sub-ranges within that range, wherein the lower limit can be any integer between 80 and 100.

[0092] As used herein, the phrase "humanized antibody" refers to an antibody derived from a non-human antibody, typically a mouse monoclonal antibody. Alternatively, a humanized antibody can be derived from a chimeric antibody that retains or substantially retains the antigen-binding properties of the parent non-human antibody, but exhibits reduced immunogenicity when administered to humans compared to the parent antibody.

[0093] As used herein, the phrase "chimeric antibody" refers to an antibody in which the immunologically active region or site is obtained or derived from a first species, while the constant region (which may be complete, partial, or modified according to the present specification) is obtained from a second species. In certain embodiments, the target binding region or site is from a non-human source (e.g., mouse or primate), while the constant region is from a human.

[0094] The scope of the multispecific antibodies of the present invention includes various compositions and methods, including: asymmetric IgG-like antibodies (e.g., triomab / quadroma, Trion Pharma / Fresenius Biotech); knobs-into-holes antibodies (Genentech); Cross MAbs (Roche); electrostatic pairing antibodies (AMGEN); LUZ-Y (Genentech); strand exchange engineered domain (SEED) antibodies (EMD Serono; Biolononic, Merus); Fab-exchange antibodies (Genmab), symmetrical IgG-like antibodies (e.g., dual-targeting (DT)-Ig (GSK / Domantis); two-in-one antibodies (Genentech); cross-linked MAbs (Karmanos Cancer Center), mAb2 (F-star); Cov X-body (Cov X / Pfizer); dual variable domain (DVD)-Ig fusions (Abbott); IgG-like bispecific antibodies (Eli Lilly); Ts2Ab (Medimmune / AZ); BsAb (ZymoGenetics); HERCULES (Biogen Idec, TvAb, Roche); scFv / Fc fusion; SCORPION (Emergent BioSolutions / Trubion, ZymoGenetics / BMS); dual affinity retargeting technology technology, Fc-DART, MacroGenics; bis(scFv)2-Fabs (National Center for Antibody Drugs); F(ab)2 fusions (Medarex / AMGEN); dual-action or Bis-Fab (Genentech); Dock-and-Lock (DNL, ImmunoMedics); Fab-Fv (UCB-Celltech); scFv- and diabody-based antibodies (e.g., bispecific T-cell engager antibodies (BiTEs, Micromet); tandem diabodies (Tandab, Affimed); DARTs (MacroGenics); single-chain diabodies; TCR-like antibodies (AIT, Receptor Logics); human serum albumin scFv fusions (Merrimack); COMBODIES (Epigen Biotech);and IgG / non-IgG fusions (e.g., immunocytokines (EMDSerono, Philogen, ImmunGene, ImmunoMedics);

[0095] By "specifically binds" or "is specific for...", it is generally meant that the antibody binds to the epitope via its antigen binding region, and that such binding requires some complementarity between the antibody binding region and the epitope. According to this definition, an antibody is described as "specifically binding" to an epitope when it binds to that epitope more easily via its antigen binding region than to a random, unrelated epitope. The term "specificity" is used herein to qualify the relative affinity with which an antibody binds to an epitope. For example, antibody "A" may be considered to have a higher specificity for a particular epitope than antibody "B", or antibody "A" may be described as binding to epitope "C" with a higher specificity for binding to a related epitope "D". In some embodiments, if an antibody or antibody fragment forms a 10 -6 M or less, 10 -7 M or less, 10 -8 M or less, 10 -9 M or less, 10 -10 An antibody or antibody fragment is “specific for an antigen” if it can form a complex with a dissociation constant (Kd) of 5 M or less.

[0096] The phrase "immune checkpoint regulator" refers to a functional class of agents that inhibit or stimulate signals through immune checkpoints. "Immune checkpoint regulators" include cell surface receptors and their associated ligands, which together provide a means of inhibiting or stimulating T cell activation-related signaling pathways. Immune checkpoint regulators of cell surface receptors are typically TNF receptors or B7 superfamily members that can induce checkpoint signaling pathways to inhibit immune responses, including agents that bind to negative costimulatory molecules, including but not limited to PD-1, TIGIT, LAG-3, TIM-3, BTLA, VISTA, CTLA-4, and their respective ligands.

[0097] The phrases "immune checkpoint regulator antagonist," "immune checkpoint binding antagonist," and "immune checkpoint antagonist" are used interchangeably herein and refer to a class of agents that interfere with (or inhibit) the activity of immune checkpoint regulators, whereby, as a result of binding to the checkpoint regulator or its ligand, signaling through the checkpoint regulator receptor is blocked or inhibited. By inhibiting this signaling, immunosuppression can be reversed so that T cell immunity against cancer cells can be re-established or enhanced. Exemplary immune checkpoint antagonists include, but are not limited to, PD-1 and its ligands, PD-L1 and PD-L2; TIGIT and its CD155 ligand, PVR; LAG-3 and its ligands, including liver sinusoidal endothelial cell lectin (LSECtin) and galectin-3; CTLA-4 and its ligands, B7-1 and B7-2; TIM-3 and its ligand, galectin-9; CD122 and its CD122R ligand; CD70, B7H3, B and T lymphocyte attenuator (BTLA), and VISTA. Immune checkpoint regulator antagonists may include antibody fragments, peptide inhibitors, dominant negative peptides, and small molecule drugs, which may be in isolated form or as part of a fusion protein or conjugate.

[0098] The phrases "immune checkpoint binding agonist" and "immune checkpoint agonist" are used interchangeably herein and are a class of agents that stimulate immune checkpoint regulators, so that the result of binding to a checkpoint regulator or its ligand is that the signal via the checkpoint regulator receptor is stimulated. By stimulating this signal, the T cell immunity against cancer cells can be re-established or enhanced. Exemplary immune checkpoint regulator agonists include but are not limited to members of the tumor necrosis factor (TNF) receptor superfamily, such as CD27, CD40, OX40 (CD 134), glucocorticoid-induced TNFR family-related protein (GITR), and 4-1BB (CD137), and its ligand. Other checkpoint regulator agonists belong to the B7-CD28 superfamily, including CD28 and ICOS. Immune checkpoint regulators may include antibody fragments, peptide inhibitors, dominant negative peptides, and small molecule drugs, which may be in isolated form or as part of a fusion protein or complex.

[0099] The term "antagonist antibody" refers to an antibody that binds to a target and prevents or reduces the biological effect of the target. In certain embodiments, the term may refer to an antibody that prevents the target (e.g., PD-1) to which it binds from performing a biological function.

[0100] As used herein, "anti-PD-1 antagonist antibodies" refer to antibodies that can inhibit PD-1 biological activity and / or downstream events mediated by PD-1. Anti-PD-1 antagonist antibodies include blocking, antagonizing, inhibiting or reducing (to any extent, including significantly) PD-1 biological activity, including downstream events mediated by PD-1, such as PD-1 binding and downstream signaling, inhibiting T cell proliferation, inhibiting T cell activation, inhibiting IFN secretion, inhibiting IL-2 secretion, inhibiting TNF secretion, inducing IL-10, and inhibiting anti-tumor immune response. For the purposes of the present invention, it should be clearly understood that the term "anti-PD-1 antagonist antibody" (interchangeable with the term "antagonist PD-1 antibody", "antagonist anti-PD-1 antibody", or "PD-1 antagonist antibody") includes all of the aforementioned confirmed terms, titles, and functional states and characteristics, thereby substantially eliminating, reducing or neutralizing PD-1 itself, PD-1 biological activity, or the results of such biological activity to any meaningful extent. In certain embodiments, the anti-PD-1 antagonist antibody binds to PD-1 and positively modulates the anti-tumor immune response.

[0101] As used herein, "anti-PD-L1 antagonist antibodies" refer to antibodies that can inhibit PD-1 biological activity and / or downstream events mediated by PD-L1. Anti-PD-L1 antagonist antibodies include blocking, antagonizing, inhibiting or reducing (to any extent, including significantly) PD-L1 biological activity, including downstream events mediated by PD-L1, such as PD-L1 binding and downstream signaling, inhibiting T cell proliferation, inhibiting T cell activation, inhibiting IFN secretion, inhibiting IL-2 secretion, inhibiting TNF secretion, inducing IL-10, and inhibiting anti-tumor immune response. For the purposes of the present invention, it should be clearly understood that the term "anti-PD-L1 antagonist antibody" (interchangeable with the term "antagonist PD-L1 antibody", "antagonist anti-PD-L1 antibody", or "PD-L1 antagonist antibody") includes all of the aforementioned confirmed terms, titles, and functional states and characteristics, thereby substantially eliminating, reducing or neutralizing PD-L1 itself, PD-L1 biological activity, or the results of the biological activity to any meaningful extent. The anti-PD-L1 antagonist antibody is designed to bind to PD-L1 and positively regulate the anti-tumor immune response.

[0102] The phrase "dominant-negative protein" or "dominant-negative peptide" refers to a protein or peptide derived from a wild-type protein that has been modified, typically by mutation and / or deletion, such that the modified protein or peptide interferes with the function of the endogenous wild-type protein from which it is derived.

[0103] The phrase "VEGF binding antagonist" refers to a functional class of agents that bind to VEGF-A or its receptor, VEGFR-2, thereby blocking or inhibiting VEGFR-2 activation by VEGF-A. As used herein, the term "VEGF binding antagonist" includes antibody fragments, peptide inhibitors, dominant negative peptides, and small molecule drugs, which can be in isolated form or as part of a fusion protein or conjugate.

[0104] The phrase "Tie2 tyrosine kinase receptor binding antagonist" refers to a functional class of agents that bind to the Tie2 tyrosine kinase receptor or one of its ligands, thereby, upon binding, blocking or inhibiting Tie2 tyrosine kinase receptor activation by one or more of its ligands (i.e., Ang1, Ang2, Ang3, and Ang4). As used herein, the term "Tie2 tyrosine kinase receptor binding antagonist" includes antibody fragments, peptide inhibitors, dominant negative peptides, and small molecule drugs, which can be in isolated form or as part of a fusion protein or complex.

[0105] The phrase "wherein one or more mutations reduce proteolytic cleavage of the anti-tumor antagonist" should be interpreted as relating to otherwise identical antagonists containing a wild-type ECD.

[0106] The phrase "small molecule drug" refers to a molecular entity that is typically organic or organometallic and non-polymeric, that has pharmaceutical activity and has a molecular weight of less than about 2 kDa, less than about 1 kDa, less than about 900 Da, less than about 800 Da, or less than about 700 Da. Although small peptides or nucleic acid analogs may be considered small molecule drugs, the phrase encompasses most pharmaceutical compounds other than proteins or nucleic acids that are referred to as "drugs." Examples include chemotherapeutic anticancer drugs and enzyme inhibitors. Small molecule drugs can be synthesized, semi-synthesized (i.e., from naturally occurring precursors), or obtained biologically.

[0107] When describing polypeptide regions with hyphens between the various regions (eg, CH2-CH3), it is understood that the regions are listed in order from amino-terminus to carboxyl-terminus.

[0108] The term "immunoconjugate" refers to an antibody fused to an inhibitory peptide or small molecule drug by a covalent linkage. The peptide or small molecule drug can be linked to the C-terminus of the constant heavy chain or the N-terminus of the variable light chain and / or heavy chain.

[0109] A "linker" can be used to link a peptide or small molecule drug (e.g., maytansinoid) to an anti-tumor antagonist in a stable, covalent manner. Under conditions where the compound or antibody remains active, the linker may be susceptible to or substantially unaffected by acid-induced cleavage, photo-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage. Suitable linkers are known in the art and include, for example, disulfide groups, thioether groups, acid-labile groups, photo-labile groups, peptidase-labile groups, and esterase-labile groups. As described herein and as known in the art, linkers also include GGGGS, charged linkers, and hydrophilic forms thereof. The immunoconjugate may further include a flexible 3-15 amino acid peptide (or spacer) between the anti-tumor antagonist and the peptide and / or small molecule drug. In some embodiments, the linker comprises 3, 4, 5, 6, 7, or 8 repeats of GGGGS. In some embodiments, the linker consists of 3 or 4 repeats of GGGGS.

[0110] As used herein, the term "scaffold" refers to any amino acid polymer that exhibits the properties required to support antagonist function, including increasing antibody specificity, enhancing antibody function, or supporting antibody structure and stability. The scaffold can be grafted with the binding region of a donor polypeptide to impart the binding specificity of the donor polypeptide to the scaffold.

[0111] As used herein, the phrase "multispecific inhibitor" refers to a molecule comprising at least two targeting domains with different binding specificities. In some embodiments, the multispecific inhibitor comprises a scaffold and a polypeptide comprising two or more immunoglobulin antigen-binding regions that target different antigens or epitopes. In certain embodiments, the multispecific inhibitor is a bispecific antibody or antagonist. In other embodiments, the multispecific inhibitor is a trispecific antibody or antagonist.

[0112] As used herein, the phrase "bispecific" refers to a molecule comprising at least two targeting domains with different binding specificities. Each targeting domain is capable of specifically binding to a target molecule and, after binding to the target molecule, inhibiting the biological function of the target molecule. In some embodiments, the bispecific checkpoint regulator antagonist is a polymeric molecule having two or more peptides. In some embodiments, the targeting domain comprises an antigen-binding region or CDR of an antibody. In some embodiments, the bispecific inhibitor is a bispecific antibody.

[0113] The terms "bispecific antibody" and "bispecific antagonist" are used interchangeably herein and refer to antibodies that specifically bind to two different antigens (or epitopes). In some embodiments, the bispecific antibody is a full-length antibody that binds to one antigen (or epitope) on one of its two binding arms (a pair of HC / LC) and binds to a different antigen (or epitope) on its second binding arm (a different pair of HC / LC). In these embodiments, the bispecific antibody has two different antigen-binding arms (in terms of both specificity and CDR sequence) and is monovalent for each antigen to which it binds.

[0114] In other embodiments, the bispecific antibody is a full-length antibody that can bind two different antigens (or epitopes) on each of its binding arms (two pairs of HC / LC). In these embodiments, the bispecific antibody has two identical antigen-binding arms (with identical specificity and identical CDR sequences), and each of the antigens bound thereto is bivalent.

[0115] Exemplary bispecific antibodies may include asymmetric IgG-like antibodies (e.g., triomab / quadroma, Trion Pharma / Fresenius Biotech); knobs-into-holes antibodies (Genentech); Cross MAbs (Roche); electrostatic pairing antibodies (AMGEN); LUZ-Y (Genentech); chain exchange domain (SEED) antibodies (EMDSerono, biolonic, Merus); Fab-exchange antibodies (Genmab); symmetric IgG-like antibodies (e.g., dual targeting (DT)-Ig (GSK / Domantis); two-in-one antibodies (Genentech); cross-linked MAbs (Karmanos Cancer Center), mAb 2(F-star); Cov X-body (Cov X / Pfizer); dual variable domain (DVD)-Ig fusion (Abbott); IgG-like bispecific antibody (Eli Lilly); Ts2Ab (Medimmune / AZ); BsAb (ZymoGenetics); HERCULES (Biogen Idec, TvAb, Roche); scFv / Fc fusion; SCORPION (Emergent BioSolutions / Trubion, ZymoGenetics / BMS); dual affinity retargeting technology (Fc-DART), MacroGenics; bi-(scFv)2-Fabs (National Center for Antibody Drug Development); F(ab)2 fusions (Medarex / AMGEN); dual-acting or Bis-Fab (Genentech); Dock-and-Lock (DNL, ImmunoMedics); Fab-Fv (UCB-Celltech); scFv- and diabody-based antibodies (e.g., bispecific T cell-engaging antibodies (BiTEs, Micromet); tandem diabodies (Tandab, Affimed); DARTs (MacroGenics); single-chain antibodies; TCR-like antibodies (AIT, Receptor Logics); human serum albumin scFv fusions (Merrimack); combodies (Epigen Biotech); and IgG / non-IgG fusions (e.g., immunocytokines (EMDSerono, Philogen, ImmunGene, ImmunoMedics).

[0116] The terms "treat" and "treatment" refer to ameliorating one or more symptoms associated with a cell proliferative disorder; preventing or delaying the onset of one or more symptoms of a cell proliferative disorder; and / or lessening the severity or frequency of one or more symptoms of a cell proliferative disorder.

[0117] The phrases "to a patient in need thereof," "to a patient in need of treatment," or "a subject in need of treatment" include subjects (e.g., mammalian subjects) who would benefit from administration of the anti-tumor antagonists of the disclosure for treatment of a cell proliferative disorder.

[0118] The terms "therapeutically effective amount," "pharmacologically effective amount," and "physiologically effective amount" are used interchangeably to refer to the amount of an anti-tumor antagonist required to provide a threshold level of active antagonist in the bloodstream or in the target tissue. The exact amount depends on many factors (e.g., the specific active agent, the ingredients and physical properties of the composition, the intended patient population, patient considerations, etc.) and can be readily determined by one skilled in the art based on the information provided herein or other available information from the relevant literature.

[0119] As used herein, the terms "improve," "increase," or "decrease" refer to a value or parameter measured relative to a baseline value, such as that measured in the same individual before starting a treatment described herein, or in a control individual (or multiple control individuals) in the absence of a treatment described herein.

[0120] A "control individual" is an individual with the same cell proliferative disorder as the treated individual and is approximately the same age as the treated individual (to ensure that the disease stages of the treated individual and the control individual are comparable). The treated individual (also referred to as a "patient" or "subject") can be a fetus, infant, child, adolescent, or adult with a cell proliferative disorder.

[0121] The term "cell proliferative disorder" refers to a disorder characterized by abnormal cell proliferation. A proliferative disorder does not imply any limitation in the rate of cell growth, but rather a loss of normal controls that influence growth and cell division. Thus, in some embodiments, cells with a proliferative disorder may have the same cell division rate as normal cells but may not respond to signals that limit their growth. Neoplasms, cancers, or tumors are included within the scope of "cell proliferative disorders."

[0122] The term "cancer" or "tumor" refers to any of a variety of malignant neoplasms characterized by cell proliferation, characterized by the ability to invade surrounding tissues and / or metastasize to new colonization sites, and includes leukemia, lymphoma, carcinoma, melanoma, sarcoma, germ cell tumor, and blastoma. Exemplary cancers treated by the methods of the present disclosure include brain cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, head and neck cancer, kidney cancer, lung cancer, non-small cell lung cancer, mesothelioma, ovarian cancer, prostate cancer, gastric cancer and uterine cancer, leukemia, and medulloblastoma.

[0123] The term "leukemia" refers to a progressive malignant disease of the hematopoietic organs and is usually characterized by abnormal proliferation and development of white blood cells and their precursors in the blood and bone marrow. Exemplary leukemias include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute promyelocytic leukemia, adult T-cell leukemia, leukocytic leukemia, nonleukocytic leukemia, basophilic leukemia, blast cell leukemia, bovine leukemia, chronic myeloid leukemia, leukemia cutis, embryonic leukemia, eosinophilic leukemia, Gross' leukemia, hairy cell leukemia, hematopoietic leukemia, hematoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphocytic leukemia, lymphoblastic leukemia, lymphocytic leukemia, leukemia), lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, plasmacytic leukemia, promyelocytic leukemia, Riedercel cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemic leukemia leukemia), and undifferentiated cell leukemia.

[0124] The term "carcinoma" refers to a malignant growth of epithelial cells that tends to infiltrate surrounding tissues and metastasize. Exemplary malignant tumors include, for example, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, adrenocortical carcinoma, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma sclera encuirasse), skin cancer, cylindrical carcinoma, cylindrical cell carcinoma, ductal carcinoma, carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epidermoid carcinoma, adenoid carcinoma (carcinoma epitheliale adenoides), exophytic carcinoma, ulcerative carcinoma, fibrous carcinoma, gelatiniform carcinoma, gelatinous carcinoma, giant cell carcinoma, giant cell carcinoma (carcinoma gigantocellulare), glandular carcinoma, granulosa cell carcinomacarcinoma, hair-matrix carcinoma, hematoid carcinoma, hepatocellular carcinoma, oncocytic carcinoma, hyaline carcinoma, hypemeproid carcinoma, infantile embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky-cell carcinoma, large-cell carcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatous carcinoma, lymphoepithelial carcinoma, carcinoma medullary, medullary carcinoma, melanotic carcinoma, carcinoma molle, mucinous carcinoma, carcinoma muciparum, carcinoma mucocellulare, mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes, naspharyngeal carcinoma, oat cell carcinoma, carcinoma ossificans, osteoid carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, prickle cell carcinoma, pultaceous carcinomacarcinoma, renal cell carcinoma, reserve cell carcinoma, carcinoma sarcomatodes, Schneiderian carcinoma, scirrhous carcinoma, carcinoma scroti, signet-ring cell carcinoma, carcinoma simplex, small cell carcinoma, solanoid carcinoma, spheroid cell carcinoma, spindle cell carcinoma, carcinoma spongiosum, squamous carcinoma, squamous cell carcinoma, string carcinoma, carcinoma telangiectaticum, carcinoma telangiectodes, transitional cell carcinoma, carcinoma tuberosum, tuberous carcinoma, verrucous carcinoma carcinoma), and carcinoma villosum.

[0125] The term "sarcoma" refers to a tumor composed of material similar to embryonic connective tissue and usually composed of tightly packed cells embedded in a fibrous or homogeneous substance. Exemplary sarcomas include, for example, chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft parts sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, choriocarcinoma, embryonal sarcoma, Wilson's tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, and ulcerative colitis. sarcoma), idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma (e.g., non-Hodgkin's lymphoma), immunoblastic sarcoma of T cells, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukosarcoma, malignant mesenchymoma sarcoma, parosteal sarcoma, reticulocytic sarcoma, Rous sarcoma, serocystic sarcoma sarcoma), synovial sarcoma and telangiectaltic sarcoma.

[0126] The term "melanoma" refers to a tumor arising from the melanocyte system of the skin or other organs. Melanomas include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigomaligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, and superficial spreading melanoma.

[0127] Other cancers include, for example, Hodgkin's disease, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, rhabdomyosarcoma, essential thrombocythemia, essential macroglobulinemia, small cell lung tumors, primary brain tumors, gastric cancer, colon cancer, malignant pancreatic insulinoma, malignant carcinoid tumors, premalignant skin lesions, testicular cancer, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, hypercalcemia of malignancy, cervical cancer, endometrial cancer, and adrenocortical carcinoma.

[0128] I. Bispecific antagonists targeting the TGF-β pathway

[0129] TGF-β is considered to be the main cytokine that mediates immunosuppression by inducing and maintaining T regulatory cells and directly inhibiting innate and adaptive immune cells (such as NK, DC and T cells). TGF-β also acts on angiogenesis and stabilization of tumor blood vessels, and directly affects tumors through epithelial-mesenchymal transition that leads to cell migration and invasion. As a potent inducer of angiogenesis, TGF-β1 provides a critical support system for solid tumors and plays an important role in the spread of tumor cells. Therefore, TGF-β status is a powerful predictor of anti-PD1 / PD-L1 resistance and overall survival for various cancers.

[0130] Many cells synthesize TGF-β and almost all of them have specific receptors for these peptides. TGF-β1, TGF-β2, and TGF-β3 all function through the same receptor signaling system. The active form of TGF-β is a dimer that signals by forming a membrane-bound heterotetramer composed of serine-threonine type 1 receptor and type 2 receptor (TGF-βRI and TGFβRII), respectively. In recent years, inhibitors of the TGF-β pathway have been developed, for example, in the form of antibodies or binding fragments directly targeting TGF-β1 or TGF-β1RII, such as dominant-negative fusion protein fragments containing the extracellular domain (ECD) of TGF-β1RII.

[0131] However, during the development of these binding agents, the inventors of the present application discovered that antagonists containing the TGFβ1RII ECD region exhibited unacceptable levels of protein degradation or truncation over time. To address this issue, variants of the TGFβ1RII ECD mutation that reduced truncation within this region have been developed. As further described herein, TGFβ1RII ECDs have been further combined with other binding agents targeting other checkpoint regulator pathways or angiogenesis pathways to generate bispecific antagonists with significantly reduced levels of protein degradation or truncation over time.

[0132] In one aspect, the present invention provides a bispecific antagonist that inhibits both the TGFβ pathway and the PD-1 / PD-L1 checkpoint regulator pathway.

[0133] In another aspect, the present invention provides a bispecific antagonist that inhibits the TGFβ pathway and the vascular endothelial growth factor (VEGF) pathway, the vascular endothelial growth factor receptor (VEFGR), or both.

[0134] A. Bispecific antagonists targeting TGF-β and PD-1 / PD-L1 pathways

[0135] In some embodiments, the bispecific antagonist comprises a first targeting domain that specifically inhibits the TGF-β pathway and a second targeting domain that specifically binds to PD-1 or PD-L1. In some embodiments, the first targeting domain comprises a TGF-β pathway inhibitor.

[0136] TGF-β pathway inhibitors

[0137] The TGF-β pathway involves a multifunctional group of peptides that control cell proliferation and differentiation, migration and adhesion, extracellular matrix modification (including tumor stroma and immunosuppression), angiogenesis and desmoplasia, apoptosis, and other functions in many cell types. TGF-β is considered to be the main cytokine that mediates immunosuppression by inducing and maintaining T regulatory cells and directly inhibiting innate and adaptive immune cells (such as NK, DC and T cells). TGF-β also acts on angiogenesis and stabilization of tumor blood vessels, and directly affects tumors through epithelial-mesenchymal transition that leads to cell migration and invasion. As a potent inducer of angiogenesis, TGF-β1 provides a critical support system for solid tumors and plays an important role in the dissemination of tumor cells.

[0138] TGF-β status is a strong predictor of anti-PD1 / PD-L1 resistance and overall survival in various cancers. For example, high TGF-β1 levels are associated with poor response to PD1 / PD-L1 inhibition in patients with metastatic urothelial carcinoma (Nature (2018) 554(7693):544-548), while a high TGFβ signature is associated with poor prognosis in 33 different cancer types (Immunity (2018) 48:812-830). Inhibiting TGFβ while simultaneously targeting PD / PD-L1 can further unleash CD8 effector cells to kill tumor cells and stimulate other cell types to increase tumor killing capacity.

[0139] Many cells synthesize TGF-β, and nearly all of them have specific receptors for these peptides. TGF-β1, TGF-β2, and TGF-β3 all function through the same receptor signaling system. The active form of TGF-β is a dimer that signals by forming a membrane-bound heterotetramer composed of serine-threonine type 1 and type 2 receptors (TGF-βRI and TGFβRII), respectively.

[0140] As used herein, a TGF-β pathway inhibitor can be in the form of, for example, an antibody or binding fragment directed against TGF-β1 or TGF-β1RII, such as a dominant negative fusion protein fragment containing the extracellular domain (ECD) of TGF-β1RII.

[0141] TGF-β1RII ECD and variants

[0142] In some embodiments, the TGF-β pathway inhibitor comprises TGF-β1RII ECD. An exemplary human TGF-β1RII ECD (wild type) has the amino acid sequence set forth in SEQ ID NO: 89. The inventors of the present application have discovered that antagonists containing the TGFβ1RII ECD region exhibit unacceptable levels of protein degradation or truncation over time upon storage, as described in Example 9. Therefore, in some embodiments, the TGF-β pathway inhibitor of the present invention comprises a variant of the human TGF-β1RII ECD (hereinafter referred to as a "TGFBR variant") containing one or more modifications that reduce protein degradation or truncation. In some embodiments, the modification comprises a substitution of an amino acid residue, a deletion of an amino acid residue, an insertion of an amino acid residue, or a combination thereof. In some embodiments, the TGFBR variant comprises one or more substitution mutations at positions 6, 7, 13, 16, 17, 20, 22, and / or 23 of SEQ ID NO: 89. In some embodiments, the one or more substitution mutations are substitutions of a non-polar amino acid residue with a polar or hydrophobic amino acid residue.

[0143] In some embodiments, the TGFBR variant comprises one or more amino acid deletions compared to the wild-type human TGF-β1RII ECD sequence. In some embodiments, the one or more deletions are in the region comprising amino acid residues 1-20 of SEQ ID NO: 89, and may include any residue therein. In more specific embodiments, the one or more deletions comprise deletions of amino acid residues 1-7, 1-12, 1-13, 1-15, 1-20, 7-12, 7-13, 7-15, 7-20, 8-20, 9-20, 10-20, 11-20, 12-20, 13-20, 14-20, 15-20, 16-20, and / or 17-20 of SEQ ID NO: 89. In more specific embodiments, the one or more deletions comprise amino acid residues 6, 7, 12, 13, 15, 16, 17, or 20 of SEQ ID NO: 89.

[0144] In some embodiments, the TGFBR variant comprises: (1) a deletion of one or more amino acid residues in the region of amino acid residues 1-20 of SEQ ID NO: 89; and one or more substitutions of amino acid residues 6, 7, 13, 16, 17, 20, 22, and / or 23 of SEQ ID NO: 89. In some embodiments, the TGFBR variant comprises: (1) a deletion of amino acid residues 1-7 of SEQ ID NO: 89; and (2) an amino acid substitution of amino acid residues 13, 16, 17, 20, 22, and 23 of SEQ ID NO: 89, or a two-amino acid substitution of amino acid residues 16 and 17 of SEQ ID NO: 89. In some embodiments, one or more of amino acid residues 6, 7, 13, 16, 17, 20, 22, and / or 23 of SEQ ID NO: 89 is substituted with one or more polar amino acid residues. In some embodiments, one or more hydrophobic amino acid residues are substituted for one or more of amino acid residues 6, 7, 13, 16, 17, 20, 22, and / or 23 of SEQ ID NO:89.

[0145] In some embodiments, the TGFBR variant comprises a member selected from the group consisting of SEQ ID NOs: 114-123 and 251-270 ( Figures 41A-41C ) is an amino acid sequence of a group consisting of .

[0146] In some embodiments, the TGFBR variant comprises an immunoglobulin heavy chain comprising a sequence selected from the group consisting of SEQ ID NOs: 124-133, 148, 150, and 271-290 ( Figures 42A-42H , 44A).

[0147] In other embodiments, the TGFBR variant comprises an immunoglobulin heavy chain comprising SEQ ID NO: 145, SEQ ID NO: 147, or SEQ ID NO: 303 ( Figure 43 )'s amino acid sequence.

[0148] In other embodiments, the TGFBR variant comprises an immunoglobulin heavy chain comprising SEQ ID NO: 148, SEQ ID NO: 150, or SEQ ID NOs: 291-302 ( Figures 44A-44D )'s amino acid sequence.

[0149] It should be understood that regardless of whether the TGFBR variants described herein comprise an immunoglobulin heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 124-133, 145, 147, 148, 150, and 271-303 (hereinafter referred to as "specific amino acid sequences"), such embodiments should be further interpreted as representing other heavy chain embodiments in combination with all heavy chain sequences derived therefrom, wherein one or more existing anti-PD-1 amino acid sequences (including, for example, Figure 1 HCDR1, HCDR2 and HCDR3 listed), or one or more existing anti-PD-L1 amino acid sequences (including Figure 3 The listed HCDR1, HCDR2, and HCDR3) substitutions replace the existing anti-PD1 CDR sequence or anti-PD-L1 CDR sequence present in the "specified amino acid sequence".

[0150] Similarly, with respect to the preceding paragraph, any immunoglobulin light chain described as being paired with the heavy chain set forth in SEQ ID NOs: 124-133, 145, 147, 148, 150, and 271-303 should be further interpreted as representing other light chain embodiments in combination with all light chain sequences derived therefrom, wherein one or more of the existing anti-PD-1 amino acid sequences (including Figure 1 LCDR1, LCDR2 and LCDR3 listed), or one or more existing anti-PD-L1 amino acid sequences (including Figure 3 The listed LCDR1, LCDR2, and LCDR3) substitutions replace the existing anti-PD1 CDR sequence or anti-PD-L1 CDR sequence present in the "specific amino acid sequence".

[0151] Likewise, it should be understood that regardless of whether the TGFBR variants described herein comprise an immunoglobulin heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 124-133, 145, 147, 148, 150, and 271-303 (hereinafter referred to as "specific amino acid sequences"), such embodiments should be further interpreted as representing other heavy chain embodiments comprising combinations of all light chain sequences derived therefrom, wherein the "specific amino acid sequence" is replaced with an existing anti-PD1 heavy chain variable region (HCVR) amino acid sequence, wherein the anti-PD1 HCVR is selected from the group consisting of, for example, Figures 2A-2B The group consisting of SEQ ID NOs: 29, 31, 33, 35, 37 and 39 shown in the table, or wherein the existing anti-PD-L1 HCVR amino acid sequence is substituted for a different anti-PD-L1 HCVR in the "specific amino acid sequence", and the anti-PD-L1 HCVR is selected from the group consisting of Figures 4A-4CThe group consisting of SEQ ID NOs: 72, 74, 76, 78, 80, 82, 84 and 86 shown.

[0152] Similarly, with respect to the preceding paragraph, any immunoglobulin light chain described as being paired with the aforementioned heavy chain in a "specific amino acid sequence" should be further interpreted as meaning other light chain embodiments including combinations of all light chain sequences derived therefrom, wherein the existing anti-PD1 light chain variable region (LCVR) amino acid sequence in the "specific amino acid sequence" is replaced with a different anti-PD1 LCVR selected from the group consisting of Figures 2A-2B The group consisting of SEQ ID NOs: 30, 32, 34, 36, 38 and 40 shown in FIG, or wherein the existing anti-PD-L1 LCVR amino acid sequence is substituted for a different anti-PD-L1 LCVR in the "specific amino acid sequence", the anti-PD-L1 LCVR being selected from the group consisting of Figures 4A-4C The group consisting of SEQ ID NOs: 73, 75, 77, 79, 81, 83, 85 and 87 shown.

[0153] In some embodiments, a TGF-β pathway inhibitor is fused to the carboxyl terminus of an IgG in a bispecific anti-tumor antagonist, such as, for example Figures 5A-5B , 8A-8C and 20A-20B. Alternatively, the TGF-β1RII ECD can be fused to the amino terminus of IgG in a bispecific anti-tumor antagonist. In another embodiment, the TGF-β1RII ECD is inserted into the IgG Fc receptor (i.e., CH2 or CH3 region) of IgG, such as Figure 5B Depicted.

[0154] In some embodiments, anti-TGF-β1, anti-TGF-β1RII, or a variable region fragment thereof can be used to replace the TGF-β1RII ECD. Exemplary anti-TGF-β1 antibodies are described in U.S. Pat. Nos. 7,067,637, 7,494,651, 7,527,791, and 7,619,069. Exemplary anti-TGF-β1RII antibodies are described in U.S. Pat. No. 7,579,186. Alternatively, the TGF-β1RII ECD can be replaced with one or more anti-TGF-β1 and / or anti-TGF-β1RII peptide inhibitors. An exemplary TGF-β1 peptide inhibitor is KRIWFIPRSSWYERA (SEQ ID NO: 155).

[0155] Anti-PD-1 antibodies and anti-PD-1 antibody fragments

[0156] In some embodiments, the bispecific TGFβ pathway antagonist comprises an anti-PD-1 antibody or antibody fragment. In one embodiment, the PD-1 inhibitor used in the present invention is an antibody, or an antigen-binding portion thereof, comprising: an immunoglobulin heavy chain complementarily determining region 1 (CDR1) sequence selected from the group consisting of SEQ ID NOs: 1, 4, 7, 9, and 12; an immunoglobulin heavy chain CDR2 sequence selected from the group consisting of SEQ ID NOs: 2, 5, 10, and 13; an immunoglobulin heavy chain CDR3 sequence selected from the group consisting of SEQ ID NOs: 3, 6, 8, 11, and 14; an immunoglobulin light chain CDR1 sequence selected from the group consisting of SEQ ID NOs: 15, 18, 21-23, and 26; an immunoglobulin light chain CDR2 sequence selected from the group consisting of SEQ ID NOs: 16, 19, 24, and 27; or an immunoglobulin light chain CDR3 sequence selected from the group consisting of SEQ ID NOs: 17, 20, 25, and 28.

[0157] In another embodiment, the PD-1 inhibitor (e.g., the second targeting domain) used in the present invention is an antibody, or an antigen-binding portion thereof, comprising: an immunoglobulin heavy chain CDR1 sequence selected from the group consisting of SEQ ID NOs: 1, 4, 7, 9, and 12; an immunoglobulin heavy chain CDR2 sequence selected from the group consisting of SEQ ID NOs: 2, 5, 10, and 13; an immunoglobulin heavy chain CDR3 sequence selected from the group consisting of SEQ ID NOs: 3, 6, 8, 11, and 14; an immunoglobulin light chain CDR1 sequence selected from the group consisting of SEQ ID NOs: 15, 18, 21-23, and 26; an immunoglobulin light chain CDR2 sequence selected from the group consisting of SEQ ID NOs: 16, 19, 24, and 27; or an immunoglobulin light chain CDR3 sequence selected from the group consisting of SEQ ID NOs: 17, 20, 25, and 28.

[0158] In another embodiment, the PD-1 inhibitor for use in the present invention comprises: an immunoglobulin heavy chain variable region (HCVR) having at least 80%, 85%, 90%, 95%, or 99% identity to a HCVR amino acid sequence selected from the group consisting of SEQ ID NOs: 29, 31, 33, 35, 37, and 39; an immunoglobulin light chain variable region (LCVR) having at least 80%, 85%, 90%, 95%, or 99% identity to a LCVR amino acid sequence selected from the group consisting of SEQ ID NOs: 30, 32, 34, 36, 38, and 40; or both.

[0159] In another embodiment, the PD-1 inhibitor used in the present invention comprises: an HCVR amino acid sequence selected from the group consisting of SEQ ID NOs: 29, 31, 33, 35, 37, and 39; an LCVR amino acid sequence selected from the group consisting of SEQ ID NOs: 30, 32, 34, 36, 38, and 40; or both.

[0160] In one embodiment, the PD-1 inhibitor comprises: a HCVR having at least 80%, 85%, 90%, 95%, or 99% identity to the HCVR amino acid sequence of SEQ ID NO: 39; a LCVR having at least 80%, 85%, 90%, 95%, or 99% identity to the LCVR amino acid sequence of SEQ ID NO: 40; or both.

[0161] In another embodiment, the PD-1 inhibitor has an immunoglobulin heavy chain variable region comprising: (1) HCDR1 of SEQ ID NO: 12; HCDR2 of SEQ ID NO: 13; and HCDR3 of SEQ ID NO: 14, (2) HFR1 having at least 80%, 85%, or 90% identity to the amino acid sequence of SEQ ID NO: 196; HFR2 having at least 80%, 85%, or 90% identity to the amino acid sequence of SEQ ID NO: 190; HFR3 having at least 80%, 85%, or 90% identity to the amino acid sequence of SEQ ID NO: 201; and HFR4 having at least 80%, 85%, or 90% identity to the amino acid sequence of SEQ ID NO: 187, and an immunoglobulin light chain variable region comprising: (1) LCDR1 of SEQ ID NO: 26; LCDR2 of SEQ ID NO: 27; and LCDR3 of SEQ ID NO: 28, (2) an HFR1 having at least 80%, 85%, or 90% identity to the amino acid sequence of SEQ ID NO: 190; The amino acid sequence of NO:202 has an LFR1 that is at least 80%, 85% or 90% identical to the amino acid sequence of SEQ ID NO:203; the LFR3 has at least 80%, 85% or 90% identity to the amino acid sequence of SEQ ID NO:204; and the LFR4 has at least 80%, 85% or 90% identity to the amino acid sequence of SEQ ID NO:205.

[0162] In another embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-1 inhibitor comprising: an immunoglobulin heavy chain having at least 80%, 85%, 90%, 95%, or 99% identity to the amino acid sequence of SEQ ID NO: 92 or SEQ ID NO: 113; an immunoglobulin light chain having at least 80%, 85%, 90%, 95%, or 99% identity to the amino acid sequence of SEQ ID NO: 93; or both. In a more specific embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-1 inhibitor comprising: an immunoglobulin heavy chain having the amino acid sequence of SEQ ID NO: 92 or SEQ ID NO: 113; an immunoglobulin light chain having the amino acid sequence of SEQ ID NO: 93; or both.

[0163] In another embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-1 inhibitor comprising: an immunoglobulin heavy chain having at least 80%, 85%, 90%, 95%, or 99% identity to the amino acid sequence of SEQ ID NO: 94 or SEQ ID NO: 172; an immunoglobulin light chain having at least 80%, 85%, 90%, 95%, or 99% identity to the LCVR amino acid sequence of SEQ ID NO: 95; or both of the foregoing. In a more specific embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-1 inhibitor comprising: an immunoglobulin heavy chain having the amino acid sequence of SEQ ID NO: 94 or SEQ ID NO: 172; an immunoglobulin light chain having the amino acid sequence of SEQ ID NO: 95; or both of the foregoing. In another embodiment, the PD-1 / TGF-β1 anti-tumor antagonist comprises as Figure 5B Depicted is the TGF-β1RII ECD inserted within the CH3 loop.

[0164] In one embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-1 inhibitor comprising: a heavy chain having at least 80%, 85%, 90%, 95%, or 99% identity to the amino acid sequence of SEQ ID NO: 151; a light chain having at least 80%, 85%, 90%, 95%, or 99% identity to the amino acid sequence of SEQ ID NO: 152; or both. In a more specific embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-1 inhibitor comprising: an immunoglobulin heavy chain having the amino acid sequence of SEQ ID NO: 151; an immunoglobulin light chain having the amino acid sequence of SEQ ID NO: 152; or both.

[0165] Other PD-1-targeted antagonists include anti-PD-1 antibodies, such as nivolumab (BMS-936558, MDX-1106, OPDIVO TM ), human immunoglobulin G4 (IgG4) mAb (Bristol-Myers Squibb); pembrolizumab (MK-3475, lambrolizumab, Keytruda TM ), humanized immunoglobulin G4 (IgG4) mAb (Merck); pidilizumab (CT-011) (Medivation); and AMP-224 (Merck). Anti-PD-1 antibodies are commercially available, for example, from ABCAM (AB137132), BIOLEGEND TM (EH12.2H7, RMP1-14) and AFFYMETRIX EBIOSCIENCE (J105, J116, MIH4). Anti-PD-1 targeted anti-tumor antagonists may include any HCVRs, LCVRs, and / or CDRs derived from any of the anti-PD-1 antibodies described herein, including Figure 1 -2 depicted.

[0166] Anti-PD-L1 antibodies and anti-PD-L1 antibody fragments

[0167] In some embodiments, the bispecific TGF-β1 pathway antagonist further comprises an anti-PD-L1 antibody or antibody fragment. In one embodiment, the PD-L1 inhibitor for use in the present invention is an antibody, or an antigen-binding portion thereof, comprising: an immunoglobulin heavy chain CDR1 sequence selected from the group consisting of SEQ ID NOs: 41, 44, 50, and 53; an immunoglobulin heavy chain CDR2 sequence selected from the group consisting of SEQ ID NOs: 42, 45, 47, 49, 51, and 54; an immunoglobulin heavy chain CDR3 sequence selected from the group consisting of SEQ ID NOs: 43, 46, 48, 52, and 55; an immunoglobulin light chain CDR1 sequence selected from the group consisting of SEQ ID NOs: 56, 59, 63, 66, and 69; an immunoglobulin light chain CDR2 sequence selected from the group consisting of SEQ ID NOs: 57, 60, 64, 67, and 70; or an immunoglobulin light chain CDR3 sequence selected from the group consisting of SEQ ID NOs: 58, 61, 62, 65, 68, and 71.

[0168] In another embodiment, the PD-L1 inhibitor (e.g., the second targeting domain) used in the present invention is an antibody, or an antigen-binding portion thereof, comprising: an immunoglobulin heavy chain CDR1 sequence selected from the group consisting of SEQ ID NOs: 41, 44, 50, and 53; an immunoglobulin heavy chain CDR2 sequence selected from the group consisting of SEQ ID NOs: 42, 45, 47, 49, 51, and 54; an immunoglobulin heavy chain CDR3 sequence selected from the group consisting of SEQ ID NOs: 43, 46, 48, 52, and 55; an immunoglobulin light chain CDR1 sequence selected from the group consisting of SEQ ID NOs: 56, 59, 63, 66, and 69; an immunoglobulin light chain CDR2 sequence selected from the group consisting of SEQ ID NOs: 57, 60, 64, 67, and 70; or an immunoglobulin light chain CDR3 sequence selected from the group consisting of SEQ ID NOs: 58, 61, 62, 65, 68, and 71.

[0169] In another embodiment, the PD-L1 inhibitor for use in the present invention comprises an immunoglobulin HCVR having at least 80%, 85%, 90%, 95%, or 99% identity to a HCVR amino acid sequence selected from the group consisting of SEQ ID NOs: 72, 74, 76, 78, 80, 82, 84, and 86; an immunoglobulin LCVR having at least 80%, 85%, 90%, 95%, or 99% identity to a LCVR amino acid sequence selected from the group consisting of SEQ ID NOs: 73, 75, 77, 79, 81, 83, 85, and 87; or both. In another embodiment, the PD-L1 inhibitor for use in the present invention comprises: a HCVR amino acid sequence selected from the group consisting of SEQ ID NOs: 72, 74, 76, 78, 80, 82, 84, and 86; a LCVR amino acid sequence selected from the group consisting of SEQ ID NOs: 73, 75, 77, 79, 81, 83, 85, and 87; or both.

[0170] In one embodiment, the PD-L1 inhibitor comprises: a HCVR having at least 80%, 85%, 90%, 95%, or 99% identity to the HCVR amino acid sequence of SEQ ID NO: 86; a LCVR having at least 80%, 85%, 90%, 95%, or 99% identity to the LCVR amino acid sequence of SEQ ID NO: 87; or both. In a more specific embodiment, the PD-L1 inhibitor comprises: a HCVR having the amino acid sequence of SEQ ID NO: 86; a LCVR having the amino acid sequence of SEQ ID NO: 87; or both.

[0171] In another embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-L1 inhibitor comprising: an immunoglobulin heavy chain having at least 80%, 85%, 90%, 95%, or 99% identity to the amino acid sequence of SEQ ID NO: 94 or SEQ ID NO: 172; an immunoglobulin light chain having at least 80%, 85%, 90%, 95%, or 99% identity to the amino acid sequence of SEQ ID NO: 95; or both. In a more specific embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-L1 inhibitor comprising: an immunoglobulin heavy chain having the amino acid sequence of SEQ ID NO: 94 or SEQ ID NO: 172; an immunoglobulin light chain having the amino acid sequence of SEQ ID NO: 95; or both.

[0172] In another embodiment, the PD-L1 / TGF-β1 anti-tumor antagonist includes Figure 5B Depicted is the TGF-β1RII ECD inserted within the CH3 loop.

[0173] In a specific embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-L1 inhibitor comprising: an immunoglobulin heavy chain having at least 80%, 85%, 90%, 95%, or 99% identity to the amino acid sequence of SEQ ID NO: 153; an immunoglobulin light chain having at least 80%, 85%, 90%, 95%, or 99% identity to the amino acid sequence of SEQ ID NO: 154; or both. In a more specific embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-L1 inhibitor comprising: an immunoglobulin heavy chain having the amino acid sequence of SEQ ID NO: 153; an immunoglobulin light chain having the amino acid sequence of SEQ ID NO: 154; or both.

[0174] Other anti-PD-L1 targeted antagonists include anti-PD-L1 antibodies, such as atezolizumab (MPDL3280A, RG7446, Tecentriq); fully humanized IgG1 mAb (Genentech / Roche); BMS-936559 (MDX-1105); fully human IgG4 mAb (Bristol-Myers Squibb); durvalumab (MEDI4736, Imfinzi); human IgG1 antibody (Medimmune / AstraZeneca); and avelumab (MSB0010718C, Bavencio), a fully human IgG4 monoclonal antibody (Merck, EMD Serono). Anti-PD-L1 targeted anti-tumor antagonists may include any HCVRs, LCVRs, and / or CDRs derived from any of the anti-PD-L1 antibodies described herein, including Figure 3 -4 mentioned.

[0175] B. Bispecific antagonists targeting TGF-β1 and angiogenesis pathways

[0176] In another aspect, the bispecific anti-tumor antagonists of the present invention include a first targeting domain that specifically binds to TGFβ1 or TGFβ1RII and a second targeting domain that specifically binds to VEGF-A, VEGFR, Ang1, Ang2, Tie2R, or a combination thereof. In these embodiments, any of the TGFβ1- or TGFβ1RII-binding fragments described above can be used in combination with the second targeting domain.

[0177] Angiogenesis pathway

[0178] Angiogenesis (the development of new blood vessels from existing ones) is essential for tumor growth and migration. Inhibiting angiogenesis is a potentially valuable strategy for treating diseases such as cancer, where the course of the disease (e.g., metastasis) depends on the formation of new blood vessels. Inhibiting angiogenesis leads to tumor cell death, which can supply tumor antigens to the host's antigen presentation pathways. Angiogenesis pathway inhibitors can be in the form of, for example, antibodies, variable region fragments, or dominant-negative fusion protein fragments.

[0179] 1.VEGF / VEGFR pathway

[0180] The main VEGF pathway is mediated by the transmembrane tyrosine kinase VEGF R2. Various VEGF isoforms (especially VEGF-A) bind to VEGF-R2, causing it to dimerize and activate through phosphorylation by various downstream tyrosine kinases.

[0181] In some embodiments, the antagonists of the present invention include VEGF pathway antagonists that bind to VEGF-A or its receptor VEGFR-2, thereby blocking or inhibiting VEGFR-2 activation by VEGF-A upon binding.

[0182] In one embodiment, the TGFβ pathway antagonist further includes a VEGF pathway antagonist in the form of a dominant-negative VEGFR antagonist corresponding to the extracellular domain (ECD) of human VEGF receptor 1 or 2. In a specific embodiment, the TGFβ pathway antagonist includes aflibercept (also known as Zaltrap), a recombinant fusion protein containing a VEGF-A binding region, which is a fusion of the extracellular domains of human VEGF receptors 1 and 2 with the Fc portion of human IgG1. VEGFR ECDs (e.g., aflibercept) serve as soluble receptor decoys for VEGF-A.

[0183] In one embodiment, the bispecific anti-tumor antagonist comprises a first targeting domain comprising a TGFβ pathway inhibitor and a second targeting domain that specifically binds to VEGF-A, wherein the second targeting domain comprises aflibercept. A suitable source of aflibercept comprises the amino acid sequence set forth in SEQ ID NO: 88. In some embodiments, the bispecific anti-tumor antagonist comprises a modified immunoglobulin heavy chain comprising Figure 8C The amino-terminal aflibercept domain is shown, with its carboxyl terminus linked to the TGF-β1RII ECD or TGF-β1RII ECD variant via an IgG1 or IgG4 Fc receptor (Bi-ZB-1). In one embodiment, the modified immunoglobulin heavy chain has the amino acid sequence of SEQ ID NO: 105. Alternatively, the TGF-β1RII ECD or TGF-β1RII ECD variant can be located at the amino terminus, and the aflibercept domain can be located at the carboxyl terminus.

[0184] In another embodiment, the TGFβ pathway antagonist further comprises a VEGF pathway antagonist, wherein the VEGF pathway antagonist comprises an anti-VEGFA or anti-VEGFR2 variable region sequence, such as one derived from bevacizumab. TM) is a humanized antibody comprising human IgG1 framework regions (FRs) and antigen-binding complementarity-determining regions from mouse anti-hVEGF monoclonal antibody A.4.6.1, which blocks binding of human VEGF-A to VEGFR1 and VEGFR-2. Approximately 93% of the bevacizumab amino acid sequence (including most of the framework regions) is derived from human IgG1, and approximately 7% of the sequence is derived from mouse antibody A4.6.1. Bevacizumab has a molecular mass of approximately 149,000 daltons and is glycosylated. In one embodiment, the bevacizumab HCVR used in the present invention has the amino acid sequence set forth in SEQ ID NO:90, and the bevacizumab LCVR has the amino acid sequence set forth in SEQ ID NO:91.

[0185] In some embodiments, the bevacizumab / Avastin antibody or fragment thereof described in U.S. Patent No. 7,575,893 may include amino acid substitutions. Exemplary amino acid substitutions include, but are not limited to, E1Q, E6Q, L11V, Q13K, L18V, R19K, A23K, or combinations thereof. In one embodiment, the mutant HCVR of bevacizumab used in the present invention has the amino acid sequence set forth in SEQ ID NO:96, which can be used for conjugation with the LCVR of SEQ ID NO:91.

[0186] In one embodiment, the bispecific anti-tumor antagonist comprises a first targeting domain that specifically binds to TGFβ1, such as TGFβ1RII ECD (or contains an anti-TGFβ1 or anti-TGFβ1RII variable region), and comprises a second targeting domain that specifically binds to VEGFA or VEGFR2, such as bevacizumab or any other anti-VEGF or anti-VEGFR2 antibody, a variable region fragment thereof, or a functionally active mutant fragment thereof.

[0187] In a specific embodiment, the bispecific anti-tumor TGF-β / VEGF-VEGFR2 antagonist comprises an immunoglobulin heavy chain having the amino acid sequence of SEQ ID NO: 102, an immunoglobulin light chain having the amino acid sequence of SEQ ID NO: 103, or both, such as Bi-AB-1 ( Figure 8A ), which contains the wild-type bevacizumab variable region sequence.

[0188] In another embodiment, the bispecific anti-tumor TGF-β antagonist further comprises an immunoglobulin heavy chain having the amino acid sequence of SEQ ID NO: 104, an immunoglobulin light chain having the amino acid sequence of SEQ ID NO: 103, or both, such as Bi-A1B-1 ( Figure 8B ), which contains a mutated bevacizumab variable region sequence.

[0189] Other anti-VEGF or anti-VEGFR antibodies or fragments thereof may be based on ranibizumab (trade name Lucentis TM ), monoclonal antibody fragments derived from the same parent mouse antibody as bevacizumab; G6 or B20 series antibodies (e.g., G6-23, G6-31, B20-4.1) described in U.S. Patent Publication Nos. 2006 / 0280747, 2007 / 0141065, and / or 2007 / 0020267, and described in U.S. Patent Nos. 7,297,334, 7,060, 269, 6,884,879, 6,582,959, 6,703,020, 6,054,297, and U.S. Patent Publication Nos. 2007 / 059312, 2006 / 009360, 2005 / 0186208, 2003 / 0206899, 2003 / 0190317, and 2003 / 0203409.

[0190] An exemplary anti-VEGFR-2 antibody antagonist is the humanized IgG1 monoclonal antibody Ramucirumab, which binds to the extracellular domain of VEGFR-2, thereby blocking its interaction with VEGF-A. Other anti-VEGFR-2 antibodies are described in U.S. Patent Nos. 7,498,414, 6,448,077, and 6,365,157.

[0191] In some embodiments, the anti-tumor antagonist may further include one or more small molecule antagonists of the VEGF pathway, such as multi-kinase inhibitors of VEGFR-2, including sunitinib, sorafenib, cediranib, pazonpanib, and nintedanib.

[0192] Ang-Tie2R pathway

[0193] In some embodiments, the bispecific antagonist comprises a targeting domain comprising at least one Tie2 receptor binding antagonist. The Tie2 tyrosine kinase receptor binding antagonist binds to the Tie2 tyrosine kinase receptor or one of its ligands (i.e., Ang1, Ang2, Ang3, and Ang4), thereby blocking or inhibiting activation of the Tie2 tyrosine kinase receptor by one or more ligands upon binding. Like VEGF, angiopoietin-2 (Ang2) plays a key role in tumor angiogenesis. ANG2 and VEGF also work together to prevent antigen presentation by dendritic cells and macrophages, enhance Treg aggregation, and inhibit Teff aggregation. It has been previously shown that inhibition of VEGF and Ang2 improves survival in the mouse breast cancer model Tg MMTV-PyMT. Moreover, the addition of anti-PD-1 can further improve the response.

[0194] Tie2 tyrosine kinase receptor binding antagonists used in the present invention may include antibody fragments, peptide inhibitors, dominant negative peptides, and small molecule drugs, either in isolated form or as part of a fusion protein or conjugate. In one embodiment, the Tie2 receptor binding antagonist is an inhibitory peptide derived from trebananib, TBN-P. In a specific embodiment, the inhibitory peptide comprises the following amino acid sequence: AQQEECEWDPWTCEHMGSGSATGGSGSTASSGSGSATHQEECEWDPWTCE HMLE (SEQ ID NO: 157). In another embodiment, the Tie2 receptor bound by the antagonist comprises SEQ ID NO: 158 (TBN-P-IgG).

[0195] Other peptide inhibitors that inhibit Tie2 activation (including Ang-2 inhibitors) for use in the present invention include A-11 (Compugen), which comprises the amino acid sequence: ETFLSTNKLENQ (SEQ ID NO: 167); CVX-060 peptide: QK(Ac)YQPLDEK(Ac)DK(OP)TLYDQFMLQQG (SEQ ID NO: 168, Pfizer); CVX-037 peptide: (DFB)TNFMPMDDLEK(OP)RLYEQFILQQG (SEQ ID NO: 169, Pfizer); and CGEN-25017 (Compugen). Other peptide inhibitors that inhibit Tie2 activation are described in U.S. Patent No. 7,138,370.

[0196] Antibody inhibitors that inhibit Tie2 activation (and / or Angiopoietin-2) for use in the present invention include AMG-780 (Amgen), MEDI-3617 (MedImmune / AstraZeneca), DX-2240 (Dyax / Sanofi-Aventis), REGN-910 (Sanofi / Regeneron), RG7594 (Roche), LC06 (Roche), TAvi6 (Roche), and AT-006 (Roche / Affitech). Other Tie2 receptor-binding antibody antagonists and their antibody-binding sequences are described in U.S. Patent Nos. 7,521,053, 7,658,924, and 8,030,025, and U.S. Patent Publication Nos. 2013 / 0078248, 2013 / 0259859, and 2015 / 0197578.

[0197] Tie2 binding antagonists used in the present invention may further include small molecule inhibitors: CGI-1842 (CGI Pharmaceuticals), LP-590 (Locus Pharmaceuticals), ACTB-1003 (Act Biotech / Bayer AG), CEP-11981 (Cephalon / Teva), MGCD265 (Methylgene), Regorafenib (Bayer), Cabozantinib / XL-184 / BMS-907351 (Exelixis), Foretnib (Exelixis), MGCD-265 (MethylGene Inc.).

[0198] In certain specific embodiments, the bispecific checkpoint regulator antagonist is a full-length antibody that binds to human PD-1 or PD-L1 on one of its two binding arms (a pair of HC / LC) and binds to a different antigen (or epitope) on its second binding arm (a different pair of HC / LC). In these embodiments, the bispecific antibody has two different antigen-binding arms (each with specificity and CDR sequences) and is monovalent for each antigen to which it is attached.

[0199] In some embodiments, the bispecific checkpoint regulator antagonist is a full-length antibody that can bind to human PD-1 and / or PD-L1 on each of its two binding arms (a pair of HC / LC). In these embodiments, the bispecific checkpoint regulator antagonist has two identical antigen-binding arms (with the same specificity and the same CDR sequence) and is bivalent to each of the antigens to which it is attached.

[0200] Immunoglobulin and non-immunoglobulin scaffolds

[0201] The bispecific anti-tumor antagonists of the present invention can be constructed using an immunoglobulin scaffold or a non-immunoglobulin scaffold as described herein. In some embodiments, the bispecific antagonists of the present invention are constructed using an immunoglobulin scaffold, such as an IgG1, IgG2, or IgG4 scaffold comprising a CH1, CH2, and / or CH3 region. When the target is present on an antigen-presenting cell that can mediate antibody-dependent cell-mediated cytotoxicity (ADCC), it is preferred to use an IgG1 scaffold for cancer treatment. When antigen binding alone is sufficient to produce the desired therapeutic benefit, the use of an IgG4 scaffold can target the antigen. IgG4-based antagonists prevent adverse effector functions associated with, for example, IgG1 antibodies, including FcγR binding and complement activation.

[0202] Preferably, the first and second targeting domains are present in a humanized IgG1 or IgG4 scaffold. Furthermore, the second targeting domain may be fused to the carboxyl terminus of the IgG1 or IgG4 scaffold. In addition, the IgG1 or IgG4 scaffold may have an amino acid substitution of N297A or K447A. In some embodiments, the first targeting domain may comprise one or more framework regions comprising one or more amino acid substitutions selected from the group consisting of E1Q, E6Q, L11V, Q13K, L18V, R19K, A23K, or any combination thereof. In other embodiments, one or more amino acid residues in the IgG1 or IgG4 scaffold are deglycosylated or mutated to generate a glycosyl variant. Exemplary immunoglobulin scaffolds for the bispecific molecules described herein may be selected from the group consisting of SEQ ID NOs: 159-166 and 173-175.

[0203] Any of the antibodies or antagonists can be constructed in the form of a monoclonal antibody, a chimeric antibody, a humanized antibody, a scFv, or a multispecific antibody. In addition, any antibody antagonist described herein may include multiple binding specificities that target PD-1, PD-L1, VEGF, VEGFR, angiogenin, and / or Tie2R. Moreover, any antibody antagonist can be designed to target multiple epitopes in a particular target. And, in some embodiments, the checkpoint antagonist and / or angiogenesis specificity may be included in the form of a dominant negative fusion protein, for example, corresponding to the extracellular domain (ECD) of a receptor.

[0204] The HCVRs and LCVRs described herein can be linked to naturally occurring Fc regions, or non-naturally occurring or mutated Fc regions, such as effector-free (IgG1 N297A / G) or largely effector-free Fc (e.g., human IgG2 or IgG4), or alternatively, to Fc that enhances binding to one or more activating Fc receptors (FcγRI, FcγRIIa, or FcγRIIIa) to enhance T cell survival in the tumor environment. reg Consumption. Therefore, in certain embodiments, the anti-PD-1, anti-PD-L1, and / or anti-VEGF HCVRs and LCVRs described herein may be linked to an Fc comprising one or more modifications, typically to alter one or more functional properties of the antibody (e.g., serum half-life, complement fixation, Fc receptor binding, and / or antigen-dependent cellular cytotoxicity). Furthermore, the antibodies described herein may be chemically modified (e.g., the antibody may be linked to one or more chemical moieties) or modified to alter its glycosylation to alter one or more functional properties of the antibody. More specifically, in certain embodiments, the antibodies of the present invention may include modifications to the Fc region to produce Fc variants having: (a) increased or decreased antibody-dependent cell-mediated cytotoxicity (ADCC), (b) increased or decreased complement-mediated cytotoxicity (CDC), (c) increased or decreased C1q affinity, and / or (d) increased or decreased Fc affinity relative to the parent Fc. These Fc region variants typically comprise at least one amino acid modification in the Fc region. Combinations of amino acid modifications are particularly contemplated. For example, a variant Fc region may include two, three, four, five, etc., substitutions at specific Fc region sites, e.g., identified herein.

[0205] For applications where effector function is to be completely avoided, for example, when antigen binding alone is sufficient to produce the desired therapeutic benefit and effector function only results in undesirable side effects (or increases their risk), IgG4 antibodies can be used, or antibodies or fragments lacking the Fc region or a substantial portion thereof can be designed, or the Fc region can be mutated to completely eliminate glycosylation (e.g., N297A). Alternatively, composite constructs of human IgG2 (CH1 and hinge regions) and human IgG4 (CH2 and CH3 regions) can be generated that lack effector function, the ability to bind FcγRs (e.g., IgG2) and activate complement (e.g., IgG4). When using an IgG4 constant region, it is generally preferred to include the S228P substitution, which mimics the hinge sequence of IgG1, thereby stabilizing the IgG4 molecule and reducing Fab arm exchange between the therapeutic antibody and endogenous IgG4 in the treated patient.

[0206] In certain embodiments, anti-PD-1, anti-PD-L1, anti-VEGF, anti-angiogenic, and / or anti-Tie2R antibodies or fragments thereof may be modified to increase their biological half-life. Various methods can be used, including, for example, increasing the binding affinity of the Fc region for FcRn. In one embodiment, the CH1 or CL region of the antibody is altered to contain a salvage receptor binding epitope taken from two loops of the CH2 region of the Fc region of IgG, as described in U.S. Patent Nos. 5,869,046 and 6,121,022. The residues in the Fc region are coded as EU index numbers. The sequence variants disclosed herein are provided by reference to the residue number, followed by the amino acid that replaces the naturally occurring amino acid, optionally with the naturally occurring residue shown before the position. When multiple amino acids can exist at a particular position, for example, if the sequence differs between naturally occurring isoforms, or if the position can be replaced by multiple mutations, they are separated by slashes (e.g., "X / Y / Z").

[0207] Exemplary Fc variants that enhance binding to FcRn and / or improve pharmacokinetic properties include substitutions at positions 259, 308, and 434, including, for example, 259I, 308F, 428L, 428M, 434S, 434H, 434F, 434Y, and 434M. Other variants that enhance Fc binding to FcRn include: 250E, 250Q, 428L, 428F, 250Q / 428L (Hinton et al., 2004, J. Biol. Chem. 279(8):6213-6216, Hinton et al. 2006 Journal of Immunology 176:346-356), 256A, 272A, 305A, 307A, 311A, 312A, 378Q, 380A, 382A, 434A (Shields et al (2 001) J. Biol. Chem., 276(9):6591-6604), 252F, 252Y, 252W, 254T, 256Q, 256E, 256D, 433R , 434F, 434Y, 252Y / 254T / 256E, 433K / 434F / 436H (Dall'Acqua et al. (2002) J. Immunol., 169:5171-5180, Dall'Acqua et al. (2006) J. Biol. Chem., 281:23514-23524; and U.S. Patent No. 8,367,805).

[0208] Modification of certain conserved residues in the IgG Fc (I253, H310, Q311, H433, N434), such as the N434A variant (Yeung et al. (2009) J. Immunol. 182:7663), has been proposed as a method to increase FcRn affinity and thereby extend the half-life of antibodies in circulation (WO 98 / 023289). A combined Fc variant comprising M428L and N434S has been shown to increase FcRn binding and serum half-life by up to fivefold (Zalevsky et al. (2010) Nat. Biotechnol. 28:157). A combined Fc variant comprising T307A, E380A, and N434A modifications also extended the half-life of IgG1 antibodies (Petkova et al. (2006) Int. Immunol. 18:1759). Furthermore, combined Fc variants comprising the M252Y-M428L, M428L-N434H, M428L-N434F, M428L-N434Y, M428L-N434A, M428L-N434M, and M428L-N434S mutations have also been shown to extend half-life ( U.S. Patent Publication No. 2006 / 173170 ). Furthermore, a combined Fc variant comprising M252Y, S254T, and T256E has been reported to increase half-life by nearly fourfold ( Dall'Acqua et al. (2006) J. Biol. Chem. 281:23514 ).

[0209] Homodimers and heterodimers

[0210] One of the challenges in efficiently manufacturing bispecific antibodies involves mispairing of light and heavy chains when co-expressing chains with different binding specificities. Table 1 lists several amino acid substitution options for overcoming mispairing of heavy chains with different binding specificities, which "enforce" or preferentially promote correct binding between the desired heavy chains. Any method for preventing or reducing mispairing between heavy chains can be used to manufacture bispecific anti-tumor antagonists according to the present disclosure.

[0211] The "knobs-into-hole" (KiH) approach relies on modifications at the interface between the two CH3 domains, where the majority of interactions occur. Generally speaking, bulky residues are introduced into the CH3 domain of one antibody heavy chain, acting like a key. A "hole" is formed in the other heavy chain, which accommodates the bulky residue, similar to a lock. The resulting heterodimeric Fc portion can be further stabilized by artificial disulfide bonds.

[0212] An alternative approach is based on charged residues with ion exchange or steric complementarity. This involves altering the charge polarity of the CH3 interface so that co-expression of electrostatically paired Fc regions supports favorable attractive interactions and heterodimer formation while retaining the hydrophobic core, while unfavorable repulsive charge interactions inhibit homodimerization. See Table 1. The amino acid code in Table 1 follows the Kabat numbering scheme and is applicable to the heavy chain amino acid sequences of the antibodies described herein.

[0213] In another approach, the bispecific molecules of the present invention can be constructed using non-immunoglobulins containing a leucine zipper (LZ) region. Leucine zippers are common three-dimensional structural motifs in proteins and are typically part of the DNA binding region in various transcription factors. A single LZ contains 4-5 leucine residues approximately every 7 residues, forming an amphipathic alpha helix with a hydrophobic region along one side. In a specific embodiment, the heterodimeric protein scaffold comprises an LZ from a c-jun transcription factor and an LZ from a c-fos transcription factor. Although it is known that c-jun forms a jun-jun homodimer and c-fos cannot form a homodimer, the formation of a jun-fos heterodimer is more favorable than a jun-jun homodimer.

[0214] The leucine zipper region can replace the CH2-CH3 sequence in the protein scaffold, or can be placed at the carboxyl termini of the two heavy chains in the bispecific anti-tumor antagonist. In the latter case, a furin cleavage site can be introduced between the CH3 carboxyl termini and the amino termini of the leucine zipper. When the heavy and light chains of the bispecific anti-tumor antagonist are co-expressed in a suitable mammalian cell expression system, this can promote furin-mediated leucine zipper cleavage after the heterodimerization step (see Wranik et al., J. Biol. Chem., 287(5):43331-43339, 2012).

[0215] Table 1

[0216]

[0217] The amino acid coding in Table 1 is based on the Kabat numbering scheme and can be applied to the heavy chain amino acid sequences of the antibodies described herein. The mutations described in Table 1 can be applied to any immunoglobulin IgG1 heavy chain and other immunoglobulin classes and subclasses (or isotypes) of the sequence (whether published or not).

[0218] When the heavy and light chains of a bispecific antibody are co-expressed, a light chain with a certain binding specificity may mispair with a heavy chain with a different binding specificity. Therefore, in certain embodiments, the heavy chain portion, the light chain portion, or both portions may be modified relative to the "wild-type" antibody chain from which they are derived to prevent or reduce mispairing of the heavy chain constant regions with each other and mispairing of the light chain constant region with its corresponding heavy chain.

[0219] The problem of light chain mispairing can be solved in several ways. In some embodiments, steric complementary mutations and / or disulfide bonds can be introduced into the two VL / VH junctions. In other embodiments, mutations can be introduced through ionic or electrostatic interactions. In some embodiments, light chain mispairing can be prevented or reduced by using a first arm having an S183E mutation in the heavy chain CH1 region and an S176K mutation in the light chain CL region. The second arm may include an S183K mutation in the heavy chain CH1 region and an S176E mutation in the light chain CL region. In other embodiments, a "CrossMab" approach is used, in which one arm of a bispecific anti-tumor antagonist (e.g., Fab) remains unchanged, but in the other arm containing the other binding specificity, one or more regions of the light chain located at the heavy chain: light chain junction are exchanged with one or more regions in the heavy chain.

[0220] Methods for preventing the heavy and light chain mispairing disclosed above in immunoglobulin sequences, including specific mutations, are further described in US Patent Publication Nos. 2014 / 0243505 and 2013 / 0022601.

[0221] Conjugate

[0222] In certain embodiments, the anti-tumor antagonists of the present invention are chemically conjugated to one or more peptides and / or small molecule drugs. The peptides or small molecule drugs may be the same or different. The peptides or small molecule drugs may be linked, for example, to reduced SH groups and / or carbohydrate side chains. Methods for producing covalent or non-covalent conjugates of peptides or small molecule drugs with antibodies are known in the art, and any of these known methods may be used.

[0223] In some embodiments, peptides or small molecule drugs are linked to the hinge region of a reduced antibody component via disulfide bond formation. Alternatively, heterobifunctional crosslinkers, such as N-succinyl 3-(2-pyridyldithio) propionate (SPDP), can be used to link these agents. General techniques for such couplings are known in the art. In some embodiments, peptides or small molecule drugs are coupled via a carbohydrate moiety in the Fc region of an antibody. This carbohydrate group can be used to increase the loading of the same agent bound to the thiol group, or the carbohydrate group can be used to bind different therapeutic or diagnostic agents. Methods for coupling peptide inhibitors or small molecule drugs to antibodies via antibody carbohydrate moieties are known to those skilled in the art. For example, in one embodiment, the method comprises reacting an antibody component having an oxidized carbohydrate moiety with a carrier polymer having at least one free amine function. This reaction results in an initial Schiff base (imine) linkage, which can be stabilized by reduction to a secondary amine to form the final conjugate. Exemplary methods for coupling small molecule drugs and peptides to antibodies are described in U.S. Patent Publication No. 2014 / 0356385.

[0224] Preferably, the anti-tumor antagonists herein retain certain desirable properties and pharmacokinetic properties of antibodies, including desirable in vitro and in vivo stability (e.g., long half-life and shelf life stability), efficient delivery to desired target cells, increased affinity for binding partners, enhanced antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and reduced renal clearance or elimination. Therefore, considerations of size and the need for specific constant region effector functions can be considered in the design of anti-tumor antagonists.

[0225] The bispecific anti-tumor antagonists described herein may have a size ranging from 50 kD to 300 kD, 50 kD to 250 kD, 60 kD to 250 kD, 80 kDa to 250 kD, 100 kD to 250 kD, 125 kD to 250 kD, 150 kD to 250 kD, 60 kD to 225 kD, 75 kD to 225 kD, 100 kD to 225 kD, 125 kD to 225 kD, 150 kD to 225 kD, 60 kD to 2 kD to 200 kD, 75 kD to 200 kD, 100 kD to 125 kD to 200 kD, 150 kD to 200 kD, 60 kD to 150 kD, 75 kD to 150 kD, 100 kD to 150 kD, 60 kD to 125 kD, 75 kD to 125 kD, 75 kD to 100 kD, or any range including or specifically referring to any combination of integers in the above stated ranges.

[0226] Reagent test kit

[0227] The present invention further provides a kit comprising a checkpoint regulator antagonist or anti-tumor antagonist of the present invention. In some embodiments, the kit includes one or more bispecific immune checkpoint regulators, which contain at least one TGFβ pathway inhibitory region. In some embodiments, the kit further contains other reagents, including a second antibody for detection, and other human antibodies as described herein (e.g., human antibodies with complement activity, which bind to different epitopes of the same antigen). The kit typically includes a label with an indication of the intended use of the contents of the kit. The so-called label includes any text or recording material provided with the kit or accompanying the kit.

[0228] II. Methods of Using Anti-tumor Antagonists

[0229] The anti-tumor antagonists of the present invention have numerous in vitro and in vivo utilities, including, for example, enhancing immune responses and the treatment of cancer, infectious diseases, or autoimmune diseases.

[0230] The anti-tumor antagonists of the present invention can be administered in vitro or ex vivo to cells in culture, or in vivo to human subjects, for example, to enhance the immune response of various diseases. Therefore, provided herein are methods for modifying the immune response in an individual, comprising administering an antibody or antigen-binding fragment as described herein to an individual to enhance, stimulate or upregulate the immune response in the individual. Preferably, the individual includes a human patient to whom an immune response is to be enhanced. This method is particularly suitable for treating patients with diseases that can be treated by enhancing an immune response (e.g., a T cell-mediated immune response). This method is particularly suitable for the treatment of cancer or chronic infections in vivo. For example, to enhance the specific immune effect of an antibody, the anti-tumor antagonist can be administered together with the desired antigen, or an antigen already present in the individual to be treated (e.g., an individual with a tumor or a virus). When the anti-tumor antagonist is administered together with other agents, the two can be administered separately or simultaneously.

[0231] In some embodiments, the checkpoint regulator antagonist in the above method is an anti-PD-1 antibody, an anti-PD-L1 antibody, a VEGF antibody, a VEGFR antibody, or any fragment thereof having TGFβRII ECD, a VEGFR ECD, or both.

[0232] In any of the antibody embodiments described herein, the antibody is preferably a human or humanized antibody.

[0233] The scope of the present invention also encompasses methods for detecting and / or measuring the presence of a target molecule in a sample, comprising contacting the sample and a control sample with an antibody, antibody fragment, or bispecific antagonist of the present invention, wherein the antibody, antibody fragment, or bispecific antagonist specifically binds to the target molecule under conditions that allow formation of a complex between the antagonist and the target molecule. Thereafter, the formation of the complex is detected, wherein a difference between the complex formed with the sample and the complex formed with the control sample indicates the presence of the target molecule in the sample.

[0234] In view of the fact that the anti-tumor antagonists of the present invention have the ability to block inhibition or co-inhibit T cell responses (e.g., antigen-specific T cell responses), provided herein are in vitro and in vivo methods for stimulating, enhancing, or raising antigen-specific T cell responses (e.g., anti-tumor T cell responses) using antibodies described herein. In certain embodiments, CD3 stimulation (e.g., by co-culturing with cells expressing membrane CD3) is also provided, and stimulation can be provided at the same time, before, or after treatment with a checkpoint regulator antagonist. For example, provided herein is a method for enhancing antigen-specific T cell responses, comprising contacting the T cells with a checkpoint regulator antagonist as described herein (and optionally with CD3) to enhance antigen-specific T cell responses (e.g., by excluding inhibitory reactions mediated by checkpoint regulators). Any suitable antigen-specific T cell response indicator can be used to measure antigen-specific T cell responses. Non-limiting examples of such suitable indicators include promoting T cell proliferation in the presence of an antibody and / or promoting cytokine production in the presence of an antibody. In a preferred embodiment, interleukin-2 and / or interferon-γ produced by antigen-specific T cells increase.

[0235] The present invention further encompasses a method for enhancing an immune response (e.g., an antigen-specific T cell response) in an individual by administering a bispecific anti-tumor antagonist as described herein to the individual to enhance the immune response (e.g., an antigen-specific T cell response). In a preferred embodiment, the individual is an individual with a tumor, and the immune response to the tumor is enhanced. The tumor may be a solid tumor or a liquid tumor (e.g., a malignant tumor of the blood system). In certain embodiments, the tumor is an immunogenic tumor. In certain embodiments, the tumor is a non-immunogenic tumor. In some embodiments, the tumor is PD-L1 positive. In other embodiments, the tumor is PD-L1 negative. The individual may also be an individual with a virus, which has an enhanced immune response to the virus after administration of a bispecific anti-tumor antagonist as described herein.

[0236] In one embodiment, a method for inhibiting tumor cell growth in a subject comprises administering to the subject a bispecific anti-tumor antagonist as described herein, thereby inhibiting tumor growth in the subject. Also provided is a method for treating a chronic viral infection in a subject, comprising administering to the subject a bispecific anti-tumor antagonist as described herein, thereby treating the chronic viral infection in the subject.

[0237] Also encompassed herein are methods for depleting the tumor microenvironment of T cells from an individual having a tumor (e.g., a cancerous tumor). reg A method for treating a cell, comprising administering to an individual a therapeutically effective amount of a bispecific anti-tumor antagonist as described herein, wherein the bispecific anti-tumor antagonist comprises a cell that stimulates T cells in the tumor microenvironment. reg Cell-depleted Fc. The Fc can, for example, be one that has effector function or enhances effector function (eg, binds to or has enhanced binding to one or more activating Fc receptors).

[0238] In a preferred embodiment, T reg Depletion of T in the tumor microenvironment eff No significant depletion or suppression and no significant T cells outside the tumor microenvironment eff cells and T reg In certain embodiments, the individual has a relatively high T cell count in, for example, the tumor microenvironment. eff T cells are high reg In some embodiments, the bispecific antagonist can deplete T cells in the tumor. reg and / or in tumor-infiltrating lymphocytes (TILs) reg For example, in the CT26 tumor model, it was found that anti-mouse TIGIT antibodies in the form of mouse IgG2a (which exhibits effector function) partially depleted Tregs and CD8 + T cells, but not CD4 + T cells. Antibodies or antagonists with effector-free counterparts, such as mouse IgG1D265A, did not deplete T cells.

[0239] In certain embodiments, the bispecific anti-tumor antagonists described herein are administered to individuals as adjuvant therapy. Treatment of cancer patients with the bispecific anti-tumor antagonists according to the present invention can produce long-term, durable responses relative to existing standard of care; long-term survival rates of at least 1, 2, 3, 4, 5, 10, or more years, and recurrence-free survival rates of at least 1, 2, 3, 4, 5, 10, or more years. In certain embodiments, treatment of cancer patients with bispecific anti-tumor antagonists prevents cancer recurrence or delays cancer recurrence for at least 1, 2, 3, 4, 5, 10, or more years. Thus, treatment with these antagonists can be used as primary or secondary therapy.

[0240] In certain preferred embodiments, the individual has a cell proliferative disease or cancer. Provided herein are methods for treating an individual with cancer, comprising administering to the individual a bispecific anti-tumor antagonist described herein to treat the individual (e.g., inhibiting or reducing the growth of a cancerous tumor and / or causing tumor regression). The bispecific anti-tumor antagonists described herein can be used alone to inhibit the growth of a cancerous tumor. Alternatively, any of these anti-tumor antagonists can be used in combination with other agents, such as other anti-cancer targets described below, immunogenic agents, standard cancer treatments, or other antibodies.

[0241] Thus, provided herein are methods for treating cancer (eg, inhibiting tumor cell growth) in an individual, comprising administering to the individual a therapeutically effective amount of a bispecific anti-tumor antagonist as described herein. Preferably, the antibody comprises a human or humanized immunoglobulin sequence.

[0242] Cancers whose growth can be inhibited using the antibodies of the invention include cancers that respond to immunotherapy. Non-limiting examples of cancers for treatment include squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, squamous non-small cell lung cancer (NSCLC), non-NSCLC, glioma, gastrointestinal cancer, renal cancer (e.g., clear cell carcinoma), ovarian cancer, liver cancer, colorectal cancer, endometrial cancer, kidney cancer (e.g., renal cell carcinoma (RCC)), prostate cancer (e.g., hormone-refractory prostate cancer), thyroid cancer, neuroblastoma, pancreatic cancer, glioblastoma (glioblastoma multiforme), cervical cancer, stomach cancer, bladder cancer, liver cancer, breast cancer, colon cancer, and head and neck cancer (or carcinoma), Gastric cancer, germ cell tumors, pediatric sarcomas, sinonasal natural killer (NK), melanoma (e.g., metastatic malignant melanoma, such as cutaneous or intraocular malignant melanoma), bone cancer, skin cancer, uterine cancer, anal region cancer, testicular cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, esophageal cancer, small intestine cancer, endocrine system cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, solid tumors in children, urethral cancer, renal pelvis cancer, central nervous system (CNS) neoplasms, primary CNS lymphoma, tumor angiogenesis, spinal axis tumors, brainstem gliomas, pituitary adenomas, cardiomyopathy, Posey's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancers (including cancers induced by asbestos), virus-related cancers (e.g., human papillomavirus (HPV)-related tumors), and hematological malignancies arising from either of the two major blood cell lines (i.e., myeloid cell lines that produce granulocytes, erythrocytes, coagulocytes, macrophages, and mast cells, or lymphoid cell lines that produce B, T, NK, and killer cells), such as all types of leukemias, lymphomas, and myelomas, such as acute, chronic, lymphocytic, and / or myeloid leukemias (e.g., acute leukemias, ALL, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML), undifferentiated AML (M0), myeloblastic leukemia (M1), myeloblastic leukemia (M2; cell maturation), promyelocytic leukemia (M3 or M3 variant [M3V]), myelomonocytic leukemia (M4 or M4 variant with eosinophilia [M4E]), monocytic leukemia (M5), erythroleukemia (M6), megakaryoblastic leukemia (M7), solitary granuloma and chloroma;Lymphomas, such as Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), B-cell lymphoma, T-cell lymphoma, lymphoplasmacytoid lymphoma, monocytoid B-cell lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, polymorphic (e.g., Ki 1+) large cell lymphoma, adult T-cell lymphoma / leukemia, mantle cell lymphoma, angioimmunoblastic T-cell lymphoma, angiocentric lymphoma, intestinal T-cell lymphoma, primary mediastinal B-cell lymphoma, precursor T-lymphoblastic lymphoma, T-lymphoblastic; and lymphoma / leukemia (T-Lbly / T-ALL), peripheral T-cell lymphoma, lymphoblastic lymphoma, post-transplant lymphoproliferative disorder, true histiocytic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, lymphoblastic lymphoma ( LBL), hematopoietic neoplasms of the lymphoid spectrum, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, Burkitt's lymphoma, follicular lymphoma, diffuse histiocytic lymphoma (DHL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, cutaneous T-cell lymphoma (CTLC) (also known as mycosis fungoides or Sézary syndrome), and lymphoplasmacytoid lymphoma (LPL) with Waldenstrom's macroglobulinemia; myelomas, such as IgG myeloma , light chain myeloma, non-secretory myeloma, smoldering myeloma (also known as indolent myeloma), solitary plasmacytoma and multiple myeloma, chronic lymphocytic leukemia (CLL), hairy cell lymphoma; myeloid hematopoietic tumors, mesenchymal tumors (including fibrosarcoma and rhabdomyosarcoma); seminoma, teratoma, central and peripheral nerve tumors (including astrocytoma), schwannoma; mesenchymal tumors, including fibrosarcoma, rhabdomyosarcoma, and osteosarcoma; and other tumors, including melanoma, xeroderma pigmentosum, keratoacanthoma, seminoma, thyroid Adenofollicular carcinoma and teratocarcinoma, lymphoid hematopoietic tumors, such as T-cell and B-cell tumors, including but not limited to: T-cell disorders, such as T-prolymphocytic leukemia (T-PLL), including small cell and brain cell types; large granular lymphocytic leukemia (LGL), preferably T cell type; and T-NHL hepatosplenic lymphoma; peripheral / post-thymic T-cell lymphoma (polymorphic and immunoblastic subtypes); angiocentric (nasal) T-cell lymphoma; head or neck cancer, kidney cancer, rectal cancer, thyroid cancer; acute myeloid lymphoma, and any combination of the above cancers. The methods described herein can also be used to treat metastatic cancer, refractory cancer (e.g., cancer that has been previously treated with immunotherapy, such as with antibodies that block CTLA-4 or PD-1) and relapsed cancer. ;

[0243] The bispecific anti-tumor antagonists of the present invention can be administered alone, in combination with other anti-tumor antagonists, or simultaneously with other anti-tumor antagonists. Alternatively, in a cancer vaccine strategy, the bispecific anti-tumor antagonist can also be administered in combination with an immunogenic agent (e.g., cancerous cells, tumor vaccines, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells transfected with genes encoding immune stimulatory cytokines (He et al. (2004) J. Immunol. 173: 4919-28), or an oncolytic virus or administered simultaneously.

[0244] Numerous experimental strategies for anticancer vaccines have been devised. In one of these strategies, vaccines utilize autologous or allogeneic tumor cells. Some of these cell-based vaccines have been shown to be most effective when tumor cells are transduced to express GM-CSF. GM-CSF has been shown to be a potential activator of antigen presentation for cancer vaccination (Dranoff et al. (1993) Proc. Natl. Acad. Sci. USA 90:3539-43). Cancer vaccines have been shown to increase effector T cell infiltration into tumors in preclinical models. The main types of cancer vaccines include peptide vaccines, vector-based antigen-specific vaccines, whole cell vaccines, and dendritic cell vaccines. All vaccine-based therapies are designed to deliver single or multiple antigenic epitopes or antigens from whole cells to the patient and induce tumor-specific effector T cells. Therefore, vaccine-based therapies may be the most effective approach for inducing T cell infiltration into tumors.

[0245] Studies of gene expression and large-scale gene expression patterns in various tumors have led to the definition of so-called tumor-specific antigens (Rosenberg, SA (1999) Immunity 10:281-7). In many cases, these tumor-specific antigens are differentiation antigens expressed in tumors and tumor-derived cells, such as the melanocyte antigen gp100, MAGE antigens, and Trp-2. More importantly, many of these antigens serve as targets for tumor-specific T cells found in the host.

[0246] Inhibition of checkpoint regulator pathways, TGF-β pathways, and / or angiogenesis pathways can be used together with a collection of recombinant proteins and / or peptides expressed in tumors to generate an immune response to these proteins. These proteins can be collectively regarded as self-antigens by the immune system, thereby being tolerant to them. Tumor antigens may include telomerase proteins, which are required for chromosome telomere synthesis, expressed in more than 85% of human cancers and only in a limited number of somatic cells (Kim et al. (1994) Science 266:2011-2013). Tumor antigens can also be "neo-antigens" expressed in cancer cells because somatic mutations exchange protein sequences or create fusion proteins between two unrelated sequences (i.e., bcr-abl in the Philadelphia chromosome) or individual genotypes (idiotypes) from B cell tumors.

[0247] Non-limiting examples of tumor vaccines include sipuleucel-T FDA-approved tumor vaccines for metastatic prostate cancer; tumor cells transfected to express the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), such as the whole-cell GM-CSF-secreting irradiated heterologous pancreatic cancer vaccine (GVAX; Johns Hopkins); peptide vaccines composed of immunogenic peptides derived from breast cancer antigens, neu, legumain, and β-catenin, which, when co-administered with anti-PD-1 antibodies, can prolong vaccine-induced disease-free survival in mice bearing breast cancer (Karyampudi L. et al. (2014) Cancer Res 74:2974-2985); melanoma antigen peptides, such as gp100, MAGE antigens, Trp-2, MARTI, and / or tyrosine. Other tumor vaccines include proteins from viruses associated with human cancers, such as human papillomavirus (HPV) (e.g. Gardasil and ); Hepatitis B virus (e.g., Engerix-B and Recombivax HB); Hepatitis C virus (HCV), Kaposi's sarcoma-associated herpesvirus (KSHV). Other forms of tumor-specific antibodies that can be used with TIGIT inhibition are purified heat shock proteins (HSPs) that are isolated from the tumor tissue itself. These heat shock proteins contain protein fragments from tumor cells and these HSPs are very effective in being delivered to antigen-presenting cells to elicit tumor immunity. Talimogene laherparepvec (T-VEC or ) is an FDA-approved oncolytic virus for use in some patients with metastatic melanoma that cannot be removed surgically.

[0248] Dendritic cells (DC) are effective antigen presenting cells that can be used to trigger antigen-specific reactions. DC can be manufactured in vitro and loaded with various proteins, peptides, and tumor cell extracts (Nestle et al. (1998) Nature Medicine 4: 328-332). DC can also be transduced to express these tumor antigens by genetic means. For the purpose of immunization, DC can also be directly fused with tumor cells (Kugler et al. (2000) Nature Medicine 6: 332-336). As a method for vaccination (vaccination), DC immunity can be effectively combined with checkpoint regulator blocking to activate (release) more effective anti-tumor response.

[0249] Inhibition of checkpoint regulator pathways, TGF-β pathways, and / or angiogenesis pathways can also be combined with standard cancer treatments (e.g., surgery, radiotherapy, and chemotherapy). In particular, checkpoint regulator inhibitors can be effectively combined with chemotherapy regimens. In this case, it may be possible to reduce the dose of the chemotherapeutic agent administered (Mokyr et al. (1998) Cancer Research 58: 5301-5304). An example of this combination is the use of anti-tumor antagonists and decarbazine to treat melanoma. Another example of this combination is the use of a checkpoint regulator antagonist or an anti-tumor antagonist with interleukin-2 (IL-2) to treat melanoma. For example, the scientific basis for combining checkpoint regulator inhibition, TGF-β1 / TGF-β1RII inhibition, and / or angiogenesis inhibition with chemotherapy can promote cell death caused by the cytotoxic effects of most chemotherapeutic compounds, thereby increasing the level of tumor antigens in the antigen presentation pathway. Other combination therapies that may synergize with checkpoint regulator inhibition, TGF-β1 / TGF-β1RII inhibition, and / or inhibition of angiogenesis through cell death are radiation therapy, surgery, and androgen-deprivation. Each of these approaches creates a source of tumor antigens in the host.

[0250] The bispecific anti-tumor antagonists described herein can also be constructed to target Fcα or Fcγ receptor-expressing effector cells to tumor cells (see, for example, U.S. Pat. Nos. 5,922,845 and 5,837,243). For example, anti-Fc receptor / anti-tumor antigen (e.g., Her-2 / neu) bispecific antibodies have been used to target macrophages to tumor sites. This type of targeting may be suitable for embodiments of the present invention to more effectively activate tumor-specific responses. The T cell arm of these reactions can be enhanced by inhibition of one or more checkpoint regulator antagonists described herein. Alternatively, antigens can be delivered directly to DCs by the use of bispecific antibodies that bind to specific cell surface markers of tumor antigens and dendritic cells.

[0251] Tumors use various mechanisms to evade host immune surveillance. Many of these mechanisms can be overcome by inactivating immunosuppressive proteins expressed by the tumor. These include TGF-β, IL-10, and Fas ligand. Antibodies directed against each of these entities can be used in combination with the anti-tumor antagonists described herein to counteract the effects of immunosuppressants and enhance the host's tumor immune response.

[0252] Other antibodies that activate the host immune response can be used in combination with the anti-tumor antagonists described herein. It includes molecules that activate DC function and antigen presentation on the surface of dendritic cells. Anti-CD40 antibodies can effectively replace helper T cell activity (Ridge et al. (1998) Nature 393:474-478) and can be used in combination with the bispecific antagonists described herein. Activation of antibodies against T cell co-stimulatory molecules, such as OX-40 (Weinberg et al. (2000) Immunol 164:2160-2169), CD137 / 4-1BB (Melero et al. (1997) Nature Medicine 3:682-685 (1997), and ICOS (Hutloff et al. (1999) Nature 397:262-266), can also increase the degree of T cell activation. In addition, inhibitors of other immune checkpoint regulators can also be used in combination with other anti-tumor antagonists described herein, as further described below.

[0253] Bone marrow transplantation is currently used to treat various hematopoietic tumors. Although this treatment can lead to graft-versus-host disease, checkpoint inhibitors can be used to enhance the effectiveness of transplanted tumor-specific T cells from the donor by reducing the graft-versus-tumor response.

[0254] In certain embodiments, the anti-tumor antagonists described herein may be administered to patients with infectious diseases (particularly chronic infections). In this case, similar to its application to cancer, antibody-mediated checkpoint regulator inhibition can be used alone or in combination with vaccines as an adjuvant to enhance the immune response to pathogens, toxins, and self-antigens. Exemplary pathogens that can be used for this treatment method include, but are not limited to, HIV, hepatitis viruses (type A, type B, and type C), influenza virus, herpes virus, Giardia lamblia, malaria, Leishmania, Staphylococcus aureus, and Pseudomonas aeruginosa. Checkpoint regulator inhibition, TGF-β1 / TGF-β1RII inhibition, and / or angiogenesis inhibition are particularly effective for infections caused by pathogens (e.g., HIV with new or altered antigens during the infection process). Administration of bispecific anti-tumor antagonists can cause these antigens to be regarded as foreign and thus induce appropriate T cell responses.

[0255] Other pathogenic viruses that cause infections that can be treated by the methods described herein include HIV, hepatitis viruses (types A, B, and C), herpes virus infections (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, human herpesvirus type 4), and infections caused by adenovirus, influenza virus, flavivirus, echovirus, rhinovirus, coxsackie virus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, varicella virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus, arboviral encephalitis virus, or a combination thereof.

[0256] Exemplary pathogenic bacteria or diseases that can be treated by the methods described herein include Chlamydia, Rickettsia, Mycobacterium, Staphylococcus, Streptococcus, Pneumococcus, Meningococcus and Gonorrhea, Klebsiella, Proteus, Serratia, Pseudomonas, Legionella, Diphtheria, Salmonella, Bacillus, Cholera, Leptospira, Tetanus, Botulinum, Anthrax, Plague, and Lyme disease.

[0257] Exemplary pathogenic fungi that cause infections that can be treated by the methods described herein include Candida species (e.g., Candida albicans, Candida krusei, Candida glabrata, Candida tropicalis, etc.), Cryptococcus neoformans, Aspergillus species (e.g., Aspergillus fumigates, Aspergillus niger, etc.), Mucorales (e.g., Mucorales, Absidia, Rhizopus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis, and Histoplasma capsulatum.

[0258] Exemplary pathogenic parasites that can be treated by the methods described herein include Entamoeba histolytica, Balantidium coli, Naegleria fowleri, Acanthamoeba sp., Giardia Zambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Nippostrongylus brasiliensis.

[0259] In all of the above approaches, checkpoint regulator inhibition, TGF-β1 / TGF-β1RII inhibition, and / or angiogenesis inhibition can be combined with other forms of immunotherapy, such as cytokine (e.g., interferon, GM-CSF, G-CSF, IL-2) treatment, or with bispecific antibody therapy using two different binding specificities to provide enhanced tumor antigen presentation.

[0260] The bispecific anti-tumor antagonists described herein can enhance antigen-specific immune responses by co-administration with one or more arbitrary antibodies and target antigens (e.g., vaccines). Therefore, provided herein are methods for enhancing the immune response to an antigen in an individual, comprising administering to the individual: (i) an antigen; (ii) a bispecific anti-tumor antagonist, thereby enhancing the immune response to the antigen in the individual. The antigen may be, for example, a tumor antigen, a viral antigen, a bacterial antigen, or an antigen from a pathogen. Non-limiting examples of such antigens include those described in the above sections, such as the tumor antigens (or tumor vaccines) discussed above, or antigens from viruses, bacteria, or other pathogens described above.

[0261] In certain embodiments, peptides or fusion proteins comprising the binding epitopes of bispecific anti-tumor antagonists can be used as vaccines instead of, or in addition to, anti-tumor antagonists.

[0262] Suitable routes of in vivo and in vitro administration of the antibody compositions described herein (e.g., human monoclonal antibodies, multispecific antibodies, or immune complexes) are well known in the art and can be selected by one skilled in the art. For example, the antibody composition can be administered by injection (intravenously or subcutaneously). The appropriate dosage of the molecule used depends on the age and weight of the individual, as well as the concentration and / or formulation of the antibody composition.

[0263] Combination therapies

[0264] On the other hand, the present invention provides a combination therapy for enhancing antigen-specific T cell responses in an individual. In one embodiment, the method includes contacting T cells with a bispecific anti-tumor antagonist and a second antibody, antibody fragment, antagonist, or drug combination to enhance antigen-specific T cell responses or apoptosis pathways. For example, in some embodiments, the first bispecific anti-tumor antagonist specifically binds to a first checkpoint regulator, such as PD-1 or PD-L1, and the second bispecific anti-tumor antagonist specifically binds to a different checkpoint regulator or a different epitope. In some embodiments, the second antibody or antibody fragment comprises one or more different HCVRs, LCVRs, or CDR(s) from PD-1 and / or PD-L1.

[0265] In a related aspect, a method for reducing or depleting regulatory T cells in an individual with a tumor in need thereof comprises administering an effective amount of an antibody or antibody fragment in combination with a secondary antibody, antibody fragment, antagonist, or drug to reduce the number of regulatory T cells in the individual.

[0266] In some embodiments, the individual has a cell proliferative disorder or cancer as described herein.

[0267] In other embodiments, the individual has a chronic viral infection, inflammatory disease, or autoimmune disease as described herein.

[0268] In terms of lymphocyte activation of resting T lymphocytes, providing two different signals to T cells is a widely accepted model. This model further provides self- and non-self identification and immune tolerance. The initial signal or antigen-specific signal is transduced by the T cell receptor (TCR) after identifying the foreign antigen peptide in the context of the major histocompatibility complex (MHC). Secondary or co-stimulatory signals are transmitted to T cells through co-stimulatory molecules expressed on antigen presenting cells (APCs). This induces T cells to promote clonal expansion, cytokine secretion and effector function. In the absence of co-stimulation, T cells may become difficult to control antigen stimulation, resulting in a tolerance response to exogenous or endogenous antigens.

[0269] In the two-signal model, T cells receive positive co-stimulatory signals and negative co-inhibitory signals. Regulating these positive and negative signals is crucial for maximizing the host's protective immune response while maintaining immune tolerance and preventing autoimmunity. Negative signals appear to be necessary for inducing T cell tolerance, while positive signals promote T cell activation. Both co-stimulatory and co-inhibitory signals are provided to antigen-exposed T cells, and the interaction between co-stimulatory and co-inhibitory signals is essential for controlling the amplitude of the immune response. Moreover, when the infection or immune stimulation is cleared, worsens, or persists, the signals provided to the T cells change, and these changes strongly affect the responding T cells and reshape the immune response.

[0270] The mechanism of co-stimulation has therapeutic implications, as manipulation of co-stimulatory signals has been shown to provide a means of enhancing or terminating cell-based immune responses. In recent years, it has been discovered that T cell dysfunction or anergy can occur concurrently with induced and sustained expression of immune checkpoint regulators, such as programmed death peptide (PD-1) and its ligands PD-L1 and PD-L2. PD-L1 is overexpressed in many cancers and is often associated with a poor prognosis (Thompson RH et al., Cancer Res 2006, 66(7):3381). Furthermore, compared with T lymphocytes in normal tissues and peripheral blood, most tumor-infiltrating T lymphocytes predominantly express PD-1, suggesting that upregulation of PD-1 on tumor-reactive T cells can lead to impaired anti-tumor immune responses (Blood 2009 114(8):1537). This may be due to the utilization of PD-L1 signaling mediated by the interaction between PD-L1-expressing tumor cells and PD-1-expressing T cells, resulting in reduced T cell activation and escape from immune surveillance. Inhibition of the PD-L1 / PD-1 interaction provides a means to enhance T cell immunity, including CD8+ T cell-mediated killing of cancer cells and tumors. Similar T cell immunity enhancement has been observed by inhibiting the binding of PD-1 to its binding partner B7-1. Therefore, therapeutic targeting of PD-1 and other immune checkpoint regulators is an area of ​​interest.

[0271] The combined inhibition of TGF-β1 signaling, checkpoint regulator signaling, and / or angiogenesis signaling with other signaling pathways that are downregulated in tumor cells may provide a means to enhance therapeutic benefit. In recent years, multiple immune checkpoint regulators in the form of receptors and their ligands have been identified. An important family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the B7 family, which includes CTLA-4 and its ligands, B7-1 and B7-2; PD-1 and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC); B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6. Other immune checkpoint regulator antagonists include, but are not limited to, TIM-3 and its ligands, galectin-9; LAG-3 and its ligands, including liver sinusoidal endothelial cell lectin (LSECtin) and galectin-3; CD122 and its CD122R ligand; CD70, B7H3, B and T lymphocyte attenuator (BTLA), and VISTA (Le Mercier et al. (2015) Front. Immunol., (6), Article 418). In addition, multiple checkpoint regulator antagonists have been identified and tested in various clinical and preclinical models and / or have received FDA approval (Kyi et al., FEBS Letters, 588:368-376 (2014)). The concept of inhibitory receptor blockade, also known as immune checkpoint blockade, has been demonstrated by the efficacy of FDA-approved PD-1 inhibitors, nivolumab and pembrolizumab, and the anti-CTLA-4 antibody, ipilimumab, in metastatic melanoma.

[0272] Immune checkpoint antagonists regulate or interfere with the activity of immune checkpoint regulators, thereby blocking or inhibiting the signal transduction by the checkpoint regulator receptor due to binding with the checkpoint regulator or its ligand.Immunosuppression can be reversed by inhibiting this signal transduction, thereby re-establishing or enhancing the T cell immunity against cancer cells.On the contrary, immune checkpoint agonists (such as co-stimulatory molecules) stimulate the activity of immune checkpoint regulators, thereby stimulating the signal transduction by the checkpoint regulator receptor due to binding with the checkpoint regulator or its ligand.By stimulating this signal transduction, the T cell immunity against cancer cells can be re-established or enhanced.

[0273] Thus, in one embodiment, a method for stimulating an immune response in a subject comprises administering to the subject a bispecific anti-tumor antagonist as described herein in combination with other immune checkpoint regulators as described above, thereby stimulating an immune response in the subject, such as inhibiting tumor growth or stimulating an antiviral response. In particular, the bispecific anti-tumor antagonist can be administered as separate antagonists or as a multispecific antagonist comprising multiple binding heterologous products.

[0274] In some embodiments, the bispecific anti-tumor antagonists of the present invention can be combined with the following to stimulate an immune response: (i) antagonists of IgSF family proteins, B7 family, or TNF family proteins that inhibit T cell activation, or antagonists of cytokines that inhibit T cell activation (e.g., IL-6, IL-10, TGF-β, VEGF, or other immunosuppressive cytokines), and / or (ii) agonists of stimulatory receptors of the IgSF family, B7 family, or TNF family, or agonists of cytokines that stimulate T cell activation, for stimulating an immune response. In other embodiments, the bispecific anti-tumor antagonist is administered to the individual in combination with an anti-CTLA-4 antibody or CTLA-4 antagonist. Exemplary CTLA-4 antibodies used according to the present invention include ipilimumab, trevilizumab, and tremelimumab.

[0275] In some embodiments, bispecific antagonists targeting different checkpoint regulator antagonists can be administered to individuals with cancers that highly express immune checkpoint regulator ligands. For example, in one embodiment, individuals with cancer that exhibit high expression of PVR (CD155) and / or Nectin-2 (CD112) and / or low expression of PD-1 can be selected for monotherapy with anti-TIGIT or anti-LAG-3 antibodies or fragments thereof, or for combined therapy with PD-1 antagonists or other immune checkpoint regulator antagonists. The bispecific anti-tumor antagonists of the present invention can be co-administered with other agents (e.g., antibodies, antagonists, or drugs) in an effective amount to stimulate an immune response and / or apoptosis to further enhance, stimulate, or upregulate the immune response and / or apoptosis of the individual.

[0276] In some embodiments, a bispecific anti-tumor antagonist is administered after treatment with a different anti-tumor antagonist. For example, in some embodiments, a bispecific anti-tumor antagonist of the present invention may be administered only after a monospecific anti-tumor antagonist has failed, has resulted in an incomplete therapeutic response, or has caused tumor recurrence or relapse (e.g., "PD-1 failure"). In some embodiments, cancers exhibiting such failures can be screened using, for example, PVR and / or Nectin-2, and only those with high expression levels are treated with the bispecific anti-tumor antagonist of the present invention.

[0277] In certain embodiments, the anti-tumor antagonist includes a dominant negative protein region of an immune checkpoint regulator. In a specific embodiment, the dominant negative protein comprises an extracellular domain derived from the group consisting of: PD-L1, PD-L2, PD-1, B7-1, B7-2, B7H3, CTLA-4, LAG-3, TIM-3, TIGIT, BTLA, VISTA, CD70, and combinations thereof. In certain specific embodiments, these extracellular domains are fused to the immunoglobulin constant region or Fc receptor of the antibodies described herein. Such mutations can bind to endogenous receptors to form complexes with insufficient signaling. In certain embodiments, the extracellular domain is fused to an immunoglobulin constant region or an Fc receptor, or to a monomer of an oligoprotein complex.

[0278] In certain embodiments, the dominant negative PD-L1 antagonist comprises the extracellular domain of PD-L1, PD-L2, or PD-1. In another embodiment, a dominant negative PD-1 antagonist is used that has a mutation that no longer binds to PD-L1. An exemplary dominant negative protein is AMP-224 (co-developed by GlaxoSmithKline and Amplimmune), a recombinant fusion protein comprising the extracellular domain of PD-L2 and the Fc region of human IgG.

[0279] Exemplary immune checkpoint regulator agonists include, but are not limited to, tumor necrosis factor (TNF) receptor superfamily members (e.g., CD27, CD40, OX40, GITR and 4-1BB (CD137)) and their ligands, or B7-CD28 superfamily members (including CD28 and ICOS (CD278)). Other checkpoint regulator agonists include CD2, CDS, ICAM-1, LFA-1 (CD11a / CD18), CD30, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, CD83 ligands. Immune checkpoint agonists may include antibodies or soluble fusion protein agonists comprising one or more costimulatory regions. Agonist antibodies include, but are not limited to, anti-CD40 mAbs, such as CP-870,893, lucatumumab, and dacetuzumab; anti-CD137 mAbs, such as BMS-663513, urelumab, and PF-05082566; anti-OX40 mAbs; anti-GITR mAbs, such as TRX518; anti-CD27 mAbs, such as CDX-1127; and anti-ICOS mAbs.

[0280] Exemplary GITR agonists include, for example, GITR fusion proteins and anti-GITR antibodies (e.g., bivalent anti-GITR antibodies), such as the GITR fusion proteins described in U.S. Patent Nos. 6,111,090 and 8,586,023, European Patent No. 090505B1, and International Patent Applications Publication Nos. WO 2010 / 003118 and WO 2011 / 090754. Anti-GITE antibodies are described, for example, in U.S. Patent Nos. 7,025,962, 7,618,632, 7,812,135, 8,388,967, and 8,591,886, European Patent Nos. 1947183B1 and 1866339, and in International Patent Applications Publication Nos. WO 2011 / 028683, WO 2013 / 039954, WO 2005 / 007190, WO 2007 / 133822, WO 2005 / 055808, WO 99 / 40196, WO 2001 / 03720, WO 99 / 20758, WO 2006 / 083289, WO 2005 / 115451, and WO 2011 / 051726. An exemplary anti-GITR antibody is TRX518.

[0281] Other families of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors are the TNF family molecules that bind to cognate TNF receptor family members, including CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 / 4-1BB, TRAIL / Apo2-L, TRAILR1 / DR4, TRAILR2 / DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR / Fn14, T WEAK, BAFFR, EDR, XEDAR, TACI, APRIL, BCMA, LTβR, LIGHT, DcR3, HVEM, VEGI / TL1A, TRAMP / DR3, EDR, EDA1, XEDAR, EDA2, TNFR1, lymphotoxin alpha / TNFγ, TNFR2, TNFα, LTβR, lymphotoxin alpha 1(32, FAS, FASL, RELT, DR6, TROY, NGFR (see, e.g., Tansey, MG et al. (2009) Drug Discovery Today, 14(23-24): 1082-1088).

[0282] Immune checkpoint agonists or co-stimulatory molecules include cell surface molecules other than antigen receptors or their ligands that are required for an effective immune response, including but not limited to class I MHC molecules, class II MHC molecules, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocyte activation molecules (SLAM proteins), activating NK cell receptors, BTLA, Toll ligand receptors, receptor), OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1(CD11a / CD18), 4-1BB(CD137), B7-H3, CDS, ICAM-1, ICOS(CD278), GITR, BAFFR, LIGHT, HVEM(LIGHTR), KIRDS2, SLAMF7, NK p80(KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL2Rβ, IL2Rγ, IL7Rα, ITGA4, VLA1, CD4 9a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, IT GAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​LAT, GADS, SLP-76, PAG / Cbp, CD19a, and a ligand that specifically binds to CD83.

[0283] In one aspect, T cell responses can be mediated by anti-PD-1 or anti-PD-L1 of the present invention. mAbs stimulate by binding to one or more of the following: (i) antagonists of proteins that inhibit T cell activation (e.g., immune checkpoint inhibitors), such as CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, Galectin-9, CEACAM-1, BTLA, CD69, Galectin-1, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD-1H, LAIR1, TIM-1, CD96, and TIM-4, and (ii) agonists of proteins that stimulate T cell activation, such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, CD40, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3, and CD28H.

[0284] Exemplary agents that modulate one of the above proteins can be used in combination with the anti-PD-1 antibody or anti-PD-L1 antibody of the present invention to treat cancer. These exemplary agents include, for example, YERVOY TM / ipilimumab or tremelimumab (targeting CTLA-4), galiximab (targeting B7.1), OPDIVO TM / nivolumab / BMS-936558 (targeting PD-1), pidilizumab / CT-011 (targeting PD-1), KEYTRUDA TM / pembrolizumab / MK-3475 (targeting PD-1), AMP224 (targeting B7-DC / PD-L2), BMS-936559 (targeting B7-H1), MPDL3280A (targeting B7-H1), MEDI-570 (targeting ICOS), AMG557 (targeting B7H2), MGA271 (targeting B7H3), IMP321 (targeting LAG-3), urelumab / BMS-663513 and PF-05082566 (targeting CD137 / 4-1BB), CDX-1127 (targeting CD27), MEDI-6383 and MEDI-6469 (targeting OX40), RG-7888 (targeting OX40L), Atacicept (targeting TACI), CP-870893 (targeting CD40), lucatumumab (targeting CD40), dacetuzumab (targeting CD40), and muromonab-CD3 (targeting CD3).

[0285] Other molecules that can be used in combination with the anti-tumor antagonists described herein for cancer treatment include antagonists of inhibitory receptors on NK cells or agonists of activating receptors on NK cells. For example, antagonist anti-PD-1 and / or anti-PD-L1 antibodies can be used in combination with KIR (e.g., Lirilumab) or CSF-1R antagonists (e.g., RG7155).

[0286] Tumors evade host immune surveillance through a variety of mechanisms. Many of these mechanisms can be overcome by inactivating tumor-expressed immunosuppressive proteins. These include TGF-β, IL-10, and Fas ligand. Antibodies against each of these entities can be used in combination with the anti-tumor antagonists described herein to counteract the effects of immunosuppressive agents and favor the host's tumor immune response.

[0287] Other antibodies that activate the host immune response can be used in combination with the anti-tumor inhibitors described herein. These include dendritic cell surface molecules that activate DC function and antigen presentation. Anti-CD40 antibodies can effectively replace T cell helper activity and can be used in combination with the anti-tumor antagonists described herein. Antibodies that activate T cell co-stimulatory molecules, such as OX-40, CD137 / 4-1BB, and ICOS, can also increase T cell activation levels.

[0288] In certain embodiments, the anti-tumor antagonists described herein can be used in combination with one or more other therapeutic agents, such as anticancer agents, radiotoxic agents, or immunosuppressive agents. Such combinations can address issues arising from drug resistance, changes in tumor antigenicity that render the antagonist unresponsive, and toxicity (by administering lower doses of one or more agents).

[0289] The anti-tumor antagonists described herein can be linked to the agent (as an immune complex) or administered separately from the agent. In the latter case (separate administration), the antibody can be administered before, after, or simultaneously with the agent, or can be administered together with other known therapies, such as anti-cancer therapy (e.g., radiation therapy). The anti-tumor antagonists described herein can be co-administered with one or more anti-cancer agents to provide two anti-cancer agents that operate synergistically through different mechanisms to produce a cytotoxic effect in human cancer cells.

[0290] The anti-tumor antagonists described herein can be combined with an anti-cancer agent, such as an alkylating agent, an anthracycline, an antimetabolite, an antidote, an interferon, a polyclonal or monoclonal antibody, an EGFR inhibitor, a HER2 inhibitor, a histone deacetylase inhibitor, a hormone, a mitotic inhibitor, a phosphatidyl alcohol-3-kinase (PI3K) inhibitor, an Akt inhibitor, a mammalian target of rapamycin (mTOR) inhibitor, a proteasome inhibitor, a poly (ADP-ribose) polymerase (PARP) inhibitor, a Ras / MAPK pathway inhibitor, a centrosome declustering agent, a multikinase inhibitor, a serine / threonine kinase inhibitor, a tyrosine kinase inhibitor, a VEGF / VEGFR inhibitor, a taxane or a taxane derivative, an aromatase inhibitor, an anthracycline, a microtubule-targeting drug, a topoisomerase poison drug, a molecularly targeted or enzyme inhibitor (e.g., a kinase or protein Jacky transferase), a cytidine analog, or a combination thereof.

[0291] Exemplary alkylating agents include, but are not limited to, cyclophosphamide (Cytoxan; Neosar); chlorambucil (Leukeran); melphalan (Alkeran); carmustine (BiCNU); busulfan (Busulfex); lomustine (CeeNU); dacarbazine (DTIC-Dome); oxaliplatin (Eloxatin); carmustine (Gliadel); ifosfamide (Ifex); mechlorethamine (Mustargen); busulfan (Myleran); carboplatin (Paraplatin); cisplatin (CDDP; Platinol); temozolomide (Temodar); thiotepa (Thioplex); bendamustine (Treanda); or streptozotocin (Zanosar).

[0292] Exemplary anthracycline antibiotics include, but are not limited to, doxorubicin (Adriamycin); liposomal doxorubicin (Doxil); mitoxantrone (Novantrone); bleomycin (Blenoxane); daunorubicin (Cerubidine); liposomal daunorubicin (DaunoXome); actinomycin (Cosmegen); epirubicin (Ellence); idarubicin (Idarubicin); plicamycin (Mithracin); mutamycin (Mutamycin); pentostatin (Nipent); or valrubicin (Valstar).

[0293] Exemplary antimetabolites include, but are not limited to, fluorouracil (Adrucil); fluorouracil capecitabine (Xeloda); hydroxyurea (Hydrea); mercaptopurine (Purisol); pemetrexed (Alimta); fludarabine (Fludara); nelarabine (Arranon); cladribine (Cladribine Novaplus; clofarabine (Clolar); cytarabine (Cytosar-U); decitabine (Dacogen); liposomal cytarabine (DepoCyt); hydroxyurea (Droxia); pralatrexate (Folotyn); floxuridine (FUDR); gemcitabine (Gemzar); cladribine (Leustatin); fludarabine (Oforta); methotrexate (MTX; Rheumatrex); methotrexate (Trexall); thioguanine (Tabloid); TS-1 or cytarabine (Tarabine PFS).

[0294] Exemplary antidotes include, but are not limited to, Ethyol or Mesnex.

[0295] Exemplary interferons include, but are not limited to, interferon alpha-2b (Intron A) or interferon alpha-2a (Roferon-A).

[0296] Exemplary polyclonal or monoclonal antibodies include, but are not limited to, trastuzumab (Herceptin); ofatumumab (Arzerra); bevacizumab (Avastin); rituximab (Rituxan); cetuximab (Erbitux); panitumumab (Vectibix); tositumomab / iodine-131 tositumomab (Bexxar); alemtuzumab (Campath); ibritumomab (Zevalin; In-111; Y-90Zevalin); gemtuzumab tuzumab (Mylotarg); eculizumab (Soliris) or denosumab.

[0297] Exemplary EGFR inhibitors include, but are not limited to, gefitinib (Iressa); lapatinib (Tykerb); cetuximab (Erbitux); erlotinib (Tarceva); panitumumab (Vectibix); PKI-166; canuvertinib (CI-1033); matuzumab (Emd7200); or EKB-569.

[0298] Exemplary HER2 inhibitors include, but are not limited to, trastuzumab (Herceptin); lapatinib (Tykerb); or AC-480.

[0299] Exemplary histone deacetylase inhibitors include, but are not limited to, vorinostat (Zolinza), valproic acid, romidepsin, entinostat, abexinostat, gvinostat, and moxidectinstat.

[0300] Exemplary hormones include, but are not limited to, tamoxifen (Soltamox; Nolvadex); raloxifene (Evista); megestrol acetate (Megace); leuprorelin (Lupron; Lupron Depot; Eligard; Viadur); fulvestrant (Faslodex); letrozole (Femara); triptorelin (Trelstar LA; Trelstar Depot; exemestane (Aromasin); goserelin (Zoladex); bicalutamide (Casodex); anastrozole (Arimidex); fluoxymesterone (Androxy; Halotestin); medroxyprogesterone (Provera; Depo-Provera); estramustine (Emcyt); flutamide (Eulexin); toremifene (Fareston); degarelix (Firmagon); nilutamide (Nilandron); abrelix (Plenaxis); or testolactone (Teslac).

[0301] Exemplary mitotic inhibitors include, but are not limited to, paclitaxel (Taxol; Onxol; Abraxane); docetaxel (Taxotere); vincristine (Oncovin; Vincasar PFS); vinblastine (Velban); etoposide (Toposar; Etopophos; VePesid); teniposide (Vumon); ixabepilone (Ixempra); nocodazole; epothilone; vinorelbine (Navelbine); camptothecin (CPT); irinotecan (Camptosar); topotecan (Hycamtin); amsacrine or lamellarin D (LAM-D).

[0302] Exemplary phosphatidylinositol-3-kinase (PI3K) inhibitors include, but are not limited to, the irreversible PI3K inhibitor wortmannin, the wortmannin derivative desmethoxypyridine LY294002, a reversible PI3K inhibitor; BKM120 (Buparlisib); Idelalisib (a PI3Kδ inhibitor); duvelisib (IPI-145, a PI3Kδ and γ inhibitor); alpelisib (BYL719), an α-specific PI3K inhibitor; TGR 1202 (formerly RP5264), an oral PI3Kδ inhibitor; and copanlisib (BAY 80-6946), a predominantly PI3Kα,δ isotype inhibitor.

[0303] Exemplary Akt inhibitors include, but are not limited to, miltefos, AZD5363, GDC-0068, MK2206, perifo, RX-0201, PBI-05204, GSK2141795, and SR13668.

[0304] Exemplary MTOR inhibitors include, but are not limited to, everolimus (Afinitor) or temsirolimus (Torisel); rapamune, ridaforolimus; deforolimus (AP23573), AZD8055 (AstraZeneca), OSI-027 (OSI), INK-128, BEZ235, PI-103, Torin 1, PP242, PP30, Ku-0063794, WAY-600, WYE-687, WYE-354, and CC-223.

[0305] Exemplary proteasome inhibitors include, but are not limited to, bortezomib (PS-341), ixazomib (MLN 2238), MLN 9708, delanzomib (CEP-18770), carfilzomib (PR-171), YU101, oprozomib (ONX-0912), marizomib (NPI-0052), and disufiram.

[0306] Exemplary PARP inhibitors include, but are not limited to, olaparib, iparib, velaparib, BMN-673, BSI-201, AG014699, ABT-888, GPI21016, MK4827, INO-1001, CEP-9722, PJ-34, Tiq-A, Phen, PF-01367338, and combinations of the foregoing.

[0307] Exemplary Ras / MAPK inhibitors include, but are not limited to, trametinib, selumetinib, cobimetinib, CI-1040, PD0325901, AS703026, RO4987655, RO5068760, AZD6244, GSK1120212, TAK-733, U0126, MEK162, and GDC-0973.

[0308] Exemplary centrosome declustering agents include, but are not limited to, griseofulvin; noscapine, noscapine derivatives, such as brominated noscapine (e.g., 9-bromobenzcapine), reduced bromonoscapine (RBN), N-(3-bromobenzyl)noscapine, amine noscapines, and water-soluble derivatives thereof; CW069; phenanthrene-derived poly (ADP-ribose) polymerase inhibitors, PJ-34; N2-(3-pyridylmethyl)-5-nitro-2-furamide, N2-(2-thienylmethyl)-5-nitro-2-furamide, and N2-benzyl-5-nitro-2-furamide.

[0309] Exemplary multi-kinase inhibitors include, but are not limited to, regorafenib; sorafenib (Nexavar); sunitinib (Sutent); BIBW 2992; E7080; Zd6474; PKC-412; motesanib; or AP24534.

[0310] Exemplary serine / threonine kinase inhibitors include, but are not limited to, ruboxistaurin; eril / easudil hydrochloride; flavonoid antineoplastic agents; seliciclib (CYC202; Roscovitrine); SNS-032 (BMS-387032); Pkc412; bryostatin; KAI-9803; SF1126; VX-680; Azd1152; Arry-142886 (AZD-6244); SCIO-469; GW681323; CC-401; CEP-1707 or PD 332991.

[0311] Exemplary tyrosine kinase inhibitors include, but are not limited to, erlotinib (Tarceva); gefitinib (Iressa); imatinib (Gleevec); sorafenib (Nexavar); sunitinib (Sutent); trastuzumab (Hecanpin); bevacizumab (Avastin); rituximab (Rituxan); lapatinib (Tykerb); cetuximab (Erbitux); panitumumab (Vectibix); everolimus (Afinitor); alemtuzumab (Campath); gemtuzumab (M ylotarg); temsirolimus (Torisel); pazopanib (Votrient); dasatinib (Sprycel); nilotinib (Tasigna); vatalanib (Ptk787; ZK222584); CEP-701; SU5614; MLN518; XL999; VX-322; Azd0530; BMS-354825; SKI-606CP-690; AG-490; WHI-P154; WHI-P131; AC-220; or AMG888.

[0312] Exemplary VEGF / VEGFR inhibitors include, but are not limited to, bevacizumab (Avastin); sorafenib (Nexavar); sunitinib (Sutent); ranibizumab; pegaptanib; or vandetinib.

[0313] Exemplary microtubule-targeting drugs include, but are not limited to, paclitaxel, docetaxel, vincristin, vinblastin, nocodazole, epothilone, and navelbine.

[0314] Exemplary topoisomerase poison drugs include, but are not limited to, teniposide, etoposide, doxorubicin, camptothecin, daunorubicin, actinomycin D, mitoxantrone, amsacrine, epirubicin, and idarubicin.

[0315] Exemplary taxanes or taxane derivatives include, but are not limited to, paclitaxel and docetaxel.

[0316] Exemplary general chemotherapeutic agents, anti-tumor agents, and anti-proliferative agents include, but are not limited to, Hexalen; Accutane; Amnesteem; Claravis; Sotret; Vesanoid; Azacitidine; Bortezomib; Elspar; Levamisole; Mitotane; Procarbazine; and Pemetrexed. Oncaspar; Ontak; Photofrin; Proleukin; Revlimid; Targretin; Thalidomide; Torisel; Trisenox; Visudyne; Leucenol; (1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyrimidine-1 M potassium oxazolidinone) or lovastatin.

[0317] In certain embodiments, the anti-tumor antagonists described herein are administered at a subtherapeutic dose, other anti-immune checkpoint regulator antibodies or antagonists are administered at a subtherapeutic dose, the angiogenesis antagonist is administered at a subtherapeutic dose, or any antagonists combined therewith are each administered at a subtherapeutic dose.

[0318] In certain embodiments, the inhibition of TGFβ / TGFβRII, checkpoint regulators, and / or angiogenesis pathways can be combined with standard cancer treatments (e.g., surgery, radiotherapy, and chemotherapy) according to common chemotherapy regimens. In these cases, the dosage of the chemotherapeutic agent administered may be reduced. Examples of such combinations are combining the checkpoint regulator antagonists of the present application with dacarbazine for the treatment of melanoma. Other examples of such combinations are combining the checkpoint regulator antagonists of the present application with interleukin-2 (IL-2) for the treatment of melanoma. It is believed that the combined use of checkpoint regulator inhibition and chemotherapy can enhance the apoptosis of cytotoxic immune effects and increase tumor antigen presentation. Other synergistic combined therapies include inhibition of checkpoint regulators via cell death when combined with radiotherapy, surgery, or hormone removal therapy. Each of these schemes creates a source of tumor antigens in the host.

[0319] In certain embodiments, the checkpoint regulator antagonists described herein can be used as multispecific antagonists, or in combination with bispecific antibodies that target effector cells expressing Fcα or Fcγ receptors to cancer cells (see, for example, U.S. Patents 5,922,845 and 5,837,243). Bispecific antibodies can be used to target two independent antigens. For example, anti-Fc receptor / anti-tumor antigen (e.g., Her-2 / neu) bispecific antibodies have been used to target macrophages to cancer cells or tumors. This targeting can more effectively activate tumor-specific responses. The T cell arm of these reactions can be enhanced by the inhibition of checkpoint regulators. Alternatively, the antigen can be delivered directly to DCs by the use of bispecific antibodies that bind to specific cell surface markers of tumor antigens and dendritic cells.

[0320] III. Nucleic Acids and Host Cells for Expressing Anti-tumor Antagonists

[0321] In another aspect, the present invention provides nucleic acids encoding the anti-tumor antagonists of the present invention, including heavy and light chains, and expression vectors comprising these nucleic acids. In particular, the nucleic acids encode one or more HCDRs, LCDRs, HCVRs, and / or LCVRs corresponding to any of the antibodies, antagonists, or fragments described herein.

[0322] Herein, in one aspect, the invention provides one or more nucleic acids encoding any of the anti-tumor antagonists, antibodies, or antigen-binding portions thereof described herein.

[0323] In another aspect, the present invention provides one or more expression vectors comprising one or more nucleic acids encoding any of the anti-tumor antagonists, antibodies, or antigen-binding portions thereof described herein.

[0324] In another aspect, the present invention provides the use of one or more host cells transfected with an expression vector comprising one or more nucleic acids encoding any of the anti-tumor antagonists, antibodies, or antigen-binding portions thereof described herein.

[0325] DNA(s) of the antigen binding site can be isolated and sequenced from monoclonal antibodies produced by hybridoma cells using common procedures (e.g., using oligonucleotide probes that specifically bind to genes encoding the heavy and light chains of the monoclonal antibodies). Alternatively, the amino acid sequence of the immunoglobulin of interest can be determined by direct protein sequencing, and an appropriate encoding nucleotide sequence can be designed based on a universal codon table. In other cases, the nucleotide and amino acid sequences of the antigen binding site or other immunoglobulin sequences (including constant regions, hinge regions, etc.) can be obtained from public sources known in the art.

[0326] In one aspect, any binding antagonist fragment of the present invention may comprise a synthetic DNA fragment optimized using codons corresponding to, for example, an antibody variable region. For example, the codons of a cDNA sequence encoding an immunoglobulin VH, VL, HC, LC, CH1, CH2, CH3, and / or framework region may be optimized for expression in various human, primate, or mammalian cells (e.g., HEK or CHO cells). The present invention also features a nucleic acid molecule comprising one or two nucleotide sequences encoding the heavy and light chain variable regions, CDRs, hypervariable loops, and framework regions of the anti-PD-L1 antibody molecules described herein.

[0327] Expression vectors encoding specific bispecific anti-tumor antagonists can be used to synthesize the anti-tumor antagonists herein in cultured cells in vitro, or they can be directly administered to patients to express the anti-tumor antagonists in vivo or ex vivo. As used herein, "expression vector" refers to a viral or non-viral vector that contains a polynucleotide encoding one or more polypeptide chains corresponding to the bispecific anti-tumor antagonist herein, and is presented in a form suitable for expressing the host polynucleotide for antibody production purposes or for direct administration as a therapeutic agent.

[0328] A nucleic acid sequence is "operably linked" to another nucleic acid sequence when the former is in a functional relationship with the latter. For example, the DNA for a presequence or signal peptide is operably linked to the DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. In general, "operably linked" means that the DNA sequences being linked are contiguous, and in the case of a signal peptide, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adapters or connecting peptides can be used according to routine procedures.

[0329] The nucleic acid sequence for expressing the checkpoint regulator antagonist generally includes an amino terminal signal peptide sequence removed from the mature protein. Since the signal peptide sequence can affect the expression level, the polynucleotide can encode any one of a variety of different N-terminal signal peptide sequences. It will be appreciated by those skilled in the art that the design of the expression vector may depend on factors such as the selection of the host cell to be transfected, the desired protein expression level, and the like.

[0330] The term "regulatory sequence" as used herein refers to a DNA sequence necessary for the expression of an operably linked coding sequence in one or more host organisms. The term "regulatory sequence" is intended to include promoters, enhancers, and other expression control components (e.g., polyadenylation signals). Regulatory sequences include those that direct the constitutive expression of a nucleotide sequence in many types of host cells or that direct the expression of a nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). Expression vectors typically contain sequences for transcription termination and may additionally contain one or more components that positively influence mRNA stability.

[0331] Expression vectors contain one or more transcriptional regulatory components, including promoters and / or enhancers, to direct the expression of anti-tumor antagonists. Promoters contain a DNA sequence that initiates transcription from a fixed transcription start site. Promoters contain the core components required for the basic interaction between RNA polymerase and transcription factors and can operate in conjunction with other upstream components and response elements.

[0332] As used herein, the term "promoter" should be used in its broadest sense and includes transcriptional regulatory elements (TREs) from genomic genes or from chimeric TREs thereof, including TATA boxes or initiator elements for precise transcription initiation, with or without additional TREs (i.e., upstream activating sequences, transcription factor binding sites, enhancers, and silencers), which regulate the activation or repression of genes to which they are operably linked in response to development and / or external stimuli, as well as trans-acting regulatory proteins or nucleic acids. A promoter may comprise a genomic fragment, or it may contain a chimera of one or more TREs combined together.

[0333] Preferred promoters are those that direct high levels of expression in target cells. Promoters may include constitutive promoters (e.g., HCMV, SV4, elongation factor-1α (EF-1α)) or promoters that exhibit better expression in specific target cell types. An enhancer generally refers to a DNA sequence that acts distal to the transcription start site and may be 5' or 3' to the transcription unit. Furthermore, enhancers may be found in introns and within coding sequences. They are typically between 10 and 300 bp in length and act in cis. The function of an enhancer is to increase and / or regulate transcription from a nearby promoter. Preferred enhancers are those that direct high levels of expression in antibody-producing cells. Cell- or tissue-specific transcriptional regulatory elements (TREs) may be introduced into expression vectors to restrict expression to desired cell types. Pol III promoters (H1 or U6) are particularly suitable for shRNAs that can express siRNAs. Expression vectors may be designed to promote expression of anti-tumor antagonists in one or more cell types.

[0334] In certain embodiments, one or more expression vectors can be designed to express an anti-tumor antagonist and one or more siRNAs targeting the Tie2 pathway, VEGF pathway, or immune checkpoint regulators.

[0335] siRNA is double-stranded RNA, which can be designed to induce gene silencing after mRNA sequence specific transcription. The siRNA produced by synthesis structurally simulates the siRNA type normally processed by the Dicer enzyme in cells. When expressed by an expression vector, the expression vector is designed to transcribe a short double-stranded hairpin RNA (shRNA) that is processed into siRNA in the target cell. siRNA and shRNA synthesized using known algorithmic design can be synthesized, and common DNA / RNA synthesizers are used to synthesize.

[0336] In order to co-express the individual chains of the anti-tumor antagonist, appropriate splice donor and splice acceptor sequences can be introduced to express two products. Alternatively, an internal ribosome binding sequence (IRES) or a 2A peptide sequence can be used to express multiple products from a single promoter. IRES provides a structure that ribosomes can bind to without having to bind at the 5' end of the mRNA. Therefore, it can guide the ribosome to initiate translation at the second start codon of the mRNA, allowing a single mRNA to produce more than one polypeptide. The 2A peptide contains a short sequence that mediates the co-translational self-cleavage of peptides upstream and downstream of the 2A site, which allows the production of two equimolar amounts of different proteins in a single transcript. CHYSEL is a non-limiting example of a 2A peptide that causes the translating ribosomes of eukaryotic organisms to release the growing polypeptide chain without dissociating from the mRNA. The ribosomes continue to translate, thereby producing a second polypeptide.

[0337] Expression vectors may include viral vectors or non-viral vectors. Viral vectors may be derived from adeno-associated virus (AAV), adenovirus, herpes virus, vaccinia virus, poliovirus, poxvirus, retrovirus (including lentiviruses such as HIV-1 and HIV-2), Sindbis and other RNA viruses, alphaviruses, astroviruses, coronaviruses, orthomyxoviruses, papovaviruses, paramyxoviruses, parvoviruses, picornaviruses, togaviruses, etc. Non-viral vectors are simply "naked" expression vectors that are not packaged with virus-derived components (e.g., capsid and / or envelope).

[0338] In some cases, these vectors can be designed to target certain diseases or cell populations by using targeting features inherent to or designed into viral vectors. Specific cells can be "targeted" for delivery and expression of polynucleotides. Thus, in this context, the term "targeting" can be based on the use of capsids, envelope proteins, endogenous or heterologous binding agents in the form of antibodies that are delivered to specific cells, tissue-specific regulatory components that restrict expressing cells to a specific subset, or both.

[0339] In some embodiments, the expression of the antibody chain is under the control of a regulatory element, such as a tissue-specific or ubiquitous promoter. In some embodiments, a ubiquitous promoter (e.g., CMV promoter, CMV-chicken β-actin hybrid (CAG) activator, tissue-specific or tumor-specific promoter) controls the expression of the specific antibody heavy chain, or light chain, or single-chain derivative thereof.

[0340] Non-viral expression vectors can be used for non-viral gene transfer, either by direct injection of naked DNA or by encapsulating polynucleotides encoding anti-tumor antagonists in liposomes, microparticles, microcapsules, virus-like particles, or erythrocyte ghosts. These compositions can be further linked to targeting domains by chemical complexation to facilitate targeted delivery and / or entry of the nucleic acid into the desired target cells. In addition, plasmid vectors can be incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations (e.g., polylysine, protamine, and albumin) and linked to cell-targeting ligands (e.g., non-sialomycin, insulin, galactose, lactose, or transferrin).

[0341] Alternatively, naked DNA can be used. The uptake efficiency of naked DNA can be improved by compaction or by using biodegradable latex beads. These deliveries can be further improved by treating the beads to increase their hydrophobicity, thereby promoting the destruction of endosomes and releasing the DNA into the cytoplasm.

[0342] IV. Methods of Making Bispecific Antagonists

[0343] In another aspect, the present invention provides a host cell transfected with a nucleic acid or expression vector encoding a bispecific anti-tumor antagonist of the present invention. The host cell can be any eukaryotic or prokaryotic cell capable of expressing the bispecific anti-tumor antagonist of the present invention (including its immunoglobulin heavy or light chain).

[0344] In another aspect, a method for producing an anti-tumor antagonist comprises culturing a host cell transfected with one or more nucleic acids or expression vectors encoding a bispecific anti-tumor antagonist of the invention under conditions that allow for the production and purification of the antagonist, antibody, or fragment thereof suitable for expression in the cell.

[0345] In another aspect, the present invention provides a method for producing an antibody, comprising culturing cells that transiently or stably express one or more structures encoding one or more polypeptide chains in an antibody; and purifying the antibody from the cultured cells. Any cell capable of producing a functional antibody can be used. In a preferred embodiment, the antibody-expressing cell is a eukaryotic or mammalian cell (preferably a human cell). Cells from various tissue cell types can be used to express antibodies. In another embodiment, the cell is a yeast cell, an insect cell, or a bacterial cell. Preferably, the antibody-producing cell is stably transfected with an antibody expression vector.

[0346] One or more expression vectors encoding the heavy and light chains of the antibodies can be introduced into the cells by any common method, such as naked DNA technology, cationic lipid-mediated transfection, polymer-mediated transfection, peptide-mediated transfection, viral-mediated infection, physical or chemical agents or treatment, electroporation, etc. In addition, cells can be transfected with one or more expression vectors and a selectable marker to facilitate the selection of stably transfected clones expressing the antibody. The antibodies produced by the cells can be purified and / or collected according to techniques known in the art, such as by centrifugation, chromatography, etc.

[0347] Examples of selectable markers suitable for mammalian cells include dihydrofolate reductase (DHFR), thymidine kinase, neomycin, the neomycin analog G418, hycomycin, and puromycin. Once a selectable marker has been successfully transferred to a mammalian host cell, the transformed mammalian host cell can survive under selective pressure. There are two widely used distinct classes of selectivity systems. The first is based on cellular metabolism and utilizes mutant cell lines that lack the ability to grow independently of supplemented medium. Two examples are CHO DHFR-cells and mouse LTK-cells. These cells lack the ability to grow without supplemented nutrients such as thymidine or hypoxanthine. These cells lack certain genes necessary for the complete nucleotide synthesis pathway and therefore cannot survive unless the missing nucleotides are provided in supplemented medium. An alternative to supplementing medium is to introduce the complete DHFR or TK gene into cells lacking the corresponding gene, thereby altering their growth requirements. Individual cells not transformed with the DHFR or TK gene will not survive in unsupplemented medium.

[0348] The second type is dominant selection, which refers to selection schemes used in any cell type and does not require the use of mutant cell lines. These schemes usually use drugs to block the growth of host cells. These cells with the new gene will express proteins that express drug resistance and will survive the selection. Examples of this dominant selection are the use of the drugs neomycin, mycophenolic acid, or hygromycin. These three examples use bacterial genes under the control of eukaryotic cells to express resistance to the appropriate drugs G418 or neomycin (geneticin), xgpt (mycophenolic acid), or hygromycin, respectively. Others include the neomycin analog G418 and puromycin.

[0349] Examples of antibody-expressing cells include human Jurkat, human embryonic kidney (HEK) 293, Chinese hamster ovary (CHO) cells, mouse WEHI fibrosarcoma cells, and single-cell protozoan species, such as Leishmania. Additionally, primary cells can be immortalized using c-myc or other immortalizing agents to generate stably transformed antibody-producing cell lines.

[0350] In one embodiment, the cell line comprises a stably transformed Leishmania cell line, such as Leishmania tarentolae. Leishmania is known to be a robust, rapidly growing, unicellular host that can express eukaryotic proteins with mammalian-type glycosylation patterns at high levels. A commercially available Leishmania expression kit (Jena Bioscience GmbH, Jena, Germany) can be used.

[0351] In some embodiments, the cell line expresses at least 1 mg, at least 2 mg, at least 5 mg, at least 10 mg, at least 20 mg, at least 50 mg, at least 100 mg, at least 200 mg, at least 300 mg, at least 400 mg, or at least 500 mg of the antibody per liter of culture medium.

[0352] The antibodies of the present invention can be cultured in any suitable culture medium (e.g., RPMI, DMEM, and ) are cultured and maintained in a culture medium and then isolated from the antibody-expressing cells. Antibodies can be purified using common protein purification methods (e.g., affinity purification, chromatography, etc.), including immunoaffinity purification using protein A or protein G. In some embodiments, the antibodies are designed to be secreted into the isolated culture supernatant.

[0353] V. Pharmaceutical Compositions and Methods of Treatment

[0354] Another aspect of the present invention relates to pharmaceutical compositions and methods for treating cell proliferative disorders (e.g., cancer, chronic infection, or immunocompromised disease states). In one embodiment, the pharmaceutical composition comprises one or more anti-tumor antagonists of the present invention. In some embodiments, the anti-tumor antagonist comprises one or more TGF-β1 inhibitors or TGF-β1RII inhibitors in combination with: (1) a PD-1 inhibitor or a PD-L1 inhibitor; or, (2) one or more angiogenesis inhibitors, such as VEGF inhibitors, VEGFR2 inhibitors, angiopoietin-1 / 2 inhibitors, and Tie2R inhibitors. The antagonist is formulated with a pharmaceutically acceptable carrier. The pharmaceutical composition of the present invention may include one or more different antibodies, one or more multispecific antibodies, one or more immune complexes, or a combination thereof as described herein.

[0355] As described above, the method of using the pharmaceutical composition described herein comprises administering an effective amount of the pharmaceutical composition according to the present specification to a subject in need thereof.

[0356] Any suitable route or mode of administration can be used to provide a therapeutically or prophylactically effective amount of an antibody or antagonist to a patient. Exemplary routes or modes of administration include parenteral (e.g., intravenous, intraarterial, intramuscular, subcutaneous, intratumoral), oral, topical (nasal, transdermal, intradermal, or intraocular), mucosal (e.g., nasal, sublingual, oral, rectal, vaginal) inhalation, intralymphatic, intraspinal, intracranial, intraperitoneal, intratracheal, intravesical, intrathecal, intestinal, intrapulmonary, intralymphatic, intravascular, intraorbital, intracystic, and transurethral, ​​as well as local delivery via a catheter or stent.

[0357] Pharmaceutical compositions comprising antibodies or antagonists according to this specification can be formulated with any pharmaceutically acceptable carrier or excipient. As used herein, the term "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial agents, and antifungal agents, isotonic agents, and absorption delaying agents that are physiologically compatible. Pharmaceutical compositions may include suitable solid or gel phase carriers or excipients. Exemplary carriers or excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycol. Exemplary pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like, as well as combinations thereof. In many cases, isotonic agents, such as sugars, polyols such as mannitol and sorbitol, or sodium chloride, are preferably included in the composition. Pharmaceutically acceptable carriers may further include small amounts of auxiliary substances, such as wetting agents or emulsifiers, preservatives, or buffers, which increase the shelf life or effectiveness of the therapeutic agent.

[0358] Checkpoint regulator antagonists can be incorporated into pharmaceutical compositions suitable for parenteral administration. Suitable buffers include, but are not limited to, sodium succinate, sodium citrate, sodium phosphate, or potassium phosphate. Sodium chloride can be used to change the toxicity of solutions with a concentration of 0-300 millimolar concentration (mM) (optimally 150 millimolar concentration for liquid dosage forms). Cryoprotectants can be included in freeze-dried dosage forms, mainly 0-10% sucrose (optimally 0.5-1.0%). Other suitable cryoprotectants include trehalose and lactose. Freeze-dried dosage forms may include fillers, mainly 1-10% mannitol (optimally 2-4%). ​​Liquid and freeze-dried dosage forms can use stabilizers, mainly L-methionine at a concentration of 1-50 millimolar (optimally 5-10 millimolar concentration). Other suitable fillers include glycine and arginine, which can be included in the form of 0-0.05% polysorbate-80 (optimally 0.005-0.01%). Additional surfactants include, but are not limited to, polysorbate 20 and BRIJ surfactant.

[0359] The therapeutic anti-tumor antagonist formulation can be lyophilized and stored as a sterile powder, preferably under vacuum, and then reconstituted in bacteriostatic water (containing a preservative such as benzyl alcohol) or in sterile water before injection. The pharmaceutical composition can be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion.

[0360] The therapeutic agent in the pharmaceutical composition can be formulated in a "therapeutically effective amount" or a "prophylactically effective amount." A "therapeutically effective amount" refers to an amount effective to achieve the desired therapeutic outcome at the necessary dosage and time period. The therapeutically effective amount of the recombinant vector can vary depending on the condition being treated, the severity and course of the condition, the mode of administration, whether the antibody or agent is being administered for preventive or therapeutic purposes, the bioavailability of the specific agent, the ability of the anti-tumor antagonist to elicit the desired response in the individual, previous therapy, the patient's age, weight, and sex, the patient's clinical history and response to the antibody, the type of anti-tumor antagonist used, the attending physician's considerations, and the like. A therapeutically effective amount is also an amount in which any toxic or deleterious effects of the recombinant vector outweigh the beneficial effects of the treatment. A "prophylactically effective amount" refers to an amount effective to achieve the desired prophylactic outcome at the necessary dosage and time period.

[0361] Preferably, the polypeptide region in the anti-tumor antagonist is derived from the same host to which it will be administered, in order to reduce the inflammatory response to the administered therapeutic agent.

[0362] The anti-tumor antagonist is suitably administered to the patient at one time or over a series of treatments and may be administered to the patient at any time from diagnosis. The anti-tumor antagonist may be administered as a monotherapy or in combination with other drugs or therapies used to treat the disease.

[0363] As a general rule, a therapeutically or prophylactically effective amount of an anti-tumor antagonist will be administered in a range of about 1 ng / kg body weight / day to about 100 mg / kg body weight / day, whether by single or multiple administrations.In certain embodiments, each anti-tumor antagonist is administered in the range of about 1 ng / kg body weight / day to about 10 mg / kg body weight / day, about 1 ng / kg body weight / day to about 1 mg / kg body weight / day, about 1 ng / kg body weight / day to about 100 μg / kg body weight / day, about 1 ng / kg body weight / day to about 10 μg / kg body weight / day, about 1 ng / kg body weight / day to about 1 μg / kg body weight / day, about 1 ng / kg body weight / day to about 100 ng / kg body weight / day, about 1 ng / kg body weight / day to about 10 ng / kg body weight / day, about 10 ng / kg body weight / day to about 100 mg / kg body weight / day, about 10 ng / kg body weight / day to about 100 kg body weight / day to about 10 mg / kg body weight / day, about 10 ng / kg body weight / day to about 1 mg / kg body weight / day, about 10 ng / kg body weight / day to about 100 μg / kg body weight / day, about 10 ng / kg body weight / day to about 10 μg / kg body weight / day, about 10 ng / kg body weight / day to about 1 μg / kg body weight / day, 10 ng / kg body weight / day to about 100 ng / kg body weight / day, about 100 ng / kg body weight / day to about 100 mg / kg body weight / day, about 100 ng / kg body weight / day to about 1 mg / kg body weight / day, about 100 n g / kg body weight / day to about 100 μg / kg body weight / day, about 100 ng / kg body weight / day to about 10 μg / kg body weight / day, about 100 ng / kg body weight / day to about 1 μg / kg body weight / day, about 1 μg / kg body weight / day to about 100 mg / kg body weight / day, about 1 μg / kg body weight / day to about 10 mg / kg body weight / day, about 1 μg / kg body weight / day to about 1 mg / kg body weight / day, about 1 μg / kg body weight / day to about 100 μg / kg body weight / day, about 1 μg / kg body weight / day to about 10 μg / kg body weight / day, about 10 μg / kg body weight / day to about 100 mg / kg body weight / day, about 10 μg / kg body weight / day g / kg body weight / day to about 10 mg / kg body weight / day, about 10 μg / kg body weight / day to about 1 mg / kg body weight / day, about 10 μg / kg body weight / day to about 100 μg / kg body weight / day, about 100 μg / kg body weight / day to about 100 mg / kg body weight / day, about 100 μg / kg body weight / day to about 10 mg / kg body weight / day, about 100 μg / kg body weight / day to about 10 mg / kg body weight / day, about 100 μg / kg body weight / day to about 1 mg / kg body weight / day, about 1 mg / kg body weight / day to about 100 mg / kg body weight / day, about 1 mg / kg body weight / day to about 100 mg / kg body weight / day, about 10 mg / kg body weight / day to about 100 mg / kg body weight / day.

[0364] In other embodiments, the anti-tumor antagonist is administered at a dose of 500 μg to 20 grams every three days, or 25 mg / kg body weight every three days.

[0365] In other embodiments, each anti-tumor antagonist is administered in a range of about 10 ng to about 100 ng per single administration, about 10 ng to about 1 μg per single administration, about 10 ng to about 10 μg per single administration, about 10 ng to about 100 μg per single administration, about 10 ng to about 1 mg per single administration, about 10 ng to about 10 mg per single administration, about 10 ng to about 100 mg per single administration, about 10 ng to about 1000 mg per injection, about 10 ng to about 10,000 mg per single administration, about 100 ng to about 1 μg per single administration, about 100 ng to about 1000 mg per single administration. ng to about 10 μg, about 100 ng to about 100 μg each time, about 100 ng to about 1 mg each time, about 100 ng to about 10 mg each time, about 100 ng to about 100 mg each time, about 100 ng to about 1000 mg each time, about 100 ng to about 10,000 mg each time, about 1 μg to about 10 μg each time, about 1 μg to about 100 μg each time, about 1 μg to about 100 μg each time, about 1 μg to about 10 mg each time, about 1 μg to about 100 mg each time, about 1 μg to about 100 mg each time, about 1 μg to about 100 mg each time g to about 1000 mg, about 1 μg to about 10,000 mg per single administration, about 10 μg to about 100 μg per single administration, about 10 μg to about 1 mg per single administration, about 10 μg to about 10 mg per single administration, about 10 μg to about 100 mg per single administration, about 10 μg to about 1000 mg per injection, about 10 μg to about 10,000 mg per single administration, about 100 μg to about 1 mg per single administration, about 100 μg to about 10 mg per single administration, about 100 μg to about 1000 mg per injection, Each single administration is about 100 μg to about 10,000 mg, each single administration is about 1 mg to about 10 mg, each single administration is about 1 mg to about 100 mg, each single administration is about 1 mg to about 1000 mg, each injection is about 1 mg to about 10,000 mg, each single administration is about 10 mg to about 100 mg, each injection is about 10 mg to about 1000 mg, each single administration is about 10 mg to about 10,000 mg, each injection is about 100 mg to about 1000 mg, each single administration is about 100 mg to about 10,000 mg, each single administration is about 100 mg to about 10,000 mg, and each single administration is about 1000 mg to about 10,000 mg. The anti-tumor antagonist can be administered daily, every 2, 3, 4, 5, 6 or 7 days, or every 1, 2, 3 or 4 weeks.

[0366] In other specific embodiments, the anti-tumor antagonist can be administered at a dose of about 0.0006 mg / day, 0.001 mg / day, 0.003 mg / day, 0.006 mg / day, 0.01 mg / day, 0.03 mg / day, 0.06 mg / day, 0.1 mg / day, 0.3 mg / day, 0.6 mg / day, 1 mg / day, 3 mg / day, 6 mg / day, 10 mg / day, 30 mg / day, 60 mg / day, 100 mg / day, 300 mg / day, 600 mg / day, 1000 mg / day, 2000 mg / day, 5000 mg / day, or 10,000 mg / day. As expected, the dosage will depend on the patient's condition, size, age, and condition.

[0367] In certain embodiments, the sequence encoding the anti-tumor antagonist is introduced into a suitable expression vector (e.g., a viral or non-viral vector) to express an effective amount of the anti-tumor antagonist in a patient suffering from a cell proliferative disorder. In certain embodiments comprising administering, for example, one or more recombinant AAV (rAAV) viruses, the pharmaceutical composition may include rAAV in an amount of at least 10 per kilogram. 10 , at least 10 11 , at least 10 12 , at least 10 13 , or at least 10 14 In certain embodiments, the pharmaceutical composition comprises an effective amount of a recombinant virus (e.g., rAAV) containing at least 10 genome copies (GC) or recombinant virus particles, or any range thereof. 10 , at least 10 11 , at least 10 12 , at least 10 13 , at least 10 14 , at least 10 15 genome copies or recombinant viral particle genome copies, or any range thereof.

[0368] Doses can be tested in several art-accepted animal models applicable to any particular cell proliferative disorder.

[0369] Delivery methods may also include the use of polycationic condensed DNA linked or not to killed viruses, ligand-linked DNA, liposomes, eukaryotic cell delivery vector cells, deposition of photopolymerizable hydrogel materials, use of handheld gene transfer particle guns, ionizing radiation, nuclear charge neutralization or fusion with cell membranes, particle-mediated gene transfer, and the like.

[0370] The present invention is further illustrated by the following examples, which should not be construed as limiting. All references, patents, and published patent applications, as well as the figures and tables cited herein are incorporated herein by reference. Example

[0371] Example 1: Production of monoclonal antibodies

[0372] Monoclonal antibodies (mAbs) of the present invention are generated and screened using techniques known in the art, see, for example, Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York. Antigen-specific fusion tumor monoclonal antibodies are cloned, sequenced, and designed using techniques known in the art, see, for example, Lo. BKC Methods in Molecular Biology. TM (Methods in Molecular Biology TM )》.Volume 248 2004.Antibody Engineering.

[0373] Example 2: Design of bispecific anti-tumor antagonists

[0374] Figure 5A and 5B Two bispecific anti-tumor antagonists, Bi-PB-1 (or Bi-PLB-1) and Bi-PB-1 (or Bi-PLB-2), are shown. These antagonists contain a checkpoint regulator antibody backbone (anti-PD-1 or anti-PD-L1) and a TGF-βRII extracellular domain (TGF-β-RII ECD): (i) fused to the carboxyl terminus of the CH3 region of each of the two heavy chains ( Figure 5A ) or (ii) inserted into the CH3 region of the Fc loop ( Figure 5B ).

[0375] exist Figure 5A and 5B In the depicted embodiment, the bispecific antibody can have an IgG1 or IgG4 backbone. Furthermore, any one or more antibody specificities can be replaced with any other checkpoint regulator antagonist specificity and / or any tumor targeting antibody specificity (e.g., CD20, EGFR, etc.).

[0376] Figure 6 Shows the corresponding Figure 5A and 5B Exemplary functional region sequences of bispecific antibodies.

[0377] Figure 7A-7B shows the corresponding Figure 5A and 5B Exemplary heavy chains (HC) and light chains (LC) of bispecific antibodies.

[0378] Example 3: Design of other bispecific antagonists

[0379] Figures 8A-8C Designs for three different bispecific antagonists are shown: Bi-AB-1, Bi-A1B-1, and Bi-ZB-1, each containing a carboxy-terminal TGF-β1 RII extracellular domain (ECD) within a mutant IgG1 (K447A) scaffold. Bi-AB-1 and Bi-A1B-1 both contain the amino-terminal anti-VEGF variable regions (VH1, VL1) from Avastin / bevacizumab; Bi-A1B-1 includes two amino acid substitutions (E6Q, L11V) in the VH region. Bi-ZB-1 contains an amino-terminal aflibercept region upstream of the IgG1 Fc (K447A) region. In other embodiments, instead of the mutant IgG1 (K447A) scaffold, the bispecific antagonist comprises a wild-type IgG1 scaffold, a different mutant IgG1 scaffold, an IgG2 scaffold, a mutant IgG2 scaffold, an IgG4 scaffold, or a mutant IgG4 scaffold.

[0380] Figure 9A and 9B Shows the existence of Figures 8A-8C Depicted are the sequences of various functional regions in the bispecific antagonists.

[0381] Figure 10 Shows the corresponding Figures 8A-8C The amino acid sequences of the heavy chain (HC) and light chain (LC) of the bispecific antagonists are depicted.

[0382] Figure 11 Summary Figures 8A-8C Depicted arrangement of the functional domains of the bispecific antagonists.

[0383] Example 4: Figure 10-11 Expression and purification of antagonists

[0384] Figure 12 Figure 2 is a Coomassie Brilliant Blue-stained polyacrylamide gel showing increased expression levels of antagonists containing wt VEGF-A, or E6Q and L11V mutations (i.e., Bi-AB-1 and Bi-A1B-1, respectively) when transiently transfected into HEK293 cells, as determined by non-reducing polyacrylamide gel electrophoresis (PAGE). Figure 12The titers depicted were determined by quantifying cell supernatants using a POROS A column (Applied Biosystems). This analysis showed that Bi-A1B-1 expression levels were increased by 167% compared to Bi-AB-1.

[0385] Figure 13A Depicted are size exclusion chromatography (SEC) profiles showing the relative levels of high molecular weight (HMW), low molecular weight (LMW) species, and dimers obtained from Protein A purified Bi-AB-1 and Bi-A1B-1. Figure 13B Using a Tosoh TSKgel UP-G3000SWXL column, SE-UPLC determined that the percentage of purified dimer (98.6% for Bi-AB-1 and 98.7% for Bi-A1B-1) was significantly greater than the HMW (1%) and LMW (0.4%) species. These results indicate that fusion of the TGF-β1RII extracellular domain (ECD) to Bi-AB-1 and Bi-A1B-1 did not result in significant levels of high molecular weight (HMW) or low molecular weight (LMW) species.

[0386] Figures 14A-14B Coomassie blue-stained PAGE analysis of supernatants obtained after transient transfection with Bi-ZB-1 under non-reducing and reducing conditions is described. This analysis demonstrates good transient expression levels of Bi-ZB-1 (220 μg / ml) after 8 days of in vitro cell growth.

[0387] Figure 15 Depicted is a size exclusion chromatography (SEC) profile showing that Protein A purified Bi-ZB-1 has low levels of high molecular weight (HMW, 3.4%) and low molecular weight (LMW, 0.5%) species compared to the dimer (96.1%).

[0388] Example 5: Figures 8A-8C Functional properties of anti-tumor antagonists

[0389] To evaluate the ability of the anti-VEGF antagonist (Bi-A1B-1) to antagonize VEGF-mediated activation of VEGFR2 (i.e., the cognate receptor), a cell-based luciferase assay was performed. In this experiment, recombinant HEK-293 cells expressing human VEGFR2 and firefly luciferase under the control of the NFAT response element were stimulated with huVEGF165 in the presence of serially diluted anti-VEGF antagonist (Bi-A1B-1). The results of this assay are shown in Figure 16As expected, increasing concentrations of anti-VEGF antagonists gradually neutralized the ability of VEGF165 to activate VEGFR2 and induce NFAT-mediated luciferase activity.

[0390] To evaluate the ability of the bispecific antagonist (Bi-A1B-1) to simultaneously bind to TGF-β1 and VEGF165, a sandwich ELISA assay was performed. In this assay, huTGF-β1 was coated on a 96-well plate and blocked with 5% BSA. Serially diluted samples of Bi-A1B-1 were then added and incubated, followed by the addition of biotinylated hu VEGF165. Bound molecules were detected by streptavidin-HRP using TMB substrate. Figure 17 The analysis results in the study showed that the bispecific antagonist (Bi-A1B-1) could bind to both TGF-β1 and VEGF165 simultaneously.

[0391] To evaluate the ability of TGF-β1RII ECD to antagonize TGF-β1-mediated activation of human TGF-β1RII (i.e., the cognate receptor), a cellular luciferase assay was performed. In this experiment, recombinant HEK-293 cells expressing the human TGF-β1RII receptor and firefly luciferase under the control of SMAD response elements were stimulated with huTGF-β1 in the presence of serially diluted antibodies fused to TGF-β1RII ECD (Bi-A1B-1, Bi-ZB-1). The results of this assay are shown in Figure 18 As expected, increasing concentrations of antibodies containing the TGF-β1RII ECD gradually neutralized TGF-β1's ability to activate human TGF-β1RII and induce SMAD-mediated luciferase activity. In this setting, Bi-A1B-1 and Bi-ZB-1 exhibited similar antagonistic potency, as reflected by an IC50 of 0.32 nM for Bi-A1B-1 and 0.31 nM for Bi-ZB-1. These IC50s are comparable to those of a control TGFBR2 fusion product (IC50 = 0.20 nM).

[0392] In order to evaluate the pharmacokinetic properties of Bi-A1B-1 in vivo, a pharmacokinetic curve was drawn. Briefly, 10 mg / kg of each antagonist was intravenously injected into the tail vein of 6-10 week old female CD1 mice (n=2 mice for each molecule). Serum was collected at 3 minutes, 3 hours, 1 day, 3 days, 7 days and 10 days after injection. To detect antibodies in the serum, 96-well plates were coated with 5 μg / kg of goat anti-human IgG F(ab')2 fragments and then blocked with 5% milk (prepared with PBS). Mouse serum serially diluted in 5% milk and serially diluted purified protein molecules as standards were added to the 96-well plates. After incubation with peroxidase covalent mouse anti-human IgG and further washing, the bispecific antagonist Bi-A1B-1 ( Figure 19 ) antibodies were detected after incubation with TMB-ELISA substrate. The results of this analysis showed that the half-life (T 1 / 2 ) is 7.4-16 days.

[0393] Example 6: Design of bispecific PD-1 / PD-L1 antagonists with TGF-β1 ECDs

[0394] Figures 20A-20B Describes two bispecific anti-tumor antagonists, Bi-PB-1.2 ( Figure 20A ) and Bi-PLB-1.2( Figure 20B ), each containing an antibody backbone ((IgG4 K447A or IgG1 K447A) and the variable regions from anti-PD-1 and anti-PD-L1, respectively, and additionally including the TGF-β-RII ECD fused to the carboxyl terminus of each heavy chain CH3 region.

[0395] Figure 21 Shows the existence of Figure 20A and 20B Functional region sequences of bispecific antibodies in . Figure 22 Shows the corresponding Figure 20A and 20B The amino acid sequences of the heavy chain (HC) and light chain (LC) of the bispecific antagonists are depicted. Figure 23 Summary Figure 20A and 20B Depicted arrangement of the functional domains of the bispecific antagonists.

[0396] Example 7: Figures 20A-20B Expression and purification of bispecific antagonists in

[0397] Figure 24ADepicted are native polyacrylamide gel (PAGE) analyses showing expression levels of Bi-PB-1.2 and Bi-PLB-1.2 compared to 1 μg of purified parental control antibody (2P17) in a transient expression system. Figure 24B Depicted are size exclusion chromatography (SEC) profiles showing that Protein A purified Bi-PB-1.2, Bi-PLB-1.2, and anti-PDL1 TGF-β1RII ECD fusion antibody (benchmark) from transiently transfected HEK293 cells have low levels of high molecular weight (HMW) and low molecular weight (LMW) species compared to the dimerized molecule ("dimer"), as shown in FIG. Figure 24C shown. Figures 25A-25B The dimer, HMW, and LMW forms of Bi-PB-1.2 and Bi-PLB-1.2 exhibited good stability at 4°C for at least 4 weeks.

[0398] Example 8: Figures 20A-20B Functional properties of Bi-PB-1.2 and Bi-PLB-1.2 antagonists in

[0399] 1. Detection of Bi-PB-1.2 binding to PD-1 and TGF-β1 using bio-layer interferometry

[0400] Bio-light interferometry was performed using the Octet RED96 system (ForteBio Octet RED96 system) to determine the binding kinetics of the antibodies to His-tagged human PD-1 protein or His-tagged TGF-β1. 20 nM of antibody was placed in the anti-human IgG capture biosensor. The binding of the analyte (His-tagged human PD-1 or His-tagged TGF-β1 protein) was observed for 5 minutes by placing the sensor in a well containing 2 or 3-fold serial dilutions of the analyte (the highest concentration was 72 nM). The degree of dissociation was measured after the biosensor was transferred to the kinetic buffer alone and the interferometer signal was monitored for 10 minutes. The observed starting and ending velocities (Ka and Kd) were fit using a 1:1 binding global fit model containing at least 5 test concentrations, and the equilibrium binding constant K was then calculated. D .

[0401] Figures 26A-26E It shows that PD-1 and TGF-β1 bind to Bi-PB-1.2 (respectively Figure 26A 、 26B ) and bound to the corresponding anti-PD-1 antibody and benchmark (M7824 purchased from Merck KGA) (respectively Figure 26C 、 26D ) and their resulting binding affinity constants ( Figure 26E The results showed that the binding affinity of Bi-PB-1.2 for PD-1 and TGF-β1 was better than that of the anti-PD-1 benchmark and the M7824 benchmark.

[0402] 2. Detection of Bi-PLB-1.2 binding to PD-L1 and TGF-β1 using biofilm interferometry

[0403] The binding of Bi-PLB-1.2 to PD-L1 and TGF-β1 was detected using biomembrane interferometry as described above for Bi-PB-1.2. Figures 27A-27E showed that PD-L1 and TGF-β1 bind to Bi-PLB-1.2 (respectively Figure 27A 、 27B ), and bound to the corresponding anti-PD-L1 and anti-TGF-β-RII ECD fusion antibodies (TGF-β1 benchmark) (respectively Figure 27C 、 27D ) and their resulting binding affinity constants ( Figure 27E The results showed that the binding affinity of Bi-PLB-1.2 for TGF-β1 was better than that of the TGF-β1 ECD benchmark, and the binding affinity of Bi-PLB-1.2 for PD-L1 was comparable to that of the anti-PD-L1 benchmark.

[0404] 3. Use Bi-PB-1.2 and Bi-PLB-1.2 to bind to PD-1 / PD-L1 simultaneously

[0405] Figure 28A An ELISA assay showing simultaneous binding of Bi-PB-1.2 to TGF-β1 and PD-1 is shown, in which a 96-well plate coated with huTGF-β1 was incubated with serially diluted samples of Bi-PB-1.2 followed by His-tagged huPD-1, and bound molecules were detected by anti-His-tagged HRP using TMB substrate. Figure 28B ELISA assay showing simultaneous binding of Bi-PLB-1.2 to TGF-β1 and PD-L1, in which a 96-well plate coated with huTGF-β1 was incubated with serially diluted samples of Bi-PLB-1.2 followed by His-tagged huPD-L1, and the bound molecules were detected by anti-His-tagged HRP using TMB substrate. 50 Values ​​reflect half-maximal effect concentrations, which produce a response midway between baseline and maximal response for binding to human PD-1 or PD-L1, respectively.

[0406] 4. Bi-PB-1.2 effectively blocks the binding of PD-L1 and TGF-β1 to their receptors

[0407] exist Figure 29A In a blocking assay, the IC50 value corresponding to the ability of Bi-PB-1.2 to block PD-1 and PD-L1 binding was calculated compared to an anti-PD-1 benchmark antibody. Briefly, a two-fold serial dilution of Bi-PB-1.2 or a benchmark anti-PD-1 antibody was prepared (highest Ab concentration: 128 nM; triplicates for each mAb). CHO-K1 cells transfected with human PD-1 were washed with FACS buffer (PBS containing 0.5% BSA and 2 mM EDTA) and 10 6 The cells were resuspended at a concentration of 100 cells / ml. FITC-labeled human PD-L1-Fc protein was added to the CHO-K1 cells transfected with human PD-1 at a final concentration of 7 μg / ml and mixed evenly. In the absence of culture, 2,000 CHO-K1 cells (with PD-L1 protein) in 20 μl FACS buffer were immediately added to a 96-well round bottom plate, and 20 μl or 2-fold serial dilutions of antibody were immediately added to the cells and incubated at 4°C for 30 minutes. The cells were then washed and resuspended in 30 μl of 7AAD solution; then, 35 μl of 10% neutral buffered formalin solution was added and incubated for 15 minutes before analysis using the iQue intellicyt system. As expected, Figure 29A The analysis showed that increasing concentrations of Bi-PB-1.2 gradually blocked the ability of PD-L1 to bind to its receptor. Furthermore, the calculated IC50 of Bi-PB-1.2 against PD-L1 was found to be comparable to that of the anti-PD-1 benchmark.

[0408] In order to evaluate the ability of TGF-β1RII ECD to antagonize the activation of human TGF-β1RII (i.e., homologous receptor) mediated by TGF-β1, a cell luciferase assay was performed. In this experiment, it was shown that in the presence of serially diluted Bi-PB-1.2 with TGF-β1RIIECD, huTGF-β1 was used to stimulate recombinant HEK-293 cells expressing human TGF-β1RII receptor and firefly luciferase under the control of SMAD response elements. Biological activity was determined by measuring the decrease in luciferase-mediated fluorescence. The results of this test are shown in Figure 29BAs expected, increasing concentrations of Bi-PB-1.2 and a benchmark anti-PD-L1 TGF-β1RII ECD gradually neutralized the ability of TGF-β1 to activate human TGF-β1RII and induce SMAD-mediated luciferase activity. Furthermore, the calculated IC50 of Bi-PB-1.2 for TGF-β1 was found to be comparable to the IC50 of the benchmark anti-PD-L1 TGF-β1RII ECD for TGF-β1.

[0409] 5. Bi-PB-1.2 binds to human and cynomolgus monkey PD-1 with similar activity

[0410] To evaluate the ability of Bi-PB-1.2 to bind to human and cynomolgus monkey (cyno) PD-1, serial dilutions of Bi-PB-1.2 were added to CHO-K1 cells (20,000 cells / well) overexpressing human or cyno PD-1. The mixture was incubated at 4°C for 20 minutes, washed three times, and stained with a secondary antibody (PE-conjugated F(ab')2-goat anti-human IgG Fc; ThermoH10104) for 20 minutes at 4°C. Cells were washed with 7AAD solution and resuspended in 7AAD solution and fixed with 10% neutral buffered formalin for 15 minutes before analysis using the iQue Intellicyt system. Figures 30A-30B showed that Bi-PB-1.2 binds to human PD-1 ( Figure 30A ) and cyno PD-1( Figure 30B As expected, the anti-human PD-1 benchmark antibody was found to bind to human PD-1 ( Figure 30A ) and cynomolgus monkey PD-1 ( Figure 30B The half-maximal effect concentration (EC 50 )'s corresponding EC 50 values ​​that are generated midway between baseline and maximal responses for binding to human PD-1 and cyno PD-L1, respectively. In this case, EC 50 Bi-PB-1.2 showed similar binding properties to the benchmark antibody.

[0411] 6. Bi-PLB-1.2 effectively blocks the binding of PD-1 and TGF-β1 to their receptors

[0412] Blocking assays were performed to calculate IC50 values ​​corresponding to the binding between Bi-PLB-1.2 and PD-L1 compared to an anti-PD-L1 benchmark antibody, as described in Section 4 of Example 8 above. Figure 31AIncreasing concentrations of Bi-PLB-1.2 or an anti-PD-L1 benchmark antibody gradually blocked the binding of PD-1 to PD-L1. As reflected by the obtained IC50, this bispecific antibody was comparable to the anti-PD-L1 benchmark.

[0413] To calculate the IC50 value corresponding to the binding between Bi-PLB-1.2 and TGF-β1 compared to an anti-TGF-β1 benchmark antibody, the cellular assay described in Section 4 of Example 8 was performed. Figure 31B The ability of serially diluted Bi-PLB-1.2 and anti-PDL1-TGF-β1RII ECD benchmarks to block TGF-β1-activated luciferase expression under the control of SMAD response elements is shown. As reflected by the obtained IC50s, the bispecific antibody exhibited similar binding properties to the anti-PDL1-TGF-β1RII ECD benchmark.

[0414] 7. Bi-PLB-1.2 binds to human and cynomolgus monkey PD-1 with similar activity

[0415] To assess the ability of Bi-PLB-1.2 to bind human and cyno PD-1, serially diluted Bi-PLB-1.2 was added to CHO-K1 cells overexpressing human or cyno PD-1 (20,000 cells / well) as described in Section 5 of Example 9. Figures 32A-32B showed that Bi-PLB-1.2 interacts with human PD-L1 ( Figure 32A ) and cyno PD-L1( Figure 32B ) combined. The obtained EC 50 Values ​​reflect the half-maximal effect concentration (EC 50 ), which were generated midway between baseline and maximal responses for binding to human PD-1 and cyno PD-L1, respectively.

[0416] 8. Bi-PB-1.2 enhances T cell activation

[0417] Human T cell assays were performed to demonstrate the efficacy of the Bi-PB-1.2 antibody. Briefly, normal healthy human PBMCs collected from donors 1 and 2 were each activated using SEB (Toxin Technology, Cat#: BT202). To detect IFN-γ production, 100,000 cells were stimulated with 0.5 μg / ml of SEB in a 96-well plate. 25,000 tumor suppressor SHP77 cells were added to provide an inhibitory signal. 66 nM of Bi-PB-1.2 mAbs or isotype control Ab were added. After 5 days, supernatants were assayed for IFN-γ and IL-2 by ELISA. Figures 33A-33DCompared with negative control treatment, Bi-PB-1.2 increased IFN-γ (donor 1, Figure 33A ; Donor 2, Figure 33B ) and IL-2 (donor 1, Figure 33C ; Donor 2, Figure 33D ).

[0418] 9. Bi-PLB-1.2 better enhances T cell activation and overcomes T cell suppression by tumor cells than the parental anti-PD-L1 antibody

[0419] Figures 34A-34B showed that IFN-γ secretion from human PBMCs treated with Bi-PLB-1.2 was increased compared to negative control treatment and parental anti-PD-L1 antibody (donor 8, Figure 34A ; Donor 9, Figure 34B ). Figures 34C-34D We showed that Bi-PLB-1.2-treated human PBMCs increased IL-2 secretion compared to negative control treatment and the parental anti-PD-L1 antibody (donor 8, Figure 34C ; Donor 9, Figure 34D These results are consistent with the notion that Bi-PLB-1.2 is better than the parental anti-PD-L1 antibody in overcoming T cell inhibition of tumor cells.

[0420] 10. Bi-PB-1.2 and Bi-PLB-1.2 have improved pharmacokinetic profiles in mice compared to benchmark antibodies

[0421] To evaluate the pharmacokinetic properties of Bi-PB-1.2, Bi-PLB-1.2, and a benchmark antibody in vivo, pharmacokinetic curves were plotted. Briefly, 10 mg / kg of each antagonist was injected intravenously into the tail vein of 6-10 week old female CD1 mice (n=2 mice per molecule). Serum was collected 3 minutes, 3 hours, 1 day, 3 days, 7 days, and 10 days after injection. To detect antibodies in serum, 96-well ELISA plates were coated with 5 μg / kg of goat anti-human IgG F(ab')2 fragments and then blocked with 5% milk (prepared in PBS). Mouse serum serially diluted in 5% milk and serially diluted purified protein molecules as standards were added to the plates.

[0422] After incubation with peroxidase-covalent mouse anti-human IgG and further washing, TMB-ELISA substrate was added and Bi-PB-1.2 ( Figure 35A )、Bi-PLB-1.2( Figure 35C ), and anti-PDL1-TGF-β1RII ECD benchmark (M8724) ( Figure 35E ). Injected antibody Bi-PB-1.2 ( Figure 35B )、Bi-PLB-1.2( Figure 35D ) and benchmark ( Figure 35F The integrity and truncation of the antibodies in mouse serum were also analyzed by anti-human Fc Western blotting. This analysis showed that Bi-PB-1.2 and Bi-PLB-1.2 exhibited improved pharmacokinetic profiles in mice compared to the benchmark antibody.

[0423] Example 9: Exploring protein truncation in the TGFβ1RII ECD region

[0424] The inventors of the present application unexpectedly discovered that when antagonists containing the TGFβ1RII ECD region are produced by stably transfected CHO cells, they exhibit an unacceptable degree of protein degradation or truncation over time after storage. This is reflected in Figure 36 , which shows the determination of Bi-PB-1.2 (PD1 / TGFβ1RII ECD; see Figure 20A The percentage of low molecular weight (LMW) species of the peptides increased with storage time at 4°C, while the percentage of dimer species decreased with time.

[0425] Because no LMW form was seen when PD1 / PDL1-TGFB RII ECD molecules were produced by transient transfection of HEK293 cells, SEC analysis was performed to compare the stable CHO-produced benchmark and Bi-PB-1.2 from two different CHO transfection pools with HEK293 cells ( Figure 37 ) produced by Bi-PB-1.2. Figure 37 As shown, the SEC profile exhibits a shoulder near the main peak, as well as a smaller second peak for the molecule produced using CHO cells but not HEK293 cells, consistent with increased protein clipping (or truncation) for the CHO-produced molecule.

[0426] To further examine the specific nature of the cleavage, the Bi-PB-1.2 antagonist was expressed in CHO-K1 cells and subjected to cation exchange column chromatography (CEX) to generate fractions that were further analyzed by liquid chromatography-mass spectrometry (LC-MS) to identify the fraction associated with the truncation ( Figure 38). The same analysis was performed on Bi-A1B-1 (data not shown). For LC-MS analysis, the sample was enzymatically deglycosylated using PNGase F. The reduced intact protein was then separated by reverse ultra-performance liquid chromatography (RP-UPLC) using TSKgel Phenyl-5PW. Mobile phase A (MPA) and mobile phase B (MPB) were 0.05% formic acid in water and 0.05% formic acid in acetonitrile, respectively. The column effluent was directly passed through an online UV detector and then entered the ESI source of an ESI-TOF (time of flight) mass spectrometer. The data were deconvoluted using Waters Masslynx software. To confirm the accuracy of the sequence, the experimental mass of the reduced deglycosylated molecule was compared with the theoretical mass calculated based on the primary amino acid sequence.

[0427] Results from LC-MS (data not shown) identified several protein cleavage fragments ( Figure 39 More specifically, these analysis results showed that Bi-PB-1.2 and Bi-AB-1 have similar cleavage sites in their respective heavy chains, such as Figure 40A and 40B are further shown separately.

[0428] Example 10: Truncation-Reducing Properties of TGFβ1RII ECD Mutants

[0429] To develop variant molecules containing TGFβ1RII ECD that exhibit reduced truncation, the following were designed: Figures 41A-41C Various ECD mutations are shown. The mutations were designed to target the proposed truncation sites. Figures 42A-42H , 43 and 44A-44D respectively show the production and expression of the heavy chain sequences of Bi-PB-1.2, Bi-PLB-1.2, and Bi-A1B-1, which contain Figures 41A-41C The different ECD mutations described. Figure 45 Highlighted are: specific amino acid deletion mutations targeting the proposed truncation sites in the absence of additional substitutions (variants Δ7, Δ12, Δ13) and with additional substitutions (variants B, C, I-B1), as well as substitution mutations in the full-length molecule (variant DH).

[0430] The resulting molecules were transiently expressed in CHO cells and affinity purified from protein A. Figures 46A-46C middle, Figures 42A-42H Reduction PAGE analysis of the expression products showed a reduction in truncation in the variant molecules. Figure 47A and 47B The SEC profiles of the expression products shown are not accompanied by those seen in Bi-PB-1.2 or Figure 37 The observed "shoulder" and second peak. Figure 48 In Figure 5, the peaks in the SEC profiles were quantified and showed that the variants exhibited a lower percentage of high molecular weight forms compared to the parental molecule.

[0431] Example 11: Functional activity of TGFβ1RII ECD mutations

[0432] To confirm that the reduced truncation in the variants did not reduce functional activity, cell-based assays were performed to assess the functional activity of the ECD variants ( Figure 49 Briefly, HEK293-produced Bi-PB-1.2 and various TGFβ1RII ECD variants were serially diluted and tested (along with a negative control antibody) to see if the antagonists could block the ability of TGF-β1 to activate luciferase expression under conditions controlled by the SMAD response element as described above. Biological activity was determined by measuring the decrease in luciferase-mediated fluorescence. The IC50 results for this assay are summarized in Figure 50 It was shown that all variants except Bi-A1B-1W, Bi-PB-1.2Δ15 and Bi-PB-1.2Δ20 retained biological activities similar to those of the parental Bi-PB-1.2 and Bi-A1B-1.

[0433] Example 12: Pharmacokinetics of Bi-PB-1C and Bi-PB-1D

[0434] To evaluate the in vivo pharmacokinetic properties of Bi-PB-1.2C and Bi-PB-1.2D relative to Bi-PB-1.2 (wt), pharmacokinetic curves were prepared. Briefly, 10 mg / kg of each antagonist was injected intravenously into the tail vein of 6-10 week old female CD1 mice (n=2 mice per molecule). Serum was collected at 3 minutes, 3 hours, 1 day, 3 days, 7 days, and 10 days after injection. To detect antibodies in serum, 96-well ELISA plates were coated with 5 μg / ml goat anti-human IgG F(ab')2 fragment (Sigma, #SAB3701274) and then blocked with 5% milk in PBS. Mouse serum serially diluted in 5% milk and serially diluted purified protein molecules as standards were added to the plates. After incubation with Peroxidase AffiniPure Mouse Anti-Human IgG, FcγFragment Specific (Jackson ImmunoResearch, #209-035-098) and further washing, Bi-PB-1.2 ( Figure 51A )、Bi-PB-1.2C( Figure 51B ), and Bi-PB-1.2D( Figure 51C ) antagonists were detected after incubation with TMB-ELISA substrate solution (Thermo-Fisher, #34029) and quantified by OD650 signal using a Perkin Elmer multi-plate reader. This analysis showed that the mouse pharmacokinetic profiles of Bi-PB-1.2C and Bi-PB-1.2D were comparable to those of Bi-PB-1.2, exhibiting an in vivo half-life (T) of approximately 5-8 days. 1 / 2 ).

[0435] Example 13: Production from Stable CHO Cell Pools

[0436] C variant molecules corresponding to the parent Bi-PB-1.2, Bi-PLB-1, and Bi-A1B-1 molecules, as well as U variants of Bi-PB-1.2 and Bi-A1B-1 molecules, were produced from CHO-K1 stable cell pools and their truncation levels were compared to their wild-type counterparts and / or counterparts with C variants. The CHO-K1 stable cell pools were grown under fed-batch conditions for 14 days and purified by protein A chromatography. The truncation levels were determined by reducing PAGE analysis of the purified mutant and variant proteins. This analysis showed that the molecules with C and U variants had significantly reduced truncation ( Figures 52A-52B ).

[0437] The above description is intended to teach one skilled in the art how to implement the present invention and is not intended to describe in detail all of the obvious modifications and variations that would be apparent to one skilled in the art upon reading the specification. However, all such obvious modifications and variations are intended to be included within the scope of the present invention, which is defined by the appended claims. Unless the context specifically indicates otherwise, the claims are intended to cover the required components and steps in any order that is effective to achieve the desired purpose. Sequence Listing <110> Jingshang Biopharmaceutical Company <120> Antagonists composed of mutant TGFβ1-RII extracellular domain and immunoglobulin scaffold <130> P2021-2877 <150> US 62 / 869,111 <151> 2019-07-01 <150> PCT / US19 / 39979 <151> 2019-06-28 <160> 303 <170> PatentIn version 3.5 <210> 1 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 1 Asn Phe Leu Met Ser 1 5 <210> 2 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 2 Thr Ile Ser Gly Gly Gly Arg Asp Thr Tyr Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 3 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 3 Arg Thr Thr Tyr Ser Met Asp Tyr 1 5 <210> 4 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 4 Asn Ser Tyr Leu Tyr 1 5 <210> 5 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 5 Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe Lys 1 5 10 15 Thr <210> 6 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 6 Arg Asp Tyr Asn Tyr Asp Gly Gly Phe Asp Ser 1 5 10 <210> 7 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 7 Asn Ser Tyr Ile Tyr 1 5 <210> 8 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 8 Arg Arg Asp Tyr Arg Tyr Asp Gly Gly Phe Asp Ser 1 5 10 <210> 9 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 9 Thr Tyr Tyr Ile Tyr 1 5 <210> 10 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 10 Gly Ile Asn Pro Gly Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe Lys 1 5 10 15 Ile <210> 11 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 11 Arg Tyr His Gly Tyr Asp Gly Gly Leu Asp Tyr 1 5 10 <210> 12 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 12 Ser Tyr Tyr Ile His 1 5 <210> 13 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 13 Trp Ile Phe Pro Gly Ser Gly Asn Ser Lys Tyr Asn Glu Asn Phe Lys 1 5 10 15 Gly <210> 14 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 14 Ser Glu Thr Tyr Asp Tyr Gly Asp Tyr 1 5 <210> 15 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 15 Leu Ala Ser Gln Thr Ile Gly Thr Trp Leu Ala 1 5 10 <210> 16 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 16 Ala Ala Thr Ser Leu Ala Asp 1 5 <210> 17 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 17 Gln Gln Phe Tyr Ser Ile Pro Trp Thr 1 5 <210> 18 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 18 Arg Ala Ser Ser Thr Leu Tyr Ser Asn Tyr Leu His 1 5 10 <210> 19 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 19 Arg Ala Ser Phe Leu Ala Ser 1 5 <210> 20 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 20 Gln Gln Gly Ser Ser Ile Pro Leu Thr 1 5 <210> twenty one <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> twenty one Ser Ala Ser Ser Ser Leu Tyr Ser Ser Tyr Leu His 1 5 10 <210> twenty two <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> twenty two Arg Ala Ser Ser Ser Leu Tyr Ser Asn Tyr Leu His 1 5 10 <210> twenty three <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> twenty three Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Phe Ser Tyr Ile His 1 5 10 15 <210> twenty four <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> twenty four Leu Ala Ser Asn Leu Glu Ser 1 5 <210> 25 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 25 Gln His Thr Trp Glu Leu Pro Asn Thr 1 5 <210> 26 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 26 Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala 1 5 10 <210> 27 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 27 Ser Ala Ser Tyr Arg Tyr Ser 1 5 <210> 28 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 28 Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr 1 5 <210> 29 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 29 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Leu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Thr Ile Ser Gly Gly Gly Arg Asp Thr Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Arg Thr Thr Tyr Ser Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 30 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 30 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Thr Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Thr Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Tyr Ser Ile Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 31 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 31 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Asp Tyr Thr Phe Thr Asn Ser 20 25 30 Tyr Leu Tyr Trp Leu Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Thr Arg Thr Thr Ser Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Val Val Tyr Tyr Cys 85 90 95 Thr Arg Arg Asp Tyr Asn Tyr Asp Gly Gly Phe Asp Ser Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 32 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 32 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Phe Thr Cys Arg Ala Ser Ser Thr Leu Tyr Ser Asn 20 25 30 Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Ala Ser Phe Leu Ala Ser Gly Val Pro Ser Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln 65 70 75 80 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ser Ile Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 33 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 33 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Asp Tyr Thr Phe Thr Asn Ser 20 25 30 Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Thr Arg Val Thr Ser Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Val Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Asp Tyr Arg Tyr Asp Gly Gly Phe Asp Ser Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 34 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 34 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Leu Tyr Ser Ser 20 25 30 Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Ala Ser Phe Leu Ala Ser Gly Val Pro Ser Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln 65 70 75 80 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ser Ile Pro 85 90 95 Leu Thr Phe Gly Ala Gly Thr Lys Leu Asp Leu Lys 100 105 <210> 35 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 35 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Asp Tyr Thr Phe Thr Asn Ser 20 25 30 Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Thr Arg Val Thr Ser Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Val Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Asp Tyr Asn Tyr Asp Gly Gly Phe Asp Ser Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 36 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 36 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Phe Thr Cys Arg Ala Ser Ser Ser Leu Tyr Ser Asn 20 25 30 Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu 35 40 45 [[ID= 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln 65 70 75 80 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ser Ile Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 37 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 37 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Asn Pro Gly Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ile Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Tyr His Gly Tyr Asp Gly Gly Leu Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 38 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 38 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly 1 5 10 15 Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 20 25 30 Gly Phe Ser Tyr Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn 65 70 75 80 Pro Val Glu Ala Asn Asp Thr Ala Asn Tyr Tyr Cys Gln His Thr Trp 85 90 95 Glu Leu Pro Asn Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 39 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 39 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15[[ID=二十四]] Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Phe Pro Gly Ser Gly Asn Ser Lys Tyr Asn Glu Asn Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Glu Thr Tyr Asp Tyr Gly Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 40 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 40 Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Ala Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 41 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 41 Asn Tyr Trp Met His 1 5 <210> 42 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 42 Met Ile His Pro Asn Thr Asn Asn Tyr Asn Tyr Asn Glu Lys Phe Lys 1 5 10 15 Ser <210> 43 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 43 Ser Asp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr 1 5 10 <210> 44 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 44 Ser Tyr Trp Met His 1 5 <210> 45 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 45 Met Ile His Pro Asn Val Gly Ser Thr Asn Tyr Asn Glu Lys Phe Lys 1 5 10 15 Ser <210> 46 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 46 Ser Arg Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr 1 5 10 <210> 47 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 47 Met Ile His Pro Asn Ser Gly Gly Asn Asn Tyr Asn Glu Lys Phe Lys 1 5 10 15 Ser <210> 48 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 48 Ser Trp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr 1 5 10 <210> 49 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 49 Met Ile His Pro Thr Gly Val Ser Thr Asp Tyr Asn Glu Lys Phe Lys 1 5 10 15 Ser <210> 50 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 50 Ser Asp Tyr Ala Trp Asn 1 5 <210> 51 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 51 Tyr Ile Ser Asp Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 52 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 52 Ser Phe Leu Arg Leu Arg Ser Tyr Phe Asp His 1 5 10 <210> 53 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 53 Ser Tyr Gly Ile Asn 1 5 <210> 54 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 54 Cys Ile Tyr Ile Gly Asn Asp Tyr Thr Asn Tyr Asn Glu Lys Phe Lys 1 5 10 15 Gly <210> 55 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 55 Ala Tyr Tyr Gly Ser Arg Val Asp Tyr 1 5 <210> 56 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 56 Arg Ala Ser Gln Asp Ile Asp Asn Tyr Leu Asn 1 5 10 <210> 57 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 57 Tyr Thr Ser Arg Leu His Ser 1 5 <210> 58 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 58 Gln Gln Gly Tyr Thr Leu Pro Trp Thr 1 5 <210> 59 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 59 Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 60 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 60 Tyr Thr Ser Arg Leu Gln Ser 1 5 <210> 61 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 61 Gln Gln Gly Asn Thr Leu Pro Trp Thr 1 5 <210> 62 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 62 Gln Gln Gly Asp Thr Leu Pro Trp Thr 1 5 <210> 63 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 63 Lys Ala Ser Gln Asp Val Asn Val Ala Val Ala 1 5 10 <210> 64 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 64 Trp Ala Ser Thr Arg His Ile 1 5 <210> 65 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 65 Gln Gln His Tyr Ser Thr Pro Tyr Thr 1 5 <210> 66 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 66 Lys Ala Ser Gln Asp Ile Asn Lys Tyr Ile Ala 1 5 10 <210> 67 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 67 Tyr Thr Ser Thr Leu Gln Pro 1 5 <210> 68 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 68 Leu Gln Tyr Asp Asn Leu Tyr Thr 1 5 <210> 69 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 69 Gln Ser Ile Ser Asp Tyr Leu His 1 5 <210> 70 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 70 Cys Ala Ser Gln Ser Ile Ser Gly 1 5 <210> 71 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 71 Gln Asn Gly His Ser Phe Pro Tyr Thr 1 5 <210> 72 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 72 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Trp Met His Trp Met Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Met Ile His Pro Asn Thr Asn Asn Tyr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Arg Val Thr Ser Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Val Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Asp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 73 <211> 107 <212> PRT <213> Artificial Sequence(Artificial Sequence) <220> <223> synthetic <400> 73 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Asp Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Lys Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Tyr Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 74 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 74 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Met Ile His Pro Asn Val Gly Ser Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Met Thr Arg Asp Lys Ser Ser Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Arg Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 75 <211> 107 <212> PRT <213> Artificial Sequence(Artificial Sequence) <220> <223> synthetic <400> 75 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 76 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 76 [[ID=3三十三]]Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr[[ID=三十八]] 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45<四十四]] Gly Met Ile His Pro Asn Ser Gly Gly Asn Asn Tyr Asn Glu Lys Phe 50 55 60 Note: There seems to be a mistake in the original text where "" is translated as "三十三" instead of the correct translation for the content within. I've corrected it in the translation above. Also, "" is left as "<四十四]]" as it's not clear what the correct translation should be based on the given rules. If this is an error in the original, it should be fixed for a proper translation.Lys Ser Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Trp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 77 <211> 107 <212> PRT <213> Artificial Sequence(Artificial Sequence) <220> <223> synthetic <400> 77 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 78 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 78 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Met Ile His Pro Thr Gly Val Ser Thr Asp Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Asp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 79 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 79 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Lys Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Asp Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 80 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 80 Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp 20 25 30 Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 35 40 45 Met Gly Tyr Ile Ser Asp Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu 50 55 60 Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 65 70 75 80 Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Asn Ser Phe Leu Arg Leu Arg Ser Tyr Phe Asp His Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 81 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 81 Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Asn Val Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45 Phe Trp Ala Ser Thr Arg His Ile Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala 65 70 75 80 Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 82 <211> 119 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 82 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 35 40 45 Gly Trp Cys Ile Tyr Ile Gly Asn Asp Tyr Thr Asn Tyr Asn Glu Lys 50 55 60 Phe Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala 65 70 75 80 Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Ala Tyr Tyr Gly Ser Arg Val Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <210> 83 <211> 106 <212> PRT <2​​​​​​​​​1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Lys Tyr 20 25 30 Ile Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 His Tyr Thr Ser Thr Leu Gln Pro Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Arg Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Tyr Thr 85 90 95 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105​​​​​​​​​​​​​​​​​​​​​​​Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 35 40 45 Gly Trp Cys Ile Tyr Ile Gly Asn Asp Tyr Thr Asn Tyr Asn Glu Lys 50 55 60 Phe Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala 65 70 75 80 Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Ala Tyr Tyr Gly Ser Arg Val Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <210> 85 <211> 104 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 85 Glu Ile Val Leu Thr Gln Ser Pro Val Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Gln Ser Ile Ser Asp Tyr Leu His Trp 20 25 30 Tyr Leu Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Lys Cys Ala 35 40 45 Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser 50 55 60 Gly Ser Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe 65 70 75 80 Ala Val Tyr Tyr Cys Gln Asn Gly His Ser Phe Pro Tyr Thr Phe Gly 85 90 954 Gly Gly Thr Lys Val Glu Ile Lys 100 <210> 86 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 86 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Met Ile His Pro Asn Ser Gly Gly Asn Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Trp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 87 <211> 107 <212> PRT <213> Artificial Sequence(Artificial Sequence) <220> <223> synthetic <400> 87 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Asp Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Lys Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Tyr Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 88 <211> 205 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 88 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu 1 5 10 15 Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val 20 25 30 Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 35 40 45 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe 50 55 60 Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu 65 70 75 80 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 85 90 95 Gln Thr Asn Thr Ile Ile Asp Val Val Leu Ser Pro Ser His Gly Ile 100 105 110 Glu Leu Ser Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr 115 120 125 Glu Leu Asn Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys 130 135 140 His Gln His Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln Ser Gly 145 150 155 160 Ser Glu Met Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr 165 170 175 Arg Ser Asp Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met 180 185 190 Thr Lys Lys Asn Ser Thr Phe Val Arg Val His Glu Lys 195 200 205 <210> 89 <211> 136 <212> PRT <213> Artificial Sequence <220> [[ID=​​​​​​​Asp Asn Asn Gly Ala Val Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp 20 25 30 Val Arg Phe Ser Thr Cys Asp Asn Gln Lys Ser Cys Met Ser Asn Cys 35 40 45 Ser Ile Thr Ser Ile Cys Glu Lys Pro Gln Glu Val Cys Val Ala Val 50 55 60 Trp Arg Lys Asn Asp Glu Asn Ile Thr Leu Glu Thr Val Cys His Asp 65 70 75 80 Pro Lys Leu Pro Tyr His Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro 85 90 95 Lys Cys Ile Met Lys Glu Lys Lys Lys Pro Gly Glu Thr Phe Phe Met 100 105 110 Cys Ser Cys Ser Ser Asp Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu 115 120 125 Glu Tyr Asn Thr Ser Asn Pro Asp 130 135 <210> 90 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 90 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys [[ID=2~1]]85 90 9~5 Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 91 <211> 107 <212> PRT [[ID=3~]]<213> Artificial Sequence <220> <223> Synthetic <400> 91 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile 35 40 45 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 92 <211> 595 <212> PRT[[ID=二十九]] <213> Artificial Sequence ><220> <223> Synthetic <400> 92 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Phe Pro Gly Ser Gly Asn Ser Lys Tyr Asn Glu Asn Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Glu Thr Tyr Asp Tyr Gly Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Gly Gly Gly Gly 435 440 445 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ile Pro Pro His Val 450 455 460 Gln Lys Ser Val Asn Asn Asp Met Ile Val Thr Asp Asn Asn Gly Ala 465 470 475 480 Val Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp Val Arg Phe Ser Thr 485 490 495 Cys Asp Asn Gln Lys Ser Cys Met Ser Asn Cys Ser Ile Thr Ser Ile 500 505 510 Cys Glu Lys Pro Gln Glu Val Cys Val Ala Val Trp Arg Lys Asn Asp 515 520 525 Glu Asn Ile Thr Leu Glu Thr Val Cys His Asp Pro Lys Leu Pro Tyr 530 535 540 His Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro Lys Cys Ile Met Lys 545 550 555 560 Glu Lys Lys Lys Pro Gly Glu Thr Phe Phe Met Cys Ser Cys Ser Ser 565 570 575 Asp Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu Glu Tyr Asn Thr Ser 580 585 590 Asn Pro Asp 595 <210> 93 <211> 214 <212> PRT [[ID=3​​​​​​​​​​​​​​​Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Ala Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 94 <211> 602 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 94 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Met Ile His Pro Asn Ser Gly Gly Asn Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Trp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 450 455 460 Gly Ser Ile Pro Pro His Val Gln Lys Ser Val Asn Asn Asp Met Ile 465 470 475 480 Val Thr Asp Asn Asn Gly Ala Val Lys Phe Pro Gln Leu Cys Lys Phe 485 490 495 Cys Asp Val Arg Phe Ser Thr Cys Asp Asn Gln Lys Ser Cys Met Ser 500 505 510 Asn Cys Ser Ile Thr Ser Ile Cys Glu Lys Pro Gln Glu Val Cys Val 515 520 525 Ala Val Trp Arg Lys Asn Asp Glu Asn Ile Thr Leu Glu Thr Val Cys 530 535 540 His Asp Pro Lys Leu Pro Tyr His Asp Phe Ile Leu Glu Asp Ala Ala 545 550 555 560 Ser Pro Lys Cys Ile Met Lys Glu Lys Lys Lys Pro Gly Glu Thr Phe 565 570 575 Phe Met Cys Ser Cys Ser Ser Asp Glu Cys Asn Asp Asn Ile Ile Phe 580 585 590 Ser Glu Glu Tyr Asn Thr Ser Asn Pro Asp 595 600 <210> 95 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 95 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Asp Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Lys Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Tyr Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 19� 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 96 <२११> १२३ <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 96 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 97 <211> 330 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 97 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330 <210> 98 <211> 330 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 98 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Ala 325 330 <210> 99 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 99 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Ala 225 <210> 100 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 100 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 <210> 101 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 101 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser Gly 20 <210> 102 <211> 610 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 102 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 450 455 460 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ile Pro Pro His Val Gln 465 470 475 480 Lys Ser Val Asn Asn Asp Met Ile Val Thr Asp Asn Asn Gly Ala Val 485 490 495 Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp Val Arg Phe Ser Thr Cys 500 505 510 Asp Asn Gln Lys Ser Cys Met Ser Asn Cys Ser Ile Thr Ser Ile Cys 515 520 525 Glu Lys Pro Gln Glu Val Cys Val Ala Val Trp Arg Lys Asn Asp Glu 530 535 540 Asn Ile Thr Leu Glu Thr Val Cys His Asp Pro Lys Leu Pro Tyr His 545 550 555 560 Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro Lys Cys Ile Met Lys Glu 565 570 575 Lys Lys Lys Pro Gly Glu Thr Phe Phe Met Cys Ser Cys Ser Ser Asp 580 585 590 Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu Glu Tyr Asn Thr Ser Asn 595 600 605 Pro Asp 610 <210> 103 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 103 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 [ Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile 35 40 45 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 104 <211> 610 <212> PRT <213 Artificial Sequence <220> <223 Synthetic <400> 104 It should be noted that there may be some inaccuracies in the tags in the original text (such as <213 Artificial Sequence should be <213> Artificial Sequence and <223 Synthetic should be <223> Synthetic). The translation is based on the original text as accurately as possible while maintaining the tag format.Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 450 455 460 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ile Pro Pro His Val Gln 465 470 475 480 Lys Ser Val Asn Asn Asp Met Ile Val Thr Asp Asn Asn Gly Ala Val 485 490 495 Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp Val Arg Phe Ser Thr Cys 500 505 510 Asp Asn Gln Lys Ser Cys Met Ser Asn Cys Ser Ile Thr Ser Ile Cys 515 520 525 Glu Lys Pro Gln Glu Val Cys Val Ala Val Trp Arg Lys Asn Asp Glu 530 535 540 Asn Ile Thr Leu Glu Thr Val Cys His Asp Pro Lys Leu Pro Tyr His 545 550 555 560 Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro Lys Cys Ile Met Lys Glu 565 570 575 Lys Lys Lys Pro Gly Glu Thr Phe Phe Met Cys Ser Cys Ser Ser Asp 580 585 590 Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu Glu Tyr Asn Thr Ser Asn 595 600 605 Pro Asp 610 <210> 105 <211> 589 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 105 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu 1 5 10 15 Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val 20 25 30 Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 35 40 45 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe 50 55 60 Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu 65 70 75 80 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 85 90 95 Gln Thr Asn Thr Ile Ile Asp Val Val Leu Ser Pro Ser His Gly Ile 100 105 110 Glu Leu Ser Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr 115 120 125 Glu Leu Asn Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys 130 135 140 His Gln His Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln Ser Gly 145 150 155 160 Ser Glu Met Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr 165 170 175 Arg Ser Asp Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met 180 185 190 Thr Lys Lys Asn Ser Thr Phe Val Arg Val His Glu Lys Asp Lys Thr 195 200 205 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 210 215 220 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 225 230 235 240 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 245 250 255 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 260 265 270 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 275 280 285 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 290 295 300 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 305 310 315 320 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 325 330 335 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 340 345 350 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 355 360 365 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 370 375 380 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 385 390 395 400 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 405 410 415 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Ala 420 425 430 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 435 440 445 Gly Gly Gly Ser Gly Ile Pro Pro His Val Gln Lys Ser Val Asn Asn 450 455 460 Asp Met Ile Val Thr Asp Asn Asn Gly Ala Val Lys Phe Pro Gln Leu 465 470 475 480 Cys Lys Phe Cys Asp Val Arg Phe Ser Thr Cys Asp Asn Gln Lys Ser 485 490 495 Cys Met Ser Asn Cys Ser Ile Thr Ser Ile Cys Glu Lys Pro Gln Glu 500 505 510 Val Cys Val Ala Val Trp Arg Lys Asn Asp Glu Asn Ile Thr Leu Glu 515 520 525 Thr Val Cys His Asp Pro Lys Leu Pro Tyr His Asp Phe Ile Leu Glu 530 535 540 Asp Ala Ala Ser Pro Lys Cys Ile Met Lys Glu Lys Lys Lys Pro Gly 545 550 555 560 Glu Thr Phe Phe Met Cys Ser Cys Ser Ser Asp Glu Cys Asn Asp Asn 565 570 575 Ile Ile Phe Ser Glu Glu Tyr Asn Thr Ser Asn Pro Asp 580 585 [[ID=3%]]<210> 106 <211> 480 <212> PRT <213> Artificial Sequence <220> }<223> Synthetic <400> 106 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 450 455 460 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ile Pro Pro His Val Gln 465 470 475 480 <210> 107 <211> 481 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 107 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 450 455 460 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ile Pro Pro His Val Gln 465 470 475 480 Lys <210> 108 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 108 Asp Asn Asn Gly Ala Val Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp 1 5 10 15 Val Arg Phe Ser Thr Cys Asp Asn Gln Lys Ser Cys Met Ser Asn Cys 20 25 30 Ser Ile Thr Ser Ile Cys Glu Lys Pro Gln Glu Val Cys Val Ala Val 35 40 45 Trp Arg Lys Asn Asp Glu Asn Ile Thr Leu Glu Thr Val Cys His Asp 50 55 60 Pro Lys Leu Pro Tyr His Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro 65 70 75 80 Lys Cys Ile Met Lys Glu Lys Lys Lys Pro Gly Glu Thr Phe Phe Met 85 90 95 Cys Ser Cys Ser Ser Asp Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu 100 105 110 Glu Tyr Asn Thr Ser Asn Pro Asp 115 120 <210> 109 <211> 130 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 109 Lys Ser Val Asn Asn Asp Met Ile Val Thr Asp Asn Asn ...

Claims

1. An anti-tumor antagonist comprising: A first targeting domain, wherein the first targeting domain is a mutated TGF-β1RII extracellular domain, wherein the amino acid sequence of the mutated TGF-β1RII extracellular domain is as shown in SEQ ID NO: 116 or 263, and the mutated TGF-β1RII extracellular domain reduces protein cleavage of an anti-tumor antagonist; and An immunoglobulin scaffold having an amino terminus and a carboxyl terminus, wherein the first targeting domain is connected to the immunoglobulin scaffold via a peptide linker, The tumor antagonist further comprises a second targeting domain, wherein: The second targeting domain comprises a PD-1 binding antagonist, and the PD-1 binding antagonist comprises: (1) an immunoglobulin heavy chain variable region (HCVR), which comprises three complementarity determining regions (HCDRs): HCDR1, HCDR2, and HCDR3, wherein the HCDR1 is as shown in SEQ ID NO: 12, wherein the HCDR2 is shown in SEQ ID NO: 13, and wherein the HCDR3 is shown in SEQ ID NO: 14; and (2) an immunoglobulin light chain variable region (LCVR), which comprises three complementarity determining regions (LCDRs): LCDR1, LCDR2, and LCDR3, Wherein the LCDR1 is as shown in SEQ ID NO: 26, wherein the LCDR2 is as shown in SEQ ID NO: 27, and wherein the LCDR3 is as shown in SEQ ID NO: 28; or The second targeting domain comprises a PD-L1 binding antagonist, and the PD-L1 binding antagonist comprises: (1) an immunoglobulin heavy chain variable region (HCVR), which comprises three complementarity determining regions (HCDRs): HCDR1, HCDR2, and HCDR3, wherein the HCDR1 is as shown in SEQ ID NO:44, wherein the HCDR2 is as shown in SEQ ID NO:47, and wherein the HCDR3 is shown in SEQ ID NO:48; and (2) an immunoglobulin light chain variable region (LCVR), which comprises three complementarity determining regions (LCDRs): LCDR1, LCDR2, and LCDR3, Wherein the LCDR1 is as shown in SEQ ID NO:56, wherein the LCDR2 is as shown in SEQ ID NO: 57, and wherein the LCDR3 is as shown in SEQ ID NO:58; or The second targeting domain specifically binds to VEGF and comprises an HCVR as shown in the amino acid sequence of SEQ ID NO:96 and an LCVR as shown in SEQ ID NO:

91.

2. The anti-tumor antagonist according to claim 1, wherein the mutated TGF-β1RII extracellular domain sequence is as shown in SEQ ID NO:

116.

3. The anti-tumor antagonist according to claim 1, wherein the mutated TGF-β1RII extracellular domain sequence is as shown in SEQ ID NO:

263. 4 . The anti-tumor antagonist of claim 1 , wherein the peptide linker comprises the amino acid sequence of SEQ ID NO:

101.

5. The anti-tumor antagonist of claim 1, wherein the peptide linker comprises the amino acid sequence of SEQ ID NO:

156.

6. The anti-tumor antagonist of claim 1, wherein the second targeting domain specifically binds to PD-1, and the second targeting domain comprises: (1) an immunoglobulin heavy chain variable region (HCVR), which comprises three complementarity determining regions (HCDRs): HCDR1, HCDR2, and HCDR3, wherein the HCDR1 is as shown in SEQ ID NO: 12, wherein the HCDR2 is as shown in SEQ ID NO: 13, and wherein the HCDR3 is shown in SEQ ID NO: 14; and (2) an immunoglobulin light chain variable region (LCVR), which comprises three complementarity determining regions (LCDRs): LCDR1, LCDR2, and LCDR3, Wherein the LCDR1 is as shown in SEQ ID NO: 26, wherein the LCDR2 is as shown in SEQ ID NO: 27, and The LCDR3 is shown in SEQ ID NO:

28.

7. The anti-tumor antagonist of claim 6, wherein the second targeting domain comprises: A HCVR having at least 90% identity to SEQ ID NO:39: and A LCVR having at least 90% identity to SEQ ID NO:

40.

8. The anti-tumor antagonist according to claim 7, comprising: The immunoglobulin HCVR having the amino acid sequence shown in SEQ ID NO:39; and The amino acid sequence of the immunoglobulin HCVR is shown in SEQ ID NO:

40.

9. The anti-tumor antagonist of claim 1, wherein the second targeting domain specifically binds to PD-L1, and the second targeting domain comprises: (1) an immunoglobulin HCVR comprising three complementarity determining regions (HCDRs): HCDR1, HCDR2, and HCDR3, wherein the HCDR1 is as shown in SEQ ID NO:44, wherein the HCDR2 is as shown in SEQ ID NO:47, and wherein the HCDR3 is as shown in SEQ ID NO:48, and (2) immunoglobulin LCVR, which contains three complementarity determining regions (LCDRs): LCDR1, LCDR2, and LCDR3, wherein the LCDR1 is shown in SEQ ID NO:56; wherein the LCDR2 is shown in SEQ ID NO:57; and The LCDR3 is shown in SEQ ID NO:

58.

10. The anti-tumor antagonist according to claim 9, comprising: An immunoglobulin HCVR having at least 90% identity to SEQ ID NO:86; and / or An immunoglobulin LCVR having at least 90% identity to SEQ ID NO:

87.

11. The anti-tumor antagonist according to claim 10, comprising: The immunoglobulin HCVR having the amino acid sequence shown in SEQ ID NO: 86; and / or The amino acid sequence of the immunoglobulin LCVR is shown in SEQ ID No:

87.

12. The anti-tumor antagonist of claim 1, wherein the second targeting domain specifically binds to VEGF, and the second targeting domain comprises the following amino acid sequences SEQ ID NOs: 96 and 91.

13. The anti-tumor antagonist of claim 1, wherein the immunoglobulin scaffold is an IgG1, IgG2 or IgG4 scaffold.

14. The anti-tumor antagonist of claim 13, wherein the immunoglobulin scaffold contains a N297A mutation, a K447A mutation, or both.

15. The anti-tumor antagonist of claim 1, wherein the immunoglobulin scaffold comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 100, 159-166, and 173-175.

16. The anti-tumor antagonist of claim 1, comprising a heavy chain amino acid sequence selected from the group consisting of SEQ ID NOs: 126, 145, 148, 283, 303 and 295.

17. The anti-tumor antagonist according to claim 1, comprising: (1) a heavy chain amino acid sequence as shown in SEQ ID NO: 126 or SEQ ID NO: 283, which is paired with a light chain amino acid sequence as shown in SEQ ID NO: 93; (2) a heavy chain amino acid sequence as shown in SEQ ID NO: 145 or SEQ ID NO: 303, which is paired with a light chain amino acid sequence as shown in SEQ ID NO: 95; or (3) The heavy chain amino acid sequence shown in SEQ ID NO:148 or SEQ ID NO:295, which is paired with the light chain amino acid sequence shown in SEQ ID NO:

103.

18. Use of an anti-tumor antagonist according to any one of claims 1 to 17 in the preparation of a medicament for treating a solid tumor in a subject.

19. One or more polynucleotides encoding the anti-tumor antagonist of any one of claims 1-17.

20. One or more vectors comprising one or more polynucleotides according to claim 19.

21. A host cell transformed with one or more vectors according to claim 20.